Integrated Approaches to the Risk Prediction of First-episode Psychosis by Leirer, Daniel Jonathan
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 












Download date: 14. Jun. 2018
Integrated Approaches to the Risk
Prediction of First-episode Psychosis
Daniel Jonathan Leirer
Supervisor: Prof. Richard Dobson
Advisor: Prof. Robin Murray
Department of Biostatistics and Health Informatics
University of London, King’s College London
This dissertation is submitted for the degree of
Doctor of Philosophy
King’s College London March 2018
"Die Welt zu durchschauen, sie zu erklären, mag großer Denker Sache sein. Mir aber liegt




I hereby declare that except where specific reference is made to the work of others, the
contents of this dissertation are original and have not been submitted in whole or in part for
consideration for any other degree or qualification in this, or any other university. The contents
of this dissertation are the result of my own work, and are not the result of collaborations
with others, unless specified in the text and acknowledgements in accordance with King’s





This work would not have been possible without the contribution and support of many others.
Foremost among them were my supervisors Richard Dobson, Steven Newhouse and Robin
Murray, who allowed me to undertake this work and offered advice, guidance and support. I
also would like to acknowledge Marta Di Forti, Diego Quattrone, Gerome Breen, Olesya
Ajnakina and the entire GAP team without whom none of this would have been possible.
I am especially grateful to Conrad Iyegbe who initially introduced me to this project, and
offered his advice over several years. My deepest gratitude goes to Lorraine Gordon, Philip
Asherson, Fruhling Rijsdijk and Baljinder Mankoo for their endless support when I needed it
most. I would like to extend my gratitude to all the students and staff at the SGDP and IOPPN
who have helped and kept me company over the last 4 years. Especially all the members of
the Dobson lab.
A special thanks goes to all the friends, family and co-workers who provided encouraging
words and commented on early drafts of this work. I would like to thank Werner Leirer,
Michelle Leirer, Anika Oellrich and Laura Kutt for reading the first drafts and giving feed-
back. My thanks also go to Max Kerz for sharing ideas and providing motivation while
writing. I would also like to thank my flatmates Marta Kutt, Neil Tan and Dickson Cheung
for keeping my spirits up.
Finally, I would like to thank the Guy’s and St’Thomas Charity and King’s Bioscience Insti-
tute for generously supporting my studies and the MRC-Social, Genetic and Developmental
Psychiatry Centre for its support.
Abstract
Psychosis is a complex condition that features in many psychiatric disorders, and significantly
affects the quality of life for both patients and family members. As part of the Genetics
and Psychosis (GAP) study, this thesis presents one of the largest blood gene expression
datasets on first-episode psychosis patients to date. This work aimed to characterise the
blood-based biological perturbations in psychosis and to investigate the predictive ability of
gene expression data.
Firstly changes in expression, between healthy controls and first-episode psychosis
patients was explored, to identify genes associated with psychosis. I identified hundreds of
differentially expressed genes and found associations to pathways involved in transcription,
oxidative stress and viral replication.
Secondly, network approaches were used to construct modules of genes based on co-
expression. I identified modules correlated to the severity of positive symptoms, and enrich-
ment for pathways associated with the stress response and multiple brain regions.
Thirdly regularised generalised linear models with bootstrapping were used to generate
predictions based on combinations of gene expression, genetic and demographic data. The
highest performance was found for models incorporating gene expression data, with minimal
improvement using additional data. Prediction accuracy for identifying psychosis samples
was found to increase with severity of positive symptoms in schizophrenia samples, but not
in other psychoses.
Finally, machine learning methods were used on public schizophrenia gene expression
data to build a variety of predictive models. These models were tested on the Genetics and
Psychosis (GAP) gene expression data. The results show increased predictive performance
on samples with a schizophrenia diagnosis, compared to other types of psychosis.
Overall the thesis presents work analysing a novel gene expression dataset. The results
suggest that blood gene expression signatures are more predictive for positive symptoms in
schizophrenia than for other psychoses. This work also highlights expression differences in
innate immune pathways and the stress response.
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Chapter 1
Introduction
Psychosis is a severe psychiatric condition affecting approximately 4 in 1000 individuals
(Jb et al., 2012) per year in the UK. The impact on quality of life, relationships and health
services is significant. Successful diagnosis and treatment is often a long process with
patients sometimes receiving multiple diagnoses and medications over several years before
finding a combination that works if such a combination is found at all.
Over the recent decades, it has become clear that psychosis is caused by a complex
interplay between genetics and the environment. Transcriptomic approaches have been used
to capture this interaction, to understand psychosis at a molecular level and to find biomarkers.
However, few studies have looked at first episode psychosis.
This thesis will present work on the largest, to our knowledge, gene expression cohort in
first episode psychosis.
In this chapter, I will give a general overview of psychosis, before discussing the literature
on heritability, genetics and environmental risk factors. I will then review the gene expression
and classification literature on this topic. Finally, I will discuss the aims of this thesis, and
provide an overview of the remaining chapters.
1.1 Psychosis
Psychosis in its broadest sense describes a condition which is defined by a loss or distortion
of reality. In a medical setting, psychosis becomes pathological if it significantly interferes
with the quality of life of individuals affected. Patients suffering from psychosis often
experience symptoms that include hallucinations, delusions, paranoia and thought disorders,
which can wreak havoc on their ability to function in everyday life. This in combination
with the still considerable stigma associated with the condition, leads to a poor long-term
outcome, which in turn places a considerable burden on relatives, healthcare providers and
1.1 Psychosis 2
the economy (Awad and Voruganti, 2008; O’Malley et al., 2011). In general, psychosis can
occur in the context of severe mental illness (such as Schizophrenia and Bipolar Disorder),
neurodegenerative diseases (such as Alzheimer’s disease) and due to pharmacologically
active compounds, such as amphetamines. This thesis focuses specifically on psychosis in
mental illness and the psychiatric context.
Historically psychiatric thinking on psychosis has been heavily influenced by the German
school of thought led by Emil Kraepelin who firmly believed in discreet classifications of
psychiatric illness. He famously introduced the Kraepelinian system for classifying mental
health disorders in 1898, in which he described what he thought were the two principal
categories of psychosis, namely dementia praecox (later renamed to schizophrenia) and
manic-depressive disorder (encompassing all affective disorders).
Since Kraeplin two main systems of classification have emerged which aim to classify
mental illness. The Diagnostic and Statistical Manual of Mental Disorders (DSM), which
is now in the 5th edition (American Psychiatric Association. and American Psychiatric
Association. DSM-5 Task Force., 2013), is primarily used by services in the United States.
The other system is the International Classification of Diseases 10 (ICD-10) compiled by the
World Health Organisation (WHO) (Organization, 1992) which aims to contain classifications
for all disorders including mental and behavioural ones.
Both the DSM-5 and ICD-10 have significantly expanded categories of mental disorders,
which has been controversial and led to confusion in assessing the literature on specific
conditions as the definitions have often changed dramatically over the last 100 years and are
continuing to do so. Recent evidence suggesting an overlap between severe mental health
problems such as schizophrenia and bipolar disorder (discussed later), has led to research
that focuses on symptoms rather than diagnostic classification. This thesis, therefore, focuses
primarily on non-organic first episode psychosis, in an attempt to bypass inconsistencies in
diagnosis.
In this section, I will give a general overview of psychosis symptoms, the main psychiatric
diagnoses that psychosis patients may receive and the rationale for focusing on first episode
psychosis sufferers in this thesis.
1.1.1 Symptom Presentation in Psychosis
The definition used for psychosis in this thesis can be summed up as including the Schizophre-
nia, Schizotypal and Delusional Disorders (ICD-10 codes F20-F29) and Mood disorders
(ICD-10 codes F30-F33). For Mood disorders, this encompasses Manic episodes, Bipolar dis-
order and Major depression. Symptom presentation can look radically different from patient
to patient, leading to the original attempts to classify psychiatric conditions. Symptoms are
1.1 Psychosis 3
routinely categorised into Positive, Negative and Psychopathology scales as is done with the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987). Here positive symptoms,
in a broad sense, refer to increases in thoughts and behaviours such as with hallucinations,
delusions, excitement or grandiosity. In contrast, negative symptoms are characterised by a
reduction in actions, emotions, social interactions, reactivity or thinking. Psychopathology
symptoms can include a larger range of symptoms, that can include guilt, depression, poor












































































































































































































































































































































































































































Schizophrenia is the most frequent diagnosis in patients with psychosis symptoms included
in this study and research on schizophrenia has led to some of the most significant results in
psychiatric biology over the last decade (discussed later). Schizophrenia is one of the most
disabling conditions discussed here, featuring prominent positive and negative symptoms
in addition to a range of psychopathology ones. While recovery is possible many patients
struggle their entire life with symptoms that can make it impossible to have lasting relation-
ships or jobs. Schizophrenia onset peaks in the late twenties, but can start to develop in the
late teens, and all throughout life. More men than women are on average affected, although
women have a second peak for age of onset around menopause (Häfner, 2003).
Much of the literature discussed in this thesis focuses on Schizophrenia since mood dis-
orders don’t always feature psychotic symptoms, at least at the level of clinical significance.
Bipolar Disorder and Major Depression with psychotic features
Bipolar disorder is characterised by at least one episode of mania or hypomania, and usually
depression.
Mania is an elevation in the mood which at the far end can resemble symptoms of
stimulant use such as high energy levels, losing the need for sleep, severe loss of insight,
racing thoughts, hallucinations and grandiose behaviour and beliefs. Elevated moods, are
often characterised by high sociability and goal-oriented behaviour, but can also prominently
feature irritability and anger.
Bipolar mania can be devastating, with patients impulsively acting in uncharacteristic
ways, starting companies, gambling, or starting romantic relationships which for many
results in financial hardship or significant problems in personal relationships. Even though
medications such as mood stabilisers are in general more tolerable in their side effects,
many patients do not comply with their prescriptions since mania in its early stages can be
extremely pleasurable.
Depression in isolation or as part of bipolar disorder can also feature psychosis, most
commonly in the form of hallucinations and unusual beliefs, this is less common than in
mania and schizophrenia, but is thought to affect up to 20% of patients. Also, episodes
of bipolar disorder can feature both manic and depressed elements, which is referred to as
mixed episodes. Depression in one form or another is among the most common mental
health problems affecting up to 30% of the population at one point or another. In severe
cases, patients don’t have the energy to work, socialise or take care of themselves. This can
reinforce depression, and lead to self-harming behaviour or even suicide.
1.1 Psychosis 6
Treatment for depression in the form of antidepressants has modest effects, with meta-
analyses (Kirsch, 2014; Kirsch et al., 2008) finding little evidence of widespread benefits
over placebo treatment. It is unclear if this merely reflects a heterogeneity in the underlying
causes of depression or a deeper problem with the medication. Another factor that has been
suggested is that misdiagnosis of bipolar disorder sufferers might skew results since some
evidence suggests that antidepressants could increase the risk of mania and suicide.
Other Psychoses
In addition to Schizophrenia, Bipolar disorder and Major Depression there are three other
diagnoses received by patients in this thesis.
The most common diagnosis is schizoaffective disorder which features prominent symp-
toms found in both schizophrenia and affective disorders. In general schizoaffective disorder
is divided into two main subcategories based on the type of affective symptoms. These are
schizoaffective manic subtype and depressed subtype.
Schizophreniform is a disorder introduced by the DSM and refers to a schizophrenia
subtype. While schizophreniform suffers often receive a diagnose of schizophrenia if the
symptoms become chronic or more severe, the outcome is often better, and recovery happens
more frequently.
Finally, Delusional disorder represents a psychotic disorder characterised, as the name
suggests, by delusions. These can take a variety of forms, from grandiose to persecution,
but patients can not meet the criteria for schizophrenia or mania, meaning that negative and
affective symptoms are not prominent parts of the disorder.
1.1.2 First Episode Psychosis
Individuals are defined as having first-episode psychosis (FEP) when they first come in
contact with health services for psychosis. This means that initial diagnosis is unclear, and
appropriate treatment can be difficult, in part because psychosis can be drug-induced or a
symptom of non-psychiatric health conditions. The main problem, however, is that response
to treatment, even with a diagnosis, often involves numerous medication trials per patient.
Most studies in psychiatry are limited to studying patients who are in a remission or are
stabilised by medication, sometimes over many years. FEP patients are drug naive at first
contact, and while stabilisation with medication is often necessary to get informed consent for
inclusion in a study the effects of chronic medication use are significantly reduced. As such,
FEP cohorts provide the opportunity to study non-static variables affected by biology and
environment, such as gene expression, or protein levels. Since antipsychotic medications can
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substantially affect these biological signatures, studies of FEP patients can provide insight
at a relatively early point when patients are minimally affected. This approach can help in
identifying biomarkers and biological signatures that may be more specific to psychosis, than
the results of studies at later stages.
From a scientific and clinical perspective, such a signature applied to FEP patients could
improve early intervention and have a significant impact on the recovery, quality of life of
patients as well as free up resources of medical services, by identifying patient subgroups
from a gene-environment perspective.
1.2 Psychosis Risk Factors
Psychosis has historically been understood from a variety of perspectives. Early German
psychiatrists such as Kraepelin strongly favoured biological underpinning. This fell out of
favour in the mid-1900s in part due to disastrous psychiatric interventions which contributed
to the rise of vocal anti-psychiatric sentiment. In the UK, R.D. Laing’s views that psychosis
can be understood in the context of victimisation that occurs in the nuclear family, became
hugely influence (Laing et al., 2016), but this was ultimately rejected with the introduction of
high-quality twin and genetic studies.
Today mental health is arguably best understood in the context of the biopsychosocial
model of mental health, which tries to account for genetic, psychological and socio-cultural
factors in the development of psychiatric diseases. In the case of the schizophrenia disease
progression, such an integrated model is examined in Figure 1.1.
In this section, I will review the current evidence for biological and environmental risk
factors for psychosis, primarily in the context of schizophrenia. I will then examine modern
ways of synthesising these views in the light of current biopsychosocial perspectives.
Finally, I will consider the hypothalamic–pituitary–adrenal (HPA) axis in the context of
psychosis, and the extent that the existing literature fits in with deregulation in this system.
1.2.1 Twin Studies and Heritability
Evidence for a genetic component in psychosis comes from three primary sources, namely
family history, twin studies and genetic studies, especially genome-wide association study.
The early evidence for a genetic component came from family studies, showing that mental
health disorders run in families (Kendler, 1983) and family history is the most important risk
factor for schizophrenia (Sullivan, 2005). This, however, is somewhat misleading, as most
cases of schizophrenia occur in individuals who do not have a close family member who is
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Figure 1.1 Schizophrenia Trajectory
Model of schizophrenia trajectory, showing progression of symptoms in the context of risk factors
such as genetics, development and social adversity. Reprinted from The Lancet, Volume 383, Howes, O.
D. and Murray, R. M., Schizophrenia: an integrated sociodevelopmental-cognitive model, 1677-1678,
Copyright 2014, with permission from Elsevier (Howes and Murray, 2014).
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affected. Family history alone is arguably just as compatible with a purely environmental
model of psychosis, in which a disruptive family environment due to mentally ill relatives
contributes to the development. In the remainder of this section, I will critically examine
evidence from twin studies.
Twin Studies: Heritability findings for Psychiatric Conditions
Early twin studies significantly strengthened evidence of a genetic component for psychosis.
The surprising results of these studies were the high heritability estimates for psychiatric
conditions, especially in the case of bipolar disorder and schizophrenia. These studies
suggested that genetics is the most significant factor and suggested little or no contribution
of the shared environment (factors that would be shared by both twins). Instead, non-shared
environment (environmental influences that are not shared by twins) surprisingly accounted
for most and in the case of schizophrenia studies almost all environmental variation. One
major study investigating schizophrenia found heritability estimate as high as 85% (Cardno
et al., 1999), and a 2003 systematic meta-analysis, which pooled 14 previously published twin
studies from 1941 to 1999 estimated heritability to be 81% (Sullivan et al., 2003). Estimates
for Bipolar Disorder are similarly high with the largest twin studies finding heritability
estimates between 60% and 87% (Smoller and Finn, 2003), while heritability for depression
was found to be around 40% (Sullivan et al., 2000).
In the context of significant advances in DNA sequencing and microarray technology, and
the human genome project nearing completion, these heritability estimates led to a focus on
identifying the genetic and molecular underpinnings of schizophrenia and other psychiatric
disorders. There are however some issues with this interpretation. In the next sections, I will
review some of the problems and limitations of twin studies and heritability as a concept.
Twin Studies: Methodology
Using Twins to disentangle environmental and genetic traits was originally conceived by Fran-
cis Galton, and first implemented in the modern sense by Siemens (1924). While statistical
approaches for analysis have become significantly more sophisticated, the underlying as-
sumptions remain largely the same. Twin studies make use of the fact that monozygotic (MZ)
and dizygotic (DZ) twins share 100% and 50% of their DNA respectively. In principle, all
traits can be understood as resulting from a combination of genetics and environment. In twin
studies this is usually represented with five variables; a for additive genetics, d for dominant
genetics effects, c for shared environment e for non-shared environment and z for error in
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measurement. To correctly account for all variables, twin studies require that twins are raised
apart. This rarely happens, so most studies use the simpler ACE additive model, dropping d.
Twin studies using the ACE model make several core assumptions that are essential to
their interpretation, as discussed by Rijsdijk and Sham (2002). Violation of these assumption
calls into question the results for a given population. The most important of these, which will
be discussed in more detail, is the assumption that MZ and DZ twins are equally affected
by their shared environment insofar as it is relevant to the trait in question. DZ who have
different genders will obviously not have the same extent of a shared environment which may
contribute to psychological traits compared to MZ twins. While there are of course more
significant reasons to use DZ twins that have the same gender, it illustrates an important
point.
In the ACE model, the variation in phenotype is simply the sum of variation in additive
genetics (A), shared environment (C) and non-shared environment (E). By calculating the
intraclass correlation r between twins (which measures the concordance), and given that all
assumptions are met (discussed later), the three variables are estimated by using Falconer’s
formula :
Falconer’s formula: (1.1)
Non-shared environment : E = 1− r(MZ) (1.2)
Additive genetics : A = 2(r(MZ)− r(DZ)) (1.3)
Shared environment : C = r(MZ)−A (1.4)
The r(MZ) captures the combined effect of C and A, since discordance in MZ twins
can only occur from the non-shared environment. Thus E is calculated by just subtracting
1 (since the model requires that variation does not exceed 100%) from the MZ correlation,
with Huntington’s in which concordance is 100% r(MZ) would be 1, resulting in E of 0. A is
calculated by subtracting the DZ from the MZ correlation and multiplying the product by 2.
Finally, C can be calculated by subtracting A from the MZ correlation.
Twin Studies: Criticism and Flaws
Heritability estimates based on the ACE model have been heavily criticised by Schönemann
(1997) who argued that these models are constructed incorrectly and fail to correct for
errors in measurements. Schonemann also argues that they are applied in a way that is
mathematically invalid often leading to paradoxical results, like negative heritability or
shared environment. This happens if r(MZ)-r(DZ) results in a value below 0 or above 0.5.
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Consider a society in which MZ twins are required by law to get a small tattoo to distinguish
them, while DZ can choose. Such a society may have an r(MZ) of 0.9 and an r(DZ) of 0.2 for
tattoos. Using falconers formula we find that A = 1.4, C = -0.5 and E = 0.1. The result is that
heritability of getting a tattoo is 140% which is clearly nonsense. This is now hidden within
complex structural computer models, that prevent negative values, despite never adequately
addressing the fundamental mathematical criticism.
When comparing the results of twin studies for a range of areas, it is striking that Twin
studies seem to show that psychiatric and behavioural traits are excessively hereditary, as can
be seen in Table 1.2. Schizophrenia here has the highest heritability out of all traits listed,
and practically no contribution from the shared environment. Schizophrenia is on par with
the "structure of the human eyeball" regarding genetic and environmental contributions.
In general shared environment seems to have little influence on psychiatric disorders,
personality disorders and personality traits. This stands in contrast to many biological
structures and diseases, such as Gout, Cystis Fibrosis, Diabetes, Endocrine Function, height,
and Structures of the mouth and head, which attribute between 27% and 54% of trait variation
to shared environmental factors. None of the psychiatric, or personality traits mentioned
here have such high environmental contributions, even though these characteristics would
reasonably be expected to be influenced significantly by the environment.
It should be noted that all of the results of twin studies simply provide a measure of
variation in a phenotype of a particular population that is estimated to be due to the respective
component of the ACE model. No trait or disease can be understood in isolation and is
by necessity always the result of interactions of genetics with the environment. Even if in
practice all environmental influences reasonably encountered, would lead to the same trait,
as with Huntington’s disease or eye colour, for example.
Heritability therefore as a measure of genetic contributions is usually meaningless without
also considering the environmental context.
An extreme illustration of this is a monogenic disease like Phenylketonuria (PKU), which
causes severe disability and early death, but is practically asymptomatic by eliminating
phenylalanine from the diet. As such an environment with sufficient phenylalanine is
required to have a disease. In a hypothetically isolated population homogeneous in PAH
gene mutations (which is disrupted in PKU), and where phenylalanine is not found in the
diet, it would be a purely environmental condition due to poisoning.
In the context of intelligence which also has very high heritability estimates, Turkheimer
et al. (2003) showed that the heritability of IQ was close to zero in low-income families, while
shared environment modulated 60% of the variation. The reverse was found in families of
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Table 1.2 Results from Twin Study meta-analysis
Trait Studied Heritability (A) Environment (C) r(MZ) r(DZ)
Psychiatric Diseases
Schizophrenia 0.77 0.013 0.7 0.3
Bipolar Affective Disorder 0.67 0.15 0.82 0.45
Mood Disorders 0.6 0.08 0.4 0.24
Recurrent Depressive Disorder 0.45 0.03 0.37 0.14
Depressive Episode 0.34 0.11 0.45 0.27
Personality Disorders
Sleep Disorders 0.51 0.12 0.48 0.24
Conduct Disorder 0.49 0.18 0.66 0.43
Phobic Anxiety Disorders 0.49 0.15 0.57 0.29
Obsessive-Compulsive Disorder 0.45 0.15 0.53 0.3
Emotional Disorder (Childhood) 0.44 0.2 0.57 0.3
Eating Disorders 0.4 0.04 0.47 0.19
Personality
Intelligence 0.67 0.12 0.69 0.45
Recreation and Leisure 0.54 0.18 0.59 0.3
Personality 0.44 0.13 0.47 0.23
Attitudes to Strangers 0.35 0.15 0.41 0.20
Societal Attitudes 0.3 0.2 0.45 0.29
Intimate Relationships 0.29 0.06 0.36 0.1
Biological Structure/Function
Structure of Eyeball 0.73 0.02 0.73 0.37
Height 0.63 0.30 0.91 0.57
Structure of Brain 0.6 0.12 0.72 0.45
Menstruation Functions 0.6 0.04 0.63 0.25
Structure of Mouth 0.57 0.34 0.82 0.4
Structure of Head and Neck 0.44 0.27 0.8 0.44
Sleep Functions 0.34 0.13 0.51 0.26
Endocrine Function 0.32 0.34 0.54 0.38
Psychomotor Functions 0.31 0.16 0.43 0.23
Disease
Development of Motor Function 0.74 0.10 0.83 0.49
Dementia in Alzheimers 0.63 0.12 0.86 0.5
Asthma 0.53 0.09 0.73 0.33
Type 1 Diabetes 0.5 0.54 0.76 0.43
Parkinson’s Disease 0.36 0.01 0.51 0.34
Cystic Fibrosis 0.17 0.45 0.49 0.59
Gout 0.17 0.34 0.42 0.48
Table of meta analysis results from twin studies, in 5 categories. Traits are ordered form
highest to lowest heritability for each category. The combined data from all studies is shown
for heritability (A) and shared environment (C). Intraclass correlations for Monozygotic
twins (r(MZ)) and Dizygotic twins (r(DZ)) are also present. Data taken from Polderman
et al. (2015).
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high socio-economic status. This understanding is essential for any interpretation of genetic
influences in other personality and psychiatric disorders.
The further problem is that the equal environment assumption is violated for personality
and psychiatric disorders (Fosse et al., 2015). That means it is evident that the shared
environment of identical twins is more similar in ways that contribute to the development of
psychiatric traits than it is for dizygotic twins. Environmental factors such as birth weight,
infections, stress and importantly childhood adversity have been shown to contribute to the
risk of psychosis (Iyegbe et al., 2014). It has been established that dizygotic twins are on
average taller and heavier than monozygotic twins (Jelenkovic et al., 2015) even at birth.
This can partially be attributed to the fact that dizygotic twins do not always share the
same placenta, while identical twins do. Childhood adversity was specifically studied in the
context of schizophrenia by Fosse et al. (2015), where they found a significantly higher rate
of concordance for stressful life events, neglect, sexual abuse and bullying in identical twins
when compared to dizygotic twins. It is easy to see why individuals that, for example, look
identical would experience such adversities with a higher concordance rate.
In response to such criticism, some twin researchers argue that genetics determines
how people look or act, and as such the social responses to individuals can be attributed
to genetics. A twin study published in psychological medicine by Sartor et al. (2011) for
example, claimed that the heritability of women being violently assaulted is over 40%, and
argued that inherited personality traits likely modulate this. According to Sartor et al. (2011)
these personality traits are what make people place themselves in situations that are more
likely to lead to being assaulted.
Such a definition of heritability simply defines environmental influences out of existence
and fails to provide any useful insights.
1.2.2 The Genetics of Psychosis
In this section, I will examine genetic studies, primarily in the context of schizophrenia. Early
research in this area focused on candidate gene studies as well as copy number variation’s
(CNV). More recently genome-wide association studies (GWAS), which due to extensive
worldwide collaborations have led to the development of novel bioinformatics methods, have
had a major impact on our current understanding of the genetic architecture of schizophrenia.
Finally, I will discuss the issue of missing heritability.
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Candidate Genes and Copy Number Variations (CNV)
Genetic studies for psychiatric disorders have until recently been relatively unsuccessful. In
the early 2000s, numerous candidate genes for schizophrenia were identified but failed to
replicate consistently. With a large replication study finding no support for any of the 14
examined genes (Sanders et al., 2008).
Research on copy number variations has been more successful, with a large replication
study finding support for 11 of 15 previously implicated CNV’s for Schizophrenia (Rees
et al., 2014). This is perhaps not surprising since duplications and deletions often span
multiple genes, and have a much more significant impact than individual genes.
One of the most replicated CNV’s implicated in schizophrenia is a deletion in 22q11.2,
which usually spans between 30 to 40 genes (Kobrynski and Sullivan, 2007). This deletion is
best know for causing DiGeorge syndrome, and is linked to a range of severe clinical symp-
toms which most commonly result in disruptions to normal development, cardiac function
(Kobrynski and Sullivan, 2007) and immune function (Sullivan, 2004). In addition patients
have a 25 fold increased risk of developing major psychiatric conditions (Shprintzen, 2008),
with 10% (Schneider et al., 2014) to 31% of patients reported to suffer from schizophrenia.
Notable among the deleted genes in that area is Catechol-O-methyl transferase (COMT)
which plays a role in dopamine metabolism and has in some studies been linked to schizophre-
nia (Caspi et al., 2005) and bipolar disorder (Lelli-Chiesa et al., 2011). Although in the case
of schizophrenia these results have not been consistently replicated (Zammit et al., 2007).
Genome Wide Association Studies
Initial results of genome-wide association study (GWAS) were not very encouraging and
failed to identify significant genes associated with psychiatric disorders. It was not until
Stefansson et al. (2009) brought together the major GWAS cohorts worldwide in 2009, that
multiple regions achieved significance for the first time. This study had a total sample size
of over 2000 subjects and over 13.000 controls. Despite that, a relatively small number of
7 genome-wide significant hits were identified, with the majority of these mapping to the
major histocompatibility complex (MHC) region. Following this the Psychiatric Genomics
Consortium (PGC) for schizophrenia has led the advance in this area and steadily increased
sample sizes, culminating in a recent nature publication which included more than 36.000
cases and 113.000 controls (Ripke et al., 2014), and these figures are continually expanding.
This study identified a total 108 genome-wide significant hits, although these results still
only account for a fraction of the estimated heritability for schizophrenia.
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Despite this, the GWAS results have led to some interesting findings regarding the genetic
architecture of major psychiatric disorders. One landmark study used the polygenic risk
score (PRS) of 5 disorders, including Bipolar Disorder, Major Depressive Disorder (MDD)
and Schizophrenia and found that the PRS for these disorders had significant predictive power
for the other disorders (Cross-Disorder Group of the Psychiatric Genomics Consortium,
2013). The highest predictive power was between Schizophrenia and Bipolar Disorder,
while the predictive power of MDD (perhaps due to lower estimated heritability and greater
heterogeneity) was less predictive, although still significant.
Missing Heritability
The problem of so-called missing heritability in GWAS studies has been the subject of
much debate. One argument has been that a substantial amount of this missing variance,
may be “hiding” in the already existing GWAS cohorts (Maher, 2008). This is because a
GWAS analyses millions of single nucleotide polymorphisms and the multiple testing burden
becomes extremely high, in these conditions. The assumption is that if schizophrenia is
highly polygenic, the contribution of any one single nucleotide polymorphism (SNP) will be
low, and the detection threshold given the high number of SNPs is too high for most genuine
signals to be identified. Attempts to circumvent this constraint led to the discovery that
by aggregating the effects of weakly associated variants into a PRS, a significant detection
power is recoverable (Purcell et al., 2009a). Using PRS the recent PGC cohort has been
able to account for at least 7% of the variation on the liability scale (Ripke et al., 2014).
Unfortunately, PRS have little predictive value in individuals of African descent. This is in
large part due to much greater genetic diversity (Lu et al., 2014) in populations of African
origin.
In any case, the heritability estimates from these studies fall short of the 60%-85% values
found by twin studies, and alternative methods such as GCTA come up with significantly
smaller heritability estimates generally between 27% (Loh et al., 2015) and 20% (Gusev
et al., 2014) for schizophrenia.
Even these heritability estimates face a problem, however. As Lander and Schork (1994)
explained, genetic associations can arise from population stratification as well as genuine
links between genotype and phenotype or linkage disequilibrium between the assayed
and functional variant. To illustrate the potential problem of population stratification, the
hypothetical example of studying chopstick proficiency has been used (Lander and Schork,
1994; Vilhjálmsson and Nordborg, 2012). This argument proposes that a GWAS on chopstick
use in San Francisco would find a high heritability and a strong association with HLA-A1
(common in east Asians). In this case, chopstick use is merely correlated with genetic
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markers, and heritability is measuring the environment being passed on, in the form of
cultural transmission and self-identification. This problem of population stratification is well
known and various methods have been developed to address this, such as EIGENSTRAT
(Price et al., 2006). In fact both Lander and Vilhjalmsson, have argued that population
stratification, while complex, can be adequately addressed. Nonetheless, this is an issue that
has to be kept in mind when examining genetic data in the context of heritability, especially
for complex traits.
Non of this invalidates the significance of genetic results, but simply underlines the
importance of cautiously evaluating results. An example for this is seen in the results of
largest GWAS for schizophrenia (Ripke et al., 2014), which found the most significant signals
in the MHC class II region, which is the same genomic region that would cause problems in
the above example.
That being said efforts have been made by Ripke et al. (2014) to account for stratification.
In addition recent experiments have shown a plausible mechanism for how complement
component 4 (C4), which is located in the MHC locus, could be linked to schizophrenia
(Sekar et al., 2016). Over-expression of C4 led to increased synapse pruning in mice, during
early development, which the authors suggest could explain structural brain differences
found in some schizophrenia suffers, as well as cognitive deficits. Besides CNVs and
major deletions, as in DiGeorge syndrome, could provide useful information about disrupted
pathways at least for subsets of patients. Although Fosse et al. (2016) have argued, that the
increased risk of schizophrenia and other psychiatric conditions, found in association with
conditions such as DiGeorge syndrome might be better explained by significant disability
and the resulting social adversity.
1.2.3 Environmental Risk Factors
There are a large variety of environmental risk factors for schizophrenia which can include
neurodevelopmental factors, famine, childhood trauma, drug use, such as the smoking of
cannabis, and even gender and socio-economic status (Iyegbe et al., 2014) (see Table 1.3 for
a more complete list). One of the differences between environmental and genetic variables
to risk is their effect size. Individual common genetic variants found in highly polygenic
diseases tend to have at best a modest effect when expressed as odds ratios which are typically
between 1.1 and 1.4. Copy number variations tend to have significantly higher effects, with
a recent study estimating the odds ratios for CNVs to range from 2 to over 50 (Rees et al.,
2014). Environmental risk factors, in contrast typically range between 1.5 and 11.0.
In addition lifetime prevalence is known to vary dramatically across gender, country and
study, from 0.7 per 1000 to 12.8 per 1000 (McGrath et al., 2008), underlining the importance
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of environmental context. This point is illustrated by one review showing that incidence of
schizophrenia is significantly higher for migrants and their children, with Black and Pakistani
individuals having 10 and 16 fold higher incidence rates of schizophrenia respectively(Jb
et al., 2012).
One study examining environmental risk relating to ethnic minority status and urban
environment, Kirkbride et al. (2010) argued that targeting these factors successfully in black
and minority communities in England could prevent up to 22% of all psychotic illness and
27% in communities that are significantly affected. While this study was criticized for not
controlling for family history (Iyegbe et al., 2014), it also did not include a series of other
environmental factors that are only partially captured by ethnicity and urban status.
Given the much higher incidence of schizophrenia in migrants (Jb et al., 2012), and
concordance rates for twins with schizophrenia falling well below 50% (Narayan et al.,
2015), it is evident that the environment plays the dominant role in the development of
psychiatric disorders, and needs to be carefully considered.
Reopening the nature vs nurture debate is not necessary for this, as it is apparent that
every trait requires both. However genetic approaches have so far provided very little to
help patients, and heritability estimates that encompass populations who experience radically
different environmental pressures provide minimal useful information.
1.2.4 Gene Environment interactions
Turkheimer (2016) in a recent article while arguing that all traits are genetically influenced,
expressed doubt that genetics can provide a coherent insight into sufficiently complex diseases
or traits, by targeting problems at the wrong level of causality. He suggests that this will
undoubtedly remain true for behaviours in society while expressing reservations for the
usefulness in psychiatric disorders.
Despite this, approaches taking into account the environment and genetics have led to
valuable insights that could have direct benefits for patients and inform policy. This is
illustrated by the genetic interaction between cannabis use and genetics, where an AKT Ser-
ine/Threonine Kinase 1 (AKT1) variant was strongly implicated with a sevenfold increased
risk of psychosis in cannabis users (Di Forti et al., 2012). This approach can, therefore, lead
to testing of at-risk populations, and more targeted advice for patients.
In a similar manner finding biomarkers that can predict response to medications, such
as antipsychotics or mood stabilisers, could substantially reduce exposure to the number of
unsuccessful treatments.
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Context Environmental risk factor
Social Urban-rural dwelling










Birth defects / obstetric complications
Vitamin D
Prenatal maternal infections
Economic Developed vs developing country
Socio-economic status
Other Gender
Table 1.3 Environmental risk factors
Environmental risk factors for schizophrenia. Adapted from Iyegbe et al. (2014).
1.2.5 Stress Response and the HPA-axis
The stress response, since it can account for genetic and environmental factors, is one way
to contextualise psychiatric disorders. A consistent finding across studies in the psychosis,
and the wider psychiatric literature is immune deregulation. While the stress response, the
immune system and disorders of the brain, such as psychosis seem fundamentally unrelated,
this is not the case.
Chronic stress negatively impacts sleep which by itself can cause psychosis-like symp-
toms. Urbanicity, where sleep, especially in poorer neighbourhoods, may be affected, could
potentially be mediated this way. Chronic stress can also cause damage to brain regions, in
severe cases. Stress experienced by the mother during pregnancy, for example, has been
shown to affect multiple brain regions including the amygdala, frontal cortex, and hippocam-
pus (Weinstock, 2008) which are involved in emotion regulation, planning, and memory
respectively. Chronic stress in adult anxiety disorder has also been suggested to contribute to
damage in the hippocampus and frontal cortex (Mah et al., 2016). A proposed mechanism
for this can be seen in Figure 1.2.
The immune system has been consistently implicated in schizophrenia studies, using
omics data examining genetics (Ripke et al., 2014) as well transcriptomics (Gardiner et al.,
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2013; Hess et al., 2016) and proteomics (Levin et al., 2010) studies. The transcriptomic and
proteomic studies have found consistent up-regulation of the innate immune system. Such an
upregulation can be modulated by genetic, environmental and psychosocial stressors. Viral
and parasite infections, as well as toxins, have been linked to schizophrenia risk (Iyegbe
et al., 2014), and they can upregulate the innate immune system via pattern recognition
receptors (PRR) as seen in Figure 1.2. Psychosocial stressors can also have this effect, by
activating the hypothalamic–pituitary–adrenal (HPA)-axis, where cortisol can be released in
response to psychological factors.
Activation of the stress response via PRRs or the HPA-axis affects the quality of sleep,
increases cortisol, down-regulates the adaptive immune system and up-regulates the innate
immune system via TNF and IL-6. Since schizophrenia and mental health disorders, in
general, occur more frequently in individuals with childhood adversity, trauma, certain
infections and other external stressors this provides a plausible mechanism that can be
mediated by genetics.
The HPA-axis plays a pivotal role in this process and has been a topic of attention for
its role in psychosis. The HPA-axis fundamentally regulates cortisol production and down-
regulation through a feedback loop. As the name suggests, it starts in the hypothalamus
with corticotropin-releasing hormone (CRH) and vasopressin, which in turn stimulate the
secretion of adrenocorticotropic hormone (ACTH) in the pituitary gland. This leads to gluco-
corticoid production in the adrenal cortex (cortisol among them), and a negative feedback
loop in the pituitary and hypothalamus. Studies have also shown reduced hippocampal size
in schizophrenia subjects, while this could be attributed to a variety of causes it is notable
that the hippocampus has high levels of glucocorticoid receptors and individuals suffering
from chronic stress show atrophy of the hippocampus.
There is debate over sex differences in cortisol production (Kirschbaum et al., 1992),
with studies, in general, finding higher baseline cortisol levels in men, in addition to higher
cortisol in response to acute stress, while women showed higher cortisol levels in the weeks
following a chronic stressor (Paris et al., 2010). This may help explain sex differences in
neuropsychiatric disorders between genders.
A recent systematic review by Karanikas et al. (2014), concluded that high blood cortisol
levels in patients with first-episode psychosis (FEP) are a robust finding, while results
for saliva cortisol levels were inconclusive. The authors suggested this may be due to
differences in medication exposure in the latter case. In addition, longitudinal studies found
that cortisol levels decreased after antipsychotic treatment. Karanikas et al. (2014) conclude
that cortisol levels are up-regulated in psychotic episodes. The exact role of cortisol in
psychiatric disorders is unclear, as results correlating cortisol levels with PANSS scores were
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Figure 1.2 The Stress response and impact on the Brain
Figure detailing mechanisms by which stress can be transmitted to the brain causing damage. Psycho-
social stressors activate the HPA-axis, leading to signal transduction via hormonal transmission to
an upregulation of the innate immune system. This is also facilitated via infections or injury, by
activation of pattern recognition receptors (PRR) such as Toll-like-Receptors (TLR). This leads to
the activation of transcription factor NF-κB and TNF, IL-6 and IL-1 up-regulation. Activation of
microglia in the brain, and macrophage migration can lead to inflammation and cell death in the brain,
in chronic stress exposure. Adapted by permission from Springer Nature: Nature Publishing Group,
Nature Reviews Immunology, The role of inflammation in depression: from evolutionary imperative to
modern treatment target, Miller, A.H. Raison, C.L., Copyright 2014, (Miller and Raison, 2016).
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contradictory, which may indicate that while stress and cortisol levels are high during an
episode, they could be an acute response to the experience of symptoms.
Overall, the stress response and HPA-axis provide a framework which can account for a
significant amount of the schizophrenia and psychosis literature. This also fits into a liability
threshold model, based on biological, psychological, social and cultural factors, were a
high genetic risk can trigger chronic stress and anxiety, leading to social withdrawal, sleep
disturbances, and in severe cases damage to the brain, due to inflammation, oxidative stress
and apoptosis.
1.3 Gene Expression Studies
While genetic information is stored in the form of DNA, most biological functions are
performed by varying levels of enzymatically active proteins and to a lesser extent RNA
(ribozymes). This is encapsulated by the central dogma of biology, introduced by Watson and
Crick, which states that DNA stores information, transcribes genes to RNA, which ultimately
gets translated into Proteins. To capture the interplay between genetics and the environment,
gene expression or protein levels can be investigated. Both of these are non-static, and
changes are the direct result of external stimuli, in contrast to DNA, which remains static (at
least to the extent that needs to be considered in this thesis). This thesis will focus primarily
on the transcriptome (global gene expression) in whole blood.
The literature on gene expression for schizophrenia and psychosis in general, while not
small, is not comparable to the sample sizes found in genetics. Most expression studies
have until recently, managed to recruit a few dozen patients at best. While more recent
studies, and meta-analyses, have managed to increase those numbers, none have exceeded
500 patients. In comparison, GWAS studies have managed to secure genetic data from
tens of thousands of patients. To further complicate this, differences in patient recruitment
and methodology lead to significant problems in comparing and replicating results. Gene
expression is significantly influenced by medication, environment, time of data collection,
the microarray manufacturer and data processing to name just a few. While this provides
many advantages, it also complicates interpretation and replication of results.
In this section, I will review the Gene Expression literature primarily in the context of
schizophrenia. I will then examine the rationale of blood-based gene expression studies.
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1.3.1 Gene Expression Studies of Schizophrenia and other Psychosis
A recent meta-analysis of transcriptomics in Schizophrenia identified 25 studies using blood
(Hess et al., 2016) between 2005 and 2016. As noted before many findings in these studies
have not been successfully replicated. Horváth and Mirnics (2015) have argued that even
if issues with sample size, methodology and confounding variables are addressed, findings
are likely to stay inconsistent due to Schizophrenia being a spectrum disorder. As such
focus on differentially expressed genes is unlikely to provide much insight. They argue that
understanding at the pathway level is required.
Studies using gene enrichment or network analysis have indeed led to some insights
that replicate across studies, and some common themes have emerged. One study using
peripheral blood mononuclear cells (PBMC) found upregulation of pathways in the innate
immune system and RNA processing (Gardiner et al., 2013). This mirrors results from
in blood-derived lymphoblastoid cell lines (LCL) from over 400 patients (Sanders et al.,
2013) which also reported enrichment for immune-related function and miRNA processing.
One study that used network analysis and was able to control for medication in chronic
schizophrenia found that the most significant pathway was also related to the immune system,
and that this pathway was enriched for brain-expressed genes (de Jong et al., 2012).
The most extensive gene expression study to date was conducted by Hess et al. (2016),
and used data from 18 previously published studies (nine brain-based and nine blood-based).
Weighted network analysis revealed significant upregulation of modules in blood associated
with innate immune function (specifically TNF-alpha, NF-KB, P38 MAPK, IL-6, STAT3,
LCN2, DEFA 1-4), cellular stress responses (hypoxia, UV exposure, unfolded protein
response, apoptosis/p53 cascades), androgen response, RNA metabolism and oncogenesis.
Downregulation of genes was prominent in genes located on chromosome 22q11.
These perturbations are not unique to schizophrenia, however, with expression studies in
depression (Jansen et al., 2016), and PTSD (Breen et al., 2017) finding similar up-regulation
in the innate immune system and specifically related to interferon I pathway. Something that
is also supported by multiple brain-based studies in the case of schizophrenia (Arion et al.,
2007; Hess et al., 2016; Mistry et al., 2013; Saetre et al., 2007).
Overall gene expression studies find consistent changes in pathways associated with
the innate immune response, the stress response, mitochondrial dysfunction and miRNA
regulation, across multiple conditions and diseases. Horváth and Mirnics (2015) suggest that
environmental factors influence the same pathways for multiple psychiatric disorders and
that genetic predisposition determines the disease. While this is plausible, they ignore the
equally likely possibility that disease could be specified by the environment.
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1.3.2 The rationale of using Blood for Transcriptomic studies in Psy-
chiatry
Using blood-based studies for the psychiatric disorder may seem counter-intuitive, since these
disorders are often presumed to be based in the brain. However, changes in the brain have
detectable influences in periphery tissues. The best example is the fight-or-flight response,
which starts with the perception of danger in the brain and is then translated into physiological
responses, such as the secretion of adrenocorticotropic hormone into the bloodstream and is
mediated by the HPA-axis or other stress responses as discussed earlier.
It is also important that biomarkers are readily accessible if they are to be clinically
useful. While brain biopsies may be more likely to result in pathologically relevant markers,
the invasiveness of such a procedure prohibits its use in a clinical setting. Additionally,
blood-based studies have the advantage that patients can be followed up over an extended
period. Thus non-specific blood-based biomarkers, which may not be of diagnostic value by
themselves, could act as a starting point to justify more expensive and or invasive screening
methodologies.
1.4 Machine Learning for Psychosis
One major issue in the treatment of psychosis-related disorders is that diagnosis is still based
on somewhat outdated ideas regarding diagnosis groups. While there are practical reasons to
use these classifications, incorporating biological markers as is done in the case N-methyl-
D-aspartate receptor (NMDAR) antibody Encephalitis (Zandi et al., 2011) or DiGeorge
syndrome for example. While these cases are easy to identify with biological markers, due to
the straightforward causality, they represent important steps towards a more individualised
and targeted treatment approach.
In the case of first episode psychosis were multiple pathways are likely disturbed by
numerous unrelated mechanisms, a more sophisticated approach will be required. One
possibility is using machine learning techniques, which have in recent years led to significant
changes in numerous industries. Machine learning algorithms can "learn" from complex data
and identify previously unknown groups or relationships by unsupervised learning, or build
complex models to classify an input based on previously seen data.
A few attempts have been made to create classifiers for psychosis from transcriptomic
data. One study using 26 first episode psychosis patients and controls matched by age, gender
and ethnicity identified a 400 gene signature that can accurately distinguish patients and
controls (Lee et al., 2012). They claimed a sensitivity and specificity of 100% and 96%
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respectively. However, this study was severely limited since it did not replicate its findings,
or even split their data into a training and testing group. Taking into consideration the use of
400 genes used to classify just 26 patients, it seems likely that they were simply overfitting
data and these results are not applicable in other settings.
A more thorough approach to building a schizophrenia classifier by using blood-based
gene expression data was performed by Takahashi et al. (2010). They used artificial neural
networks in 52 antipsychotic-free schizophrenia patients and 49 controls. They also separated
training and test data, which other studies (Lee et al., 2012; Middleton et al., 2005) failed to
do. Using this approach, they achieved 87.0% accuracy in the test data. Nonetheless, these
results need to be interpreted cautiously, something the authors freely admit, since sample
size is still a significant issue.
A recent study by (Perkins et al., 2015) followed people with high-risk symptoms and built
a classifier, to predict which individuals would develop psychosis. Their algorithm achieved
an area under curve (AUC) of 0.88 and 0.83. Interestingly they achieved these results with
just 15 and 6 transcripts, which included Lipoproteins, IL-1 Beta, Matrix metalloprotein 7,
Apolipoprotein D, Factor VII, IL-7 and IL-8. Many of which have been linked to innate
immune function, and neuropsychiatric disorders.
Hess et al. (2016) used nine publicly available gene expression datasets to build classifiers,
resulting in the largest dataset for schizophrenia trained in this way. Since the available data
came from two distinct microarray platforms (Illumina and Affymetrix), they trained their
models on Illumina data and used Affymetrix datasets for validation. Using this approach,
they achieved a predicted AUC between 90% and 99% in the training data and retained
an AUC between 72% and 77% in the unseen test data. While all patients included had
chronic schizophrenia and most were on antipsychotics, the robustness of these results is
very encouraging.
While models would ideally also integrate gene expression, environmental and clinical
variables, there is simply not enough data with this breadth at the moment. This does,
however, provide an opportunity for further integration which will likely result in clearer
signals and more relevant classifiers. The development of these classifiers has enormous
potential benefits for the prevention or early treatment of people at risk of developing a
psychotic illness. For this to become viable, the results of small exploratory studies need to
be replicated and validated.
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1.5 Aims
Since much of the literature on Psychosis focuses on Schizophrenia or Chronic Psychosis,
and due to accumulating evidence of overlapping changes in core pathways shared by
neuropsychiatric disorders, the primary aim of this thesis is to investigate if these patterns
can be found in a first episode expression cohort. With the second arm of this thesis focusing
on Machine Learning approaches.
Chapter 2 discusses methods and datasets used in this thesis. The GAP study is introduced,
and both internal and external data is described, which includes transcriptomic, clinical,
demographic and genetic information. The preprocessing pipeline, which was designed for
gene expression, and the machine learning methods used in this thesis are covered in detail.
Chapter 3 describes the differential expression experiments between psychosis patients
and healthy controls. Network analysis is also performed using weighted gene co-expression
network analysis (WGCNA), to identify modules related to psychosis and symptom severity.
Gene enrichment is used to identify enriched pathways in differentially expressed genes and
modules.
Chapter 4 uses bootstrapping and machine learning to generate a series of classification
models and classification frequencies for samples, based on combinations of gene expression
data, PRS and demographic variables. Classification accuracy is assessed and compared to
symptom severity and later diagnosis.
Chapter 5 details a machine learning based classification approach using an external
gene expression dataset, first published by de Jong et al. (2012). The data is composed of
samples taken from chronic schizophrenia patients and controls. Multiple machine learning
algorithms are trained and merged into an ensemble model, to achieve higher classification
accuracy. Accuracy is estimated in a validation dataset, and in the internal GAP expression
data. Performance is compared in subgroups of the GAP data based on demographics,
diagnosis and symptom severity.





The data used for the analysis presented in the following chapters is taken primarily from
the GAP study conducted at the Institute of Psychiatry, Psychology and Neuroscience. This
is supplemented by a publicly available gene expression cohort for replication purposes in
chapter 5. In this section, I will give an introduction of these cohorts and provide an overview
of the available data.
2.1.1 Genetics and Psychosis (GAP) study
The Genetics and Psychosis GAP study is the primary source of data for this thesis. The
GAP study is an ongoing study, that is continuously recruiting patients, collecting follow-up
data, and integrating additional data since 2005. Multiple teams across hospitals, institutes
and disciplines are involved and have contributed to this study for over a decade. As such
it is a highly valuable resource, which contains a large number of participants, and data on
clinical, environmental and biological attributes. This section aims to provide information on
1.) the overall GAP cohort, 2.) Ethical approval and recruitment and 3.) a detailed overview
of the Expression, Genetic and Patient data used in this thesis.
The GAP cohort consisted of 737 first-episode psychosis patients, 389 healthy controls
and 48 mothers of patients, with varying levels of biological and environmental data.
Regarding biological data, blood and saliva samples have been collected for individuals, to
generate "omics" data. This includes genetics, transcriptomics, proteomics and methylation.
The methylation and proteomics were not used in this thesis. The primary focus of this
thesis is on transcriptomics from RNA microarrays (Illumina Expression array HT12-v4).
Genome-wide SNP data (Illumina Human Exome Chip), processed by Dr Evangelos Vassos
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(GAP Clinician), is also used. All transcriptomic data is derived from whole blood samples.
Where possible genetic data comes from the same blood samples used for transcriptomics,
otherwise saliva was used. Genetic and transcriptomic data was matched to individuals in
collaboration with Dr Evangelos Vassos.
Ethics and Recruitment
The Study received ethical approval from the South London and Maudsley SLaM, as well as
from the Institute of Psychiatry Local Research Ethics Committee, Institute of Psychiatry,
Psychology and Neuroscience (IOPPN)/South London and Maudsley (SLaM) research ethics
approval number: 135/05. Informed written consent was obtained from all participants in the
study by the GAP team.
As part of the GAP study (Di Forti et al., 2015, 2009). Patients aged 18–65 years who
presented with first-episode psychosis at the inpatient units of SLaM were approached for
recruitment. Patients were invited to participate if they met the ICD-10 criteria for a diagnosis
of non-affective (F20–F29) or affective (F30–F33) psychosis (Guest et al., 2014), validated
by administration of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
(Aboraya et al., 1989), they were re-contacted after the start of treatment. Between May 1,
2005, and May 31, 2011, 461 patients with first-episode psychosis were recruited. The cohort
consisted of a diverse multi-ethnic population. Further patient information, blood samples
and genetic ancestry were acquired as described previously (Di Forti et al., 2012). During
the same period, a total of 389 control individuals were recruited. These individuals were
aged 18–65 years and were similar to the local population regarding gender, ethnic origin,
education, and employment status, and socio-economic status. Recruitment of controls was
done using Internet and newspaper advertisements and by distributing leaflets at train stations,
shops, and job centres. Volunteers were administered the Psychosis Screening Questionnaire
(Bebbington and Nayani, 1996) and were excluded if they met the criteria for a psychotic
disorder or if they reported a previous diagnosis of psychotic illness.
Gene Expression Data
Whole blood samples were collected using PAXgene tubes for RNA. Psychotic patients were
stabilized using antipsychotics for a week before taking blood samples. Samples were run at
the NIHR Biomedical Research Centre for Mental Health (BRC-MH) microarray facility at
the MRC-SGDP, IOPPN, and King’s College London. Microarrays were run following the
manufacturer’s protocol using Illumina HT-12 V4 beadchips (Illumina, USA), which contain
approximately 48,000 probes.
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The raw probe level gene expression data had been processed in GenomeStudio and
exported for further analysis in R using the Lumi package (Du et al., 2008). The data was
then analysed using the Illumina Gene Expression pre-processing pipeline developed by the
BRC-MH Bioinformatics core (see Section 2.3 for more details).
Figure 2.1 provides an overview of how many samples were available at each stage of
processing. In short out of 679 samples that were available to the microarray facility, 608
samples were provided after quality control in GenomeStudio. Only 480 (287 cases, 193
controls) of these samples fulfilled my initial inclusion criteria. This is because the initial
608 samples included 114 follow-up samples, as well as 14 samples representing mothers
of patients. The preprocessing pipeline used network analysis for outlier detection, which
resulted in the removal of an additional 97 samples (see Section 2.3.3 for details). It should
be noted that while the RNA integrity number (RIN) was included in the analysis, we did
not set a cut-off for it, instead it was incorporated into the pre-processing stage (see section
2.3.4). As a result 24 samples had a RIN below 8, with the lowest sample that passed our
quality control pipeline having a RIN of 5.
After preprocessing, an additional 103 samples were excluded for a variety of reasons.
A total of 34 samples were found to be duplicates, 31 samples could not be used since they
could not be identified or had withdrawn consent and 5 samples had incomplete information
for key variables (age, ethnicity, clinical gender). Finally 33 samples were removed since
they were did not have First Episode Psychosis when the blood was taken.
This resulted in 280 samples (131 FEP and 149 controls) that were available for analysis.
Chapter 3 provides analysis of the demographics from a case control perspective. The same
samples are also used in Chapters 4 and 5, however the 131 FEP patients are for some
analyses separated into Schizophrenia and Other Psychosis (based on ICD10 and DSMIV
diagnosis). Table 2.1 provides an overview of demographic variables and medication for all
3 groups.
Genetic Data
Samples of patients and controls were genotyped using the Illumina HumanCore Exome
BeadChip at the BRC Genomics Laboratory (South London and Maudsley NHS Trust, King’s
College London). Sample DNA was derived from either blood (80%) or saliva (20%). If
both samples were available for an individual Blood was used. Genotypes were processed
using Genome-studio Analysis (version 2011.1, Illuminia Inc.)
Genetic data was processed, and Polygenic Risk Scores were calculated by Evangelos
Vassos as described in (Vassos et al., 2017). Calculation of PRS was performed using the
Psychiatric Genomics Consortium (PGC2) data as the discovery sample, leaving out the
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Figure 2.1 GAP Quality Control of Samples
Flowchart of samples that were removed during processing and experimental design. A total of
679 blood samples were used. After initial processing in genome studio 608 were suitable for
further analysis. A total of 128 samples were excluded since they were blood samples from followup
appointments. A further 97 samples were removed in the preprocessing pipeline (see Section 2.3),
primary due to network based outlier detection. Finally a total of 103 samples were excluded for a
variety of reasons related to their clinical records. This included 34 samples that were either duplicate
entries, or had conflicting identifications. A further 31 samples could not be used due to clinical
records not being available. Five samples were excluded due to ambiguous demographic data. Finally
33 samples had to be removed since they were identified as Chronic Psychosis, Non-organic Psychosis,
or unconfirmed First Episode Psychosis.
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Table 2.1 GAP Demographics
Control Other Psychosis Schizophrenia
n 149 63 68
Gender = male (%) 86 (57.7) 31 (49.2) 45 (66.2)
Age (mean (sd)) 29.87 (10.53) 30.03 (9.22) 26.59 (7.67)
Ethnicity (%)
Asian 10 (6.7) 6 (9.5) 6 (8.8)
Black 43 (28.9) 22 (34.9) 33 (48.5)
Other 10 (6.7) 5 (7.9) 5 (7.4)
White 86 (57.7) 30 (47.6) 24 (35.3)
Medication (%)
Amisulpride 0 (0.0) 1 (1.6) 0 (0.0)
Antipsychotic free 0 (0.0) 9 (14.3) 9 (13.2)
Aripiprazole 0 (0.0) 3 (4.8) 9 (13.2)
CONTROL 149 (100.0) 0 (0.0) 0 (0.0)
Haloperidol 0 (0.0) 4 (6.3) 2 (2.9)
Olanzapine 0 (0.0) 24 (38.1) 22 (32.4)
Quetiapine 0 (0.0) 2 (3.2) 4 (5.9)
Risperidone 0 (0.0) 13 (20.6) 14 (20.6)
Sulpiride 0 (0.0) 0 (0.0) 1 (1.5)
Trifluoperazine 0 (0.0) 0 (0.0) 1 (1.5)
NA 0 (0.0) 7 (11.1) 6 (8.8)
Table of GAP demographics by control, other psychosis and schizophrenia. Gender, Age, Ethnicity
and Medication are listed for the 3 groups.
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Welcome Trust Case Control Consortium 2 data since 80 of those samples were present in
GAP (Psychosis Endophenotypes International Consortium et al., 2014). Genetic data were
available for 445 FEP cases and 265 controls in GAP. We successfully identified 243 out of
280 samples as having both Gene expression and PRS data available. The first ten principal
components were used to adjust PRS.
Missing Data
GAP presents a challenge due to its broad and complex nature. The cohort contains a
significant amount of information far beyond a case-control study. Data were collected by
multiple hospitals over more than a decade, and by dozens of physicians and clinical staff.
Combining clinical data with biological data was challenging, as not all patients gave
consent for the same data, or were subject to different subsets of tests. While GAP has
a wide variety of data on family history, psychological tests, assessments, clinical notes,
and biological samples, this full range was rarely available for an individual. As such
compromises had to be made in selecting data for analysis.
The work in this thesis included individuals with complete records for first episode
psychosis, age, ethnicity and gender. In cases where additional data is required, such as
Medication, BMI, PANSS, diagnosis (ICD-10 or DSMV) or Polygenic Risk Score, one of
two strategies is used.
These are imputation approaches using machine learning techniques or literature-based
predictions. Alternatively, subset analysis on the part of the cohort with full information is
performed.
This is subject to a lot of researchers degrees of freedom and can introduce significant
bias by testing many hypotheses and reporting only significant ones. To avoid this, the aim is
to be transparent about all analysis that was performed posthoc.
No attempt was made to adjust for the number alternative hypotheses tested, but results
that are the result of these analyses would need to be independently verified in separate
datasets regardless.
2.1.2 Chronic Schizophrenia Data Set
The Chronic Schizophrenia data used for validation and machine learning is freely available at
the ArrayExpress Archive (https://www.ebi.ac.uk/arrayexpress) with the identifier E-GEOD-
38484. It was originally described by de Jong et al. (2012). In the original study, 239 samples
were used from 2 platforms. Out of these 202 were from the Illumina H-12 microarray
and 37 from Illumina H-8 microarray. The decision was made to exclude the 37 samples
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from the Illumina H-8 array from analyses in this thesis, to avoid additional preprocessing
and quality control steps, which could increase variation. We obtained the E-GEOD-38484
gene expression data using the ArrayExpress R package (Kauffmann et al., 2009). The gene
expression data were mapped to corresponding reliably expressed probes in the GAP data
where possible. Missing probes were substituted with probes corresponding to the same gene
symbol.
2.2 Bio-informatics Methods
The main bioinformatic methods used in this thesis are differential gene expression (DGE),
WGCNA and gene enrichment, and are described below. All analysis and programming was
performed using R version 3.1.2 (Team, 2013), using R studio, unless otherwise specified.
2.2.1 Differential Gene Expression (DGE) Analysis
Standard differential gene expression (DGE) analysis was performed, using the R package
LIMMA (Smyth, 2004) (version 3.26.8). Prior to analysis CellMix proportions, age, sex and
ethnicity were regressed out. Probes were declared significantly differentially expressed if
the false discovery rate (FDR) adjusted q-value was less than 0.05 and the absolute log fold
change was above 0.1.
2.2.2 Weighted Gene Co-Expression Network Analysis (WGCNA)
The weighted gene co-expression network analysis (WGCNA) R package (Langfelder and
Horvath, 2008) was used to generate gene expression modules. Duplicate probes mapping
to the same gene were filtered out prior to analysis, since they tend to be highly correlated.
This was done by comparing the average expression across all samples and keeping only
the highest expressed probe for each gene for further analysis. An adjacency matrix was
generated using a β of 6 which met the scale-free topology criteria. A hierarchical clus-
tering tree was created and modules were originally defined using the WGCNA function
cutreeDynamic with a minimum module size of 20. Modules were then merged using the
mergeCloseModules function with a threshold value of 0.25. The eigengene of each module
was then correlated with phenotypic information.
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2.2.3 Gene Enrichment Analysis
All enrichment analysis was performed using the UserListEnrichment function in R (for
details see https://cran.r-project.org/web/packages/WGCNA/index.html). This function is
part of the WGCNA package (Langfelder and Horvath, 2008). Enrichment analysis, for the
results of the LIMMA analysis, was performed by testing differentially expressed probes
(q-value =< 0.05 and ± logFC > 0.1). All probes that did not pass the q-value threshold
were included as background. Gene enrichment for probe lists corresponding to the modules
identified in WGCNA analysis, was performed by using core genes of each module which
were defined as probes with an above average module membership. All probes below this
threshold, or belonging to other modules were labelled as background.
In all cases KEGG (Kanehisa et al., 2004) and GO (Ashburner et al., 2000) databases
taken from the Enrichr website were used (http://amp.pharm.mssm.edu/Enrichr/stats, ac-
cessed 05.July.2016). The databases used were ”KEGG 2016”, ”GO Molecular Function
2015”, ”GO Cellular Component” and ”GO Biological Process 2015”. Additionally, internal
lists from the UserListEnrichment function in WGCNA were used. These were Brain Mod-
ules (useBrainLists), Brain Region Markers (useBrainRegionMarkers) and Blood Atlases
(useBloodAtlases). Gene lists specifically compiled for Psychosis were included from publi-
cations by Purcell et al. (2014) and Pirooznia et al. (2016). Result categories that contained
less than 5 overlapping probes were filtered out.
2.3 Transcriptomic quality control Pipeline
Transcriptomics has become a widely used technology in biology, which allows investigation
of full expression in a tissue. This allows detection of transcriptional changes between
time-points, tissues, diseases or environments. While this makes the technology extremely
powerful and versatile, many factors must be taken into consideration, regarding experimental
design, sample handling, data processing and downstream analysis.
Two key technologies are commonly used for transcriptomics, one of them is RNA-
sequencing, which would have been cost prohibitive for this project, and the other is mi-
croarray technology based on hybridization. Gene expression microarrays fix, typically
tens of thousands, complementary RNA to a microarray. Sample RNA is then labelled with
fluorescent probes and can hybridise with the corresponding RNA on the array. This process
allows high-throughput measurements of the relative levels of all included transcripts for a
sample.
In this section, the processing of gene expression data for the thesis is explained.
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2.3.1 Gene Expression Preprocessing Overview
The pre-processing of GAP gene expression data was performed using a modified version of
the gene expression processing workflow developed by Dr Stephen Newhouse (Newhouse,
2013) for Illumina Beadarray data. The workflow contains the following five core steps.
1. Background Correction and Normalisation.
2. Outlier Detection.
3. Adjustment for confounding variables.
4. Test for expression of sex markers.
5. Detection of expressed probes.
2.3.2 Background Correction and Normalisation
Background correction in microarray gene expression experiments is a critical step in quality
control, the Illumina BeadArray platform allows for background correction using negative
non-specific control beads, of which thousands are present on each array. After careful
consideration, we opted for three progressive steps which start with model-based background
correction, followed by Log2 transformation and Robust Spline Normalisation (RSN).
This was based in part on analysis by Schmid et al. (2010) which compared a range of
preprocessing methods and found that background correction in combination with Log2 and
RSN processing provided the most accurate results across a multitude of measures. The
background correction method used in that study was the standard suggested by Illumina
which was previously reported not to make the best use of negative control beads(Barnes
et al., 2005), and alternative methods have since been developed to address this, notably
model-based background correction for BeadArrays (MBCB) (Ding et al., 2008) . The
MBCB package (Xie, 2010) implements this and several other proposed methods within R
as described by Allen et al. (2009). Of these, we use Maximum likelihood estimation.
Expression data was then further processed by using the lumiExpresso function from
the Lumi package (Du et al., 2008). Background correction was disabled, and the log2
transformation was performed followed by Robust Spline Normalisation.
2.3.3 Network Analysis for Outlier detection
To detect outlying samples within both the control and psychosis group, a network-based
approach was used. This was developed by Dr Stephen Newhouse for this pipeline and
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is based on work by Oldham et al. (2012). This process involved generating networks of
samples within each group based on expression data. Outliers were removed if standardised
connectivity (Z.K) was below the threshold of -2. Z.K provides a measure of connectivity
with the other samples in the group. A Z.K between -2 and -3 is recommended by Oldham
et al. (2012) to identify members of the network that are substantial outliers. These samples
are removed, and a new network is built on the remaining samples until all samples pass the
Z.K threshold.
2.3.4 Correcting for technical and other confounding variables
Correcting for Batch Effects is essential in expression analysis, as any variation can affect
reported expression values. It has been demonstrated that Batch effects when not properly
accounted for can have a greater effect on the data than the underlying biological signal (Leek
et al., 2010). To address this, we received available data on how samples were processed from
the BRC-MH microarray facility at the Medical Research Council (MRC)-Social, Genetic &
Developmental Psychiatry Centre (SGDP) (courtesy of Charles Curtis and Sang Hyuck Lee).
Since there is the possibility that batch effects can be introduced by unknown variables,
Surrogate Variable Analysis SVA is used to identify hidden variables, via the Surrogate
Variable Analysis (SVA) package (Leek et al., 2012). Of the known lab variables, we first
removed highly correlated ones. Following this, we performed a principal component analysis
on the gene expression matrix and extracted the first principle component. We identified four
batch variables that were significantly correlated with the first principle component. The
significant batch variables were "Date samples were thawed", "Concentration of initial RNA",
"Concentration of Labelled cRNA", and "Date of RNA purification". It should be noted that
while the RNA integrity number (RIN), was included in this step, it was not significantly
correlated with the principle component. We therefore did not adjust for RIN, nor did we use
a minimum cut-off for RIN.
We used multiple linear regression with the four batch variables as independent variables
in the model. Residuals for all probes were extracted, and the average gene expression
value of each sample was added to all probe residuals of that sample. Following this
surrogate variable analysis was performed on the gene expression matrix, to capture hidden
technical and biological variables that confound the data. As long as hidden variables are
not substantially correlated with the underlying signal of interest (in this case Phenotype or
Control vs First Episode Psychosis), SVA can be used to estimate hidden variables. This
has been illustrated in simulated gene expression data (Leek and Storey, 2007), as well
as in published data (Leek et al., 2010). SVA was performed on all datasets used in this
thesis. Phenotype representing the binary labels for Control and Psychosis samples was
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included in the model to preserve the biological signal between these groups. While in
early iterations of preprocessing, hidden variables were identified, this was not the case in
the final iteration of the pipeline used, or for publicly available data that had previously
undergone preprocessing. Since SVA can potentially detect con-founders from any source,
be it biological, environmental, or due to sample handling, this increases the confidence in
our data and subsequent results.
The CellMix package (Gaujoux and Seoighe, 2013) makes use of some publicly available
lists of marker genes for cell types to identify the likely composition of cells in a sample.
These cell proportion estimates can be used in downstream analysis as covariates or regressed
out as is described for technical variables above. The standard whole blood database by
Abbas et al. (2009) was used to assess cell proportions with CellMix.
2.3.5 Expression based Sex detection
To detect potentially mislabelled samples, we performed a sex detection step based on X
and Y chromosome expression. This was based on the X Inactive Specific Transcript (XIST)
and Protein Kinase, Y-Linked, Pseudogene (PRKY) probes. XIST is usually only expressed
in females, while PRKY is located on the Y chromosome and expressed in men. Samples
that did showed aberrant expression for these probes were flagged, and additional records
were individually examined. Initially, two samples were flagged, and they were ultimately
excluded from the analysis.
2.3.6 Probe Selection
For each sample, probes were defined as expressed if background corrected mean expression
for each probe was above the mean expression of negative beads, in the background corrected
data, before normalisation. An additional step was performed in which only probes were kept
which showed expression in more than 80% of sample per phenotype of interest (Control
and Psychosis). We performed variations of this process to test reliability and found high
agreement between methods (data not shown). This included the addition of Gender in the
second step, resulting in four groups, by splitting Controls and Psychosis samples into two
groups each, before detecting probes expressed in 80% of samples in those four groups. The
probes identified as reliably expressed using this approach were then used in later analyses.
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2.4 Machine Learning Methods
Machine Learning is a field that merges computer science and statistics with the aim of
solving a problem in a way that has not been defined explicitly. Broadly speaking this means
defining a task for a program and letting the program "learn" solutions from available data.
The distinction between traditional statistics and machine learning is not always obvious,
and definitions of what constitutes machine learning vary. In this thesis, a definition that is
restricted to generating models capable of predicting categorical or numerical outcomes is
used. This definition includes models built to predict a clinical diagnosis, or a model built to
predict polygenic risk score. Methods that fall under this definition can range in complexity
from Artificial Neural Network to simple Linear Regressions.
While these approaches can accomplish a broad spectrum of tasks, it involves several steps
that need to be carefully considered to reach an optimal outcome. Appropriate preparation of
data, selection of algorithms, training models, testing models and interpreting them correctly
is vital.
In the following sections I will provide an overview of the steps involved in developing
machine learning classifiers as well as the algorithms that were used in this thesis.
2.4.1 Data Preparation
Machine learning requires careful data preparation to generate predictive models. While
this seems obvious, it turns out to be a complex topic. Some algorithms can handle varying
amounts of missing, mislabelled or inaccurate information. Careful characterisation of
predictive and outcome variables is therefore essential for all but the most trivial tasks.
It is also critical to consider how data is processed, how many variables are used and to
what extent they are correlated. A large number of predictors (in this case RNA transcripts)
that exceed the number of available samples for prediction (patients and controls) can easily
lead to a classifier that identifies a unique signature for each sample by overfitting. Such a
classifier may be highly accurate in the data it is trained on but would have no value in any
other dataset. In addition, a large number of predictors can cause additional problems, by
increasing processing time in a non-linear fashion, depending on the approach used.
This thesis is primarily based on gene expression data, with thousands of transcripts and
only hundreds of samples, as such we use several methods to reduce the number of predictors.
We define a threshold to remove the most highly correlated predictors, as two perfectly
correlated predictors provide no additional information. We further remove predictors
with the least variance, as they provide little information. The thresholds used for this are
mentioned in the corresponding chapters. While this leads to a reduction of information
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Figure 2.2 Cross-validation
Schematic representation of threefold cross-validation. The data is split into three thirds. Each third
is iteratively left out from model building and the data is predicted on that group. Republished with
permission of Springer New York, from Applied Predictive Modelling by Johnson, Kjell; Kuhn, Max;
permission conveyed through Copyright Clearance Center (Kuhn and Johnson, 2013).
except for the most extreme examples, from a practical standpoint, this is a reasonable
strategy.
2.4.2 Re-sampling Methods
To reduce the risk of over-fitting a variety of resampling methods can be used. The most
common ones are cross-validation, repeated cross-validation and bootstrapping.
Cross-validation partitions the data into N number of equally sized sections. N number
of models are then built, with each leaving out one of the predefined sections. The models
are then evaluated on the left out data, and the results of all N models can be summarised
to assess likely performance in new data. This process can be repeated for different tuning
parameters, algorithms or predictors to find more robust combinations of all of them, before
fitting a final model on the full data. See figure 2.2 for a schematic representation.
Repeated cross-validation is an extension of this that simply repeats this process several
times, each time partitioning the data in a new way. Repeated cross-validation provides the
best performance by balancing both bias and accuracy.
Bootstrapping functions differently to cross-validation. Where cross validation uses a
subset of the overall to train, a bootstrap draws a random sample with replacement from the
data (Efron and Tibshirani, 1986). This means that samples can appear multiple times in the
training data. On average 63.2% of the samples are used in each bootstrap, meaning that
37.8% of the data used for training in each bootstrap iteration is duplicated. This also means
that 37.8% of the data is on average not used for training, and can be used in testing later on.
See figure 2.3 for a schematic representation.
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Figure 2.3 Bootstrap
Schematic representation of bootstrap resampling. Training data for the model is drawn with
replacement from the original input data. Predictions are made on the samples that do not occur in
the training data for the bootstrap iteration. Republished with permission of Springer New York, from
Applied Predictive Modelling by Johnson, Kjell; Kuhn, Max; permission conveyed through Copyright
Clearance Center (Kuhn and Johnson, 2013).
2.4.3 Generalised Linear Models with Regularisation (Glmnet)
Generalised linear models with regularisation are computationally efficient and well-defined
(Hastie et al., 2009). This thesis makes use of the Glmnet package for R (Friedman et al.,
2010) which offers efficient approaches for fitting generalised linear models with regulari-
sation using lasso or elastic-net penalty. This is also covered by (Kuhn and Johnson, 2013)
and integrated with the caret package. Glmnet has the advantage of being able to handle
large numbers of correlated predictors and internally selecting predictors. This approach
also provides estimated ranks of importance for the predictors in the final model. As such
the GLMNET package provides an interpretable and efficient approach for initial machine
learning experiments using gene expression data, where the number of predictors often
outstrip the number of available samples.
2.4.4 K-Nearest neighbour (KNN)
K Nearest Neighbour is one of the simplest and most widely implemented(Altman, 1992)
supervised learning methods. In simple terms, KNN predictions rely on calculating the
distance between samples and assigning predictions based on the closest sample used to
train the predictive model. The distance between samples can be defined in various ways
depending on context, but the most common metric is Euclidean distance (Kuhn and Johnson,
2013). This means that processing of data, especially scaling as well as the number of
predictors have a significant impact on this algorithm. The curse of high dimensionality
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is a well-known problem in machine learning, and feature selection, as well as processing,
becomes important (Aggarwal et al., 2001). We use KNN implementations via the caret
package (Kuhn, 2008), for two purposes. One is for imputation of missing values based on a
small number of predictors, and the other is as part of an effort to build ensemble classifiers
from multiple classifiers built using different algorithms.
2.4.5 Naive Bayes (NB)
Naive Bayes represents a family of classifiers based on Bayes’ theorem (Efron, 2013) , with
a core assumption of uncorrelated predictors. Bayes’ theorem is simply stated as follows:
Bayes′theorem : P(A|B) = P(B|A)×P(A)
P(B)
(2.1)
Where A is a categorical outcome and B is a predictor. The probability of observing the
outcome or predictor is represented by P(A) and P(B) respectively. P(B|A) is the probability
of the predictor given an outcome and P(A|B) is the probability of an outcome given the
predictor. Naive Bayes algorithms use an assumption of independence between predictors to
calculate the likelihood for all predictive values with the outcome variable. The likelihood of
all predictors is ultimately merged to create predictions. While the predictors here are not
independent, Naive Bayes can perform surprisingly well despite this assumption, and modern
implementations report that additional processing can produce results that are comparable to
those seen with support vector machines (Rennie et al., 2003). In this thesis we use the Naive
Bayes implementation from the klaR (Weihs et al., 2005) R package, which is supported by
the caret package (Kuhn, 2008).
2.4.6 Random Forests (RF)
Random Forests (Breiman, 2001) is one of the most widely used machine learning algorithms,
due to the many packages that are available for implementation, high performance, protection
from over-fitting, and ease of tuning and interpretation. A study of 179 popular machine
learning packages across programming languages, found that Random Forests showed the
best performance across 121 examined datasets. Three of the top five performing packages
were RF implementations (Fernández-Delgado et al., 2014). Random Forests are an ensemble
method that generates multiple decision trees and uses a random set of predictors for each
tree. This process usually involves generating thousands of unique decisions trees with
relative weak predictive power. The final prediction of a Random Forest for a sample is the
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average, or majority prediction of all trees. The Random forest implementation in this thesis
is via the randomForest package (Liaw and Wiener, 2002).
2.4.7 Support Vector Machines (SVM)
Support Vector Machines (SVM) was introduced by Cortes and Vapnik (1995) and have
provided the best performance in predictive modelling until it became practical, due to
computing power, to train finely tuned neural networks on large datasets. SVM algorithms
are still widely used and performed as similar to random forests without additional fine-tuning
by the user (Fernández-Delgado et al., 2014). SVM algorithms use kernel functions that
are applied to available features. This approach allows for operations in higher dimensional
space, which allows data that would otherwise not easily be separable with a hyperplane to be
separated. For this thesis we use SVM with linear and polynomial kernels, implemented by
the e1071 (Meyer, 2001) and kernlab (Karatzoglou et al., 2004) respectively. Both packages
are integrated with the caret package (Kuhn, 2008).
2.4.8 Artificial Neural Networks (ANN)
Arguably the most powerful machine learning methods to date make use of Artificial Neural
Networks (ANN) in some form or another. They were originally conceived in the 1940s
and 50s by revelations about the animal brains interconnection of neurons and an interest
in artificial intelligence. This led to the idea of perceptrons (Rosenblatt, 1958) which are
mathematical representations of neurons. Simply put a single perceptron produces a binary
response based on several input (I) values. Each input is assigned a weight (w), and if the
sum of the weighted inputs exceeds a threshold (σ ) the perceptron fires.




wiIi ≥ σ else output = 0 (2.2)
Multiple perceptrons can be interconnected by creating layers that overlap in the input
they receive or pass their output to other perceptrons, thus creating complex networks.
This can quickly become very computationally intensive (Minsky and Papert, 1969), which
prevented the use of Neural Networks until recently. In this thesis the pcaNNet from the
caret package (Kuhn, 2008) was used, which is based on work by Ripley (1996). This
implementation reduces computation time by using principal components to reduce the
number of features.
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2.4.9 Machine Learning Ensembles
Ensemble models are as the name suggests an ensemble of machine learning models, which
aim to provide higher performance than the individual models. Ensemble approaches have in
recent years led to the best performances in machine learning competitions, with bagging,
boosting and stacking often being combined. However, they can be difficult to tune and
implement in reality due to their complexity. Ensembles are often described in 3 subcategories.
These are bagging, boosting and stacking.
Bagging or bootstrap aggregation is exemplified in random forests, where the ensemble
is constructed from multiple models built on a random subset of the data. The resulting
ensemble takes an unweighted majority vote of its constituent models to make predictions.
Boosting is an iterative process that builds an initial model, and emphasises prediction of
misclassified data-points in following iterations. While this can lead to more accurate results,
research indicates it leads to over-fitting and poor performance for supervised classification
problems if there is a significant amount of uncertainty about the prediction labels. This is
the case for mental health categories which are often highly heterogeneous and have high
levels of uncertainty attached to them due to the subjectivity involved in making diagnoses.
While boosting is used in this thesis, this is done within the implementing of the stochastic
gradient boosting (gbm) package (Ridgeway, 2007) to train a stacking ensemble.
Stacking is an approach that combines the predictions of other algorithms. The Stacking
algorithm can be trained with any number of algorithms and uses the predictions of previous
algorithms as features. It is desirable to use uncorrelated predictive models for stacking
ensembles since perfectly correlated model predictions do not add more information. Ini-
tial algorithms were therefore selected to represent different families of machine learning
classifiers, which increases the likelihood of predictions being uncorrelated. The algorithms
were also chosen for the high performance in the extensive analysis of machine learning
algorithms on 121 datasets (Fernández-Delgado et al., 2014). The input models chosen
here are glmnet, SVM (with linear and polynomial kernels), pcaNNet, nb and rf. Two
SVM algorithms were included as the kernels significantly alter performance. In the case of
neural networks, pcaNNet was used, as it uses principal components of available features to
reduce dimensionality, and thus computational time. Stacking is implemented here using the
caretEnsemble package (developer version) (Mayer, 2017). As mentioned above gbm is used
to combine initial models built using the caret package for the final stacking ensemble in this
thesis. This algorithm was chosen for the high performance and implementation of boosting.
The rationale was the danger of over-fitting would be limited when using a handful of initial
model outputs as predictors for each sample. Bootstrapping was used for the construction of
input models, and the ensemble model.
Chapter 3
Differential Expression and Network
Analysis
3.1 Introduction
In recent years genome wide association studies (GWAS) have resulted in a substantial
advance in our understanding of the genetic components to Psychotic Disorders, such as
Schizophrenia and Bipolar Disorders (Ripke et al., 2014). Much less focus, however, has
been given to high-throughput gene expression analyses in the context of these disorders.
While complementary to GWAS, gene expression microarray studies have the advantage
of not just analysing largely static genetic factors, but potentially reflecting dynamic responses
to additional factors such as drug use, stress, age and other environmental factors. This is
important since psychotic disorders are the result of a complex gene-environment interplay.
An important factor to consider when performing gene expression studies is the iden-
tification of a disorder relevant tissue. For pragmatic reasons, in this study, we chose to
study transcriptional changes in whole blood, which is easily accessible and minimally
invasive. There is an established literature of using blood for gene expression studies of a
variety of psychiatric conditions, which include studies looking specifically at psychosis and
schizophrenia. However sample sizes in this area have been small, ranging from dozens to
about 100 patients (de Jong et al., 2012; Gardiner et al., 2013; Kumarasinghe et al., 2012;
Kuzman et al., 2009; Lee et al., 2012; Wu et al., 2016). In addition few studies in this area are
directly comparable, due to differences in microarray platform, and processing of results. In
an attempt to address this Hess et al. (2016) recently pooled 9 brain, and 9 blood expression
datasets for schizophrenia. However, it is as yet unclear if gene expression in first episode
psychosis mirrors these expression patterns.
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The aims of this study were, therefore, to identify genes with altered expression between
first episode psychosis patients and controls. We performed a differential gene expression
(DGE) analysis, followed by gene enrichment analysis and weighted gene co-expression
network analysis (WGCNA). In addition, pathways associated with symptom severity were
examined, by using PANSS. Finally, we examined the impact of medication.
3.1.1 Aims
Our aims for this study were as follows.
1. Explore differential expression between first episode psychosis cases and controls and
tie this into the existing literature.
2. Find enriched pathways for differentially expressed probes.
3. Construct gene expression networks from the available data using WGCNA.
4. Find enriched pathways for WGCNA modules.
5. Correlate differentially expressed genes and modules with PANSS scores.
6. Estimate effect of antipsychotic medication on gene expression.
3.2 Methods
3.2.1 Gene Expression Data
The Genetics and Psychosis study was used in this analysis. Ethical approval, recruitment
and detailed preprocessing are described in chapter 2.
In short, all analysis was performed using R version 3.1.2 (Team, 2013). We performed
rigorous quality control, by pre-processing the data using an adapted in-house developed
pipeline as described in chapter 2.
In short, the pipeline takes raw gene expression data exported from Illumina’s Genome-
studio, performs background correction (Xie et al., 2009) using negative bead expression
levels to correct for noise. Lumi version 2.22.1 (Du et al., 2008) was used to log base 2 trans-
form the data followed by robust spline normalization (Du et al., 2008). Outlying samples
were iteratively identified using fundamental network concepts and removed, following the
methods described by Oldham et al. (2012).
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To reduce the influence of batch effects, we identified significant confounding variables
by using the first principle component of housekeeping and undetected probes and regressing
this against technical variables. In cases where the variables were significantly associated
with the first principle component, they were regressed against expression for each probe, and
the mean adjusted residuals were taken forward. The resulting adjusted expression matrix
was subjected to Surrogate Variable Analysis, using the SVA package (Leek et al., 2012),
to identify potential unknown batch effects. Following this, we compared recorded gender
with gender determined by XIST and PRKY probes, and excluded samples that showed a
mismatch. Finally, we excluded all probes that could not be reliably detected in 80% of
the samples in at least one diagnostic group. We used the R package CellMix version 1.6
(Gaujoux and Seoighe, 2013), to test for potential significant differences in whole blood cell
populations between cases and controls. Before further analysis we controlled for CellMix
derived cell proportions, Age, Gender and Ethnicity using a linear model to create an adjusted
expression matrix.
3.2.2 Linear Models for Microarray Data (LIMMA)
To identify differentially expressed genes (DE), the R package LIMMA (Smyth, 2004)
(version 3.26.8) was used. Cell proportions, age, sex and ethnicity were previously regressed
out. Probes were declared significantly differentially expressed if the FDR (false discovery
rate) adjusted q-value was less than 0.05 and the absolute log fold change was above 0.1.
Probes annotated with the “LOC” or ”HS.” prefix were filtered out at this stage.
3.2.3 Weighted Gene Co-Expression Network Analysis (WGCNA)
To identify modules based on co-expression we used the WGCNA R package (Langfelder
and Horvath, 2008). For this analysis, we filtered out duplicate probes mapping to the same
gene. An adjacency matrix was generated using a β of 6 which met the scale-free topology
criteria. A hierarchical clustering tree was created, and modules were originally defined
using the WGCNA function cutreeDynamic with a minimum module size of 20. Modules
were then merged using the mergeCloseModules function with a threshold value of 0.25.
The eigengene of each module was then correlated with phenotype information.
3.2.4 Gene Enrichment Analysis
All enrichment analysis was performed using the UserListEnrichment function in R (see
https://cran.r-project.org/web/packages/WGCNA/index.html). This function is part of the
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WGCNA package (Langfelder and Horvath, 2008). Enrichment analysis, for the results of
the LIMMA analysis, was performed by testing differentially expressed probes (q-value =<
0.05 and ± logFC > 0.1). All probes that did not pass the q-value threshold were included as
background.
For WGCNA enrichment analysis, this was done by using core genes of each module
which were defined as probes with an above average module membership. All other probes
were labelled as background. In all cases we used KEGG (Kanehisa et al., 2004) and GO
(Ashburner et al., 2000) databases. We also used internal lists from the UserListEnrichment
function in WGCNA, Brain Modules, Brain Region Markers and Blood Atlases. A list of
Psychosis risk genes was taken from Pirooznia et al. (2016), this was an updated list, adapted
from Purcell et al. (2009b). Result categories that contained less than five overlapping probes
were filtered out.
3.2.5 Module correlation with Psychosis symptoms
Modules identified in the WGCNA were further correlated with the overall PANSS and three
PANSS sub-scale (Positive, Negative and Psychopathology) scores. The gene expression
matrices of modules associated with PANSS were scaled, centred and module genes were
correlated with PANSS. Patients were stratified based on scores into low (n = 45, PANSS
score = 7-15), medium (n = 29, PANSS score = 15-20 ) and high (n = 29, PANSS score = 20
- 49) symptom severity groups and gene expression for significant modules was plotted using
heat-maps. Controls (n = 149 ) were used for comparison. Individuals with no available
PANSS score were excluded (n=28).
3.2.6 Estimating effect of Medication
Differential expression analysis, as previously described, was used to test the effect of
medication. Data was split into four groups based on medication status at the time of
blood collection; all known Medication (Med), Olanzapine (Ola), Risperidone (Ris) and
antipsychotic-free (AF). Four DGE analyses were performed, by using previously identified
and significantly differentially expressed probes, with the following layout: 1. Med vs
Control, 2. Ola vs Control, 3. Ris vs Control, 4. AF vs Control.
Antipsychotic data was also incorporated into WGCNA analysis. The groups were AF,





Of the 395 original samples (227 cases and 168 controls), 280 samples passed quality
control and had full information on Age, Gender and Ethnicity. This corresponded to a final
population of 131 first episode psychosis cases and 149 controls. The basic demographics of
the final sample population are shown in Table 3.1. Patients were less likely to be Caucasian
(p-value = 0.049) and more likely to be smokers (p-value =< 0.001). There was no significant
difference in age, gender or body mass index.
Antipsychotic medication status at the time the blood was taken, is described below. Eigh-
teen Patients (13.7%) were unmedicated when blood samples were taken, and information
on medication for thirteen patients (9.9%) was unavailable. The remaining patients were
primarily medicated with Olanzapine (35.1%), or Risperidone (20.6%), Aripiprazole (9.2%),
Haloperidol (4.6%) and Quetiapine (4.6%). Trifluoperazine, Sulpiride and Amisulpride were
all taken by a single individual.
Diagnosis of patients is detailed in Table 3.2 The most common ICD-10 diagnosis
received by patients was schizophrenia (50.4%), followed by mania with psychosis (12.2%),
schizoaffective disorder (6.9%), delusional disorder (3.8%), bipolar disorder (1.5%). In
addition, various depression subtypes were diagnosed in 7.6% of patients, and 17.5% had
incomplete records, did not meet any criteria, or had unspecified psychosis.
3.3.2 Differential expression
Of the 4730 probes remaining after quality control, 667 were removed due to being considered
poorly annotated (LOC or HS. prefix), leaving a total of 4062 probes. In this reduced probeset
we found 877 significantly DE genes (q-values < 0.05 & absolute logFC > 0.1). Out of these,
460 were up-regulated, and 417 probes were down-regulated (Appendix A: Table 1). The
top 50 up and downregulated probes (q-values < 0.05) in terms of fold change are shown in
Table 3.3. The most significant up and downregulated probes were, SUMO3 (logFC =0.1,
q-value = 7.36E-05) and HNRNPUL2 (logFC =-0.18, q-value = 0.000206) respectively. The
significant probes with the highest and lowest logFC were DEFA1B (logFC =0.91, q-value =
0.00021) and VWCE (logFC =-0.37, q-value = 0.00394) respectively.
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Table 3.1 GAP Demographics
Control FEP p-value
Samples 149 131
Age (mean (sd)) 29.87 (± 10.53) 28.24 (± 8.59) 0.163
Gender (%) 0.96
Male 86 (57.7%) 76 (58.0%)
Female 63 (57.7%) 55 (58.0%)
Ethnicity (%) 0.049
Asian 10 ( 6.7%) 12 ( 9.2%)
Black 43 (28.9%) 55 (42.0%)
Other 10 ( 6.7%) 10 ( 7.6%)
White 86 (57.7%) 54 (41.2%)
Tobacco use (%) <0.001
Yes 79 (53.0%) 88 (67.2%)
No 68 (45.6%) 30 (22.9%)
NA 2 ( 1.3%) 13 ( 9.9%)
BMI (mean (sd)) 24.30 (± 4.55) 25.35 (± 5.59) 0.211
Table of Demographics for Controls and FEP patients. A total of 280 individuals were included in
the study. The two groups showed significant differences in Ethnicity, with a higher proportion of
White individuals in the control group. In addition Tobacco use was found to be more common in
patients. No significant difference was found for Age, Gender or BMI. P-values for Gender, Ethnicity
and Tobacco use were calculated using the chi-square test. Age and BMI p-values were calculated
using the t-test.
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Table 3.2 ICD-10 and DSM-IV diagnoses for Patients
ICD-10 (opcrit) N (%) DSM-IV (opcrit) N (%)
Schizophrenia and delusional disorders
Schizophrenia 66 (50.4) Schizophrenia 32 (24.4)
Schizophreniform Disorder* 27 (20.6)
Schizoaffective Disorder Manic 5 ( 3.8) Schizoaffective Disorder Bipolar 7 ( 5.3)
Schizoaffective Disorder Depres-
sive
4 ( 3.1) Schizoaffective Disorder De-
pressed
9 ( 6.9)
Delusional Disorder 5 ( 3.8) Delusional Disorder 7 ( 5.3)
Unspecified Non Organic Psy-
chosis
5 ( 3.8) Psychotic Disorder NOS 13 ( 9.9)
Affective Disorders
Mild Depressive Episode 2 ( 1.5)
Moderate Depressive Episode 2 ( 1.5) Major Depressive Episode 2 ( 1.5)
Severe Depressive Episode with
Psychotic Symptoms
6 ( 4.6) Major Depressive episode with
Psychotic features
11 ( 8.4)
Mania with Psychosis 16 (12.2) Manic episode with psychosis 20 (15.3)
Bipolar Affective Disorder 2 ( 1.5)
Unspecified
Not Available 2 ( 1.5) Not Available 2 ( 1.5)
No criteria Met 16 (12.2) No Criteria Met 1 ( 0.8)
Table detailing the number of patients (N) followed by the percentage (%) of patients with
the diagnosis. In total 131 patients are included. ICD-10 and DSM-IV diagnoses are based
on the OPCRIT system (Rucker et al., 2011). *(All but 2 patients with Schizophreniform































































































































































































































































































































Table 3.3 Top differentially expressed probes
Gene logFC p-value q-value Definition
Top 50 Up-regulated
SUMO3 0.1 2.4e-08 7.4e-05 Homo sapiens SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae)
(SUMO3), mRNA.
CAMP 0.63 3.1e-08 7.4e-05 Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA.
DEFA1B 0.91 2.1e-07 2.1e-04 Homo sapiens defensin, alpha 1B (DEFA1B), mRNA.
DEFA1 0.82 3.2e-07 2.1e-04 Homo sapiens defensin, alpha 1 (DEFA1), mRNA.
DEFA3 0.9 3.5e-07 2.1e-04 Homo sapiens defensin, alpha 3, neutrophil-specific (DEFA3), mRNA.
IDH1 0.13 3.8e-07 2.1e-04 Homo sapiens isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), mRNA.
TMEM170B 0.29 3.9e-07 2.1e-04 Homo sapiens transmembrane protein 170B (TMEM170B), mRNA.
LDHA 0.1 5.6e-07 2.4e-04 Homo sapiens lactate dehydrogenase A (LDHA), transcript variant 2, mRNA.
LCN2 0.58 6.1e-07 2.4e-04 Homo sapiens lipocalin 2 (LCN2), mRNA.
C9ORF72 0.23 8.7e-07 2.8e-04 Homo sapiens chromosome 9 open reading frame 72 (C9orf72), transcript vari-
ant 1, mRNA.
LYPLAL1 0.17 9.1e-07 2.8e-04 Homo sapiens lysophospholipase-like 1 (LYPLAL1), mRNA.
TFRC 0.17 1.0e-06 2.8e-04 Homo sapiens transferrin receptor (p90, CD71) (TFRC), mRNA.
S100A8 0.35 1.0e-06 2.8e-04 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA.
PCMT1 0.13 1.1e-06 2.8e-04 Homo sapiens protein-L-isoaspartate (D-aspartate) O-methyltransferase
(PCMT1), mRNA.
BNIP2 0.17 1.3e-06 3.1e-04 Homo sapiens BCL2/adenovirus E1B 19kDa interacting protein 2 (BNIP2),
mRNA.
SLC30A9 0.17 1.4e-06 3.1e-04 Homo sapiens solute carrier family 30 (zinc transporter), member 9 (SLC30A9),
mRNA.
SLC44A1 0.17 1.7e-06 3.5e-04 Homo sapiens solute carrier family 44, member 1 (SLC44A1), mRNA.
TCEB1 0.13 1.9e-06 3.6e-04 Homo sapiens transcription elongation factor B (SIII), polypeptide 1 (15kDa,
elongin C) (TCEB1), mRNA.
VAMP7 0.14 1.9e-06 3.6e-04 Homo sapiens vesicle-associated membrane protein 7 (VAMP7), mRNA.
GLRX 0.22 2.2e-06 3.7e-04 Homo sapiens glutaredoxin (thioltransferase) (GLRX), mRNA.
CLNS1A 0.17 2.4e-06 3.7e-04 Homo sapiens chloride channel, nucleotide-sensitive, 1A (CLNS1A), mRNA.
FAM96A 0.23 2.4e-06 3.7e-04 Homo sapiens family with sequence similarity 96, member A (FAM96A), tran-
script variant 1, mRNA.
H2AFZ 0.1 2.4e-06 3.7e-04 Homo sapiens H2A histone family, member Z (H2AFZ), mRNA.
SENP7 0.25 2.7e-06 3.7e-04 Homo sapiens SUMO1/sentrin specific peptidase 7 (SENP7), transcript variant
2, mRNA.
COX7A2L 0.18 2.7e-06 3.7e-04 Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 like
(COX7A2L), nuclear gene encoding mitochondrial protein, mRNA.
C14ORF100 0.14 2.9e-06 3.7e-04 Homo sapiens chromosome 14 open reading frame 100 (C14orf100), mRNA.
TAF7 0.19 2.9e-06 3.7e-04 Homo sapiens TAF7 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 55kDa (TAF7), mRNA.
PSMC2 0.14 3.0e-06 3.7e-04 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase, 2
(PSMC2), mRNA.
S100A12 0.3 3.0e-06 3.7e-04 Homo sapiens S100 calcium binding protein A12 (S100A12), mRNA.
MED28 0.12 3.3e-06 3.8e-04 Homo sapiens mediator complex subunit 28 (MED28), mRNA.
ARL6IP5 0.13 3.5e-06 3.9e-04 Homo sapiens ADP-ribosylation-like factor 6 interacting protein 5 (ARL6IP5),
mRNA.
IFNGR1 0.15 4.3e-06 4.3e-04 Homo sapiens interferon gamma receptor 1 (IFNGR1), mRNA.
SRP9 0.19 4.6e-06 4.3e-04 Homo sapiens signal recognition particle 9kDa (SRP9), mRNA.
PRDX3 0.12 4.6e-06 4.3e-04 Homo sapiens peroxiredoxin 3 (PRDX3), nuclear gene encoding mitochondrial
protein, transcript variant 1, mRNA.
ATG3 0.14 5.0e-06 4.4e-04 Homo sapiens ATG3 autophagy related 3 homolog (S. cerevisiae) (ATG3),
mRNA.
CRLS1 0.2 5.1e-06 4.4e-04 Homo sapiens cardiolipin synthase 1 (CRLS1), mRNA.
Continued on next page
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CCPG1 0.16 5.4e-06 4.4e-04 Homo sapiens cell cycle progression 1 (CCPG1), transcript variant 2, mRNA.
CLDND1 0.18 5.5e-06 4.4e-04 Homo sapiens claudin domain containing 1 (CLDND1), transcript variant 1,
mRNA.
ANXA3 0.34 5.7e-06 4.6e-04 Homo sapiens annexin A3 (ANXA3), mRNA.
TM2D1 0.11 6.3e-06 4.7e-04 Homo sapiens TM2 domain containing 1 (TM2D1), mRNA.
MAP2K1IP1 0.2 6.6e-06 4.7e-04 Homo sapiens mitogen-activated protein kinase kinase 1 interacting protein 1
(MAP2K1IP1), mRNA.
COX7A2 0.21 6.7e-06 4.7e-04 Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 (liver)
(COX7A2), mRNA.
FAM45A 0.13 7.0e-06 4.8e-04 Homo sapiens family with sequence similarity 45, member A (FAM45A),
mRNA.
ATP5C1 0.23 7.6e-06 5.1e-04 Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 complex,
gamma polypeptide 1 (ATP5C1), nuclear gene encoding mitochondrial protein,
transcript variant 2, mRNA.
CDC40 0.11 8.0e-06 5.2e-04 Homo sapiens cell division cycle 40 homolog (S. cerevisiae) (CDC40), mRNA.
VBP1 0.21 8.0e-06 5.2e-04 Homo sapiens von Hippel-Lindau binding protein 1 (VBP1), mRNA.
PHF5A 0.19 8.7e-06 5.3e-04 Homo sapiens PHD finger protein 5A (PHF5A), mRNA.
GNG10 0.3 9.0e-06 5.3e-04 Homo sapiens guanine nucleotide binding protein (G protein), gamma 10
(GNG10), mRNA.
PSMD10 0.15 9.4e-06 5.3e-04 Homo sapiens proteasome (prosome, macropain) 26S subunit, non-ATPase, 10
(PSMD10), transcript variant 1, mRNA.
HEXB 0.1 9.5e-06 5.3e-04 Homo sapiens hexosaminidase B (beta polypeptide) (HEXB), mRNA.
Continued on next page
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Top 50 Down-regulated
HNRNPUL2 -0.18 2.3e-07 2.1e-04 Homo sapiens heterogeneous nuclear ribonucleoprotein U-like 2 (HNRNPUL2),
mRNA.
RBM14 -0.12 2.5e-07 2.1e-04 Homo sapiens RNA binding motif protein 14 (RBM14), mRNA.
TMEM69 -0.11 8.6e-07 2.8e-04 Homo sapiens transmembrane protein 69 (TMEM69), mRNA.
SCAP -0.13 2.5e-06 3.7e-04 Homo sapiens SREBF chaperone (SCAP), mRNA.
FAM110A -0.15 2.5e-06 3.7e-04 Homo sapiens family with sequence similarity 110, member A (FAM110A), tran-
script variant 3, mRNA.
RBM10 -0.11 2.6e-06 3.7e-04 Homo sapiens RNA binding motif protein 10 (RBM10), transcript variant 2,
mRNA.
ZNF296 -0.15 3.6e-06 4.0e-04 Homo sapiens zinc finger protein 296 (ZNF296), mRNA.
PNPT1 -0.11 4.2e-06 4.3e-04 Homo sapiens polyribonucleotide nucleotidyltransferase 1 (PNPT1), mRNA.
RASGRP2 -0.11 4.4e-06 4.3e-04 Homo sapiens RAS guanyl releasing protein 2 (calcium and DAG-regulated)
(RASGRP2), transcript variant 1, mRNA.
DENND4B -0.11 5.0e-06 4.4e-04 Homo sapiens DENN/MADD domain containing 4B (DENND4B), mRNA.
ZC3H5 -0.1 6.1e-06 4.7e-04 PREDICTED: Homo sapiens zinc finger CCCH-type containing 5 (ZC3H5),
mRNA.
CXXC1 -0.11 6.6e-06 4.7e-04 Homo sapiens CXXC finger 1 (PHD domain) (CXXC1), mRNA.
SUPT5H -0.13 7.2e-06 4.9e-04 Homo sapiens suppressor of Ty 5 homolog (S. cerevisiae) (SUPT5H), mRNA.
GANAB -0.11 8.1e-06 5.2e-04 Homo sapiens glucosidase, alpha; neutral AB (GANAB), transcript variant 2,
mRNA.
PHF15 -0.13 8.7e-06 5.3e-04 Homo sapiens PHD finger protein 15 (PHF15), mRNA.
KIAA1267 -0.1 9.3e-06 5.3e-04 Homo sapiens KIAA1267 (KIAA1267), mRNA.
CLSTN1 -0.15 9.6e-06 5.3e-04 Homo sapiens calsyntenin 1 (CLSTN1), transcript variant 1, mRNA.
POM121C -0.12 1.0e-05 5.3e-04 Homo sapiens POM121 membrane glycoprotein C (POM121C), mRNA.
TSSC4 -0.1 1.0e-05 5.3e-04 Homo sapiens tumor suppressing subtransferable candidate 4 (TSSC4), mRNA.
UBQLN4 -0.11 1.0e-05 5.3e-04 Homo sapiens ubiquilin 4 (UBQLN4), mRNA.
RANGAP1 -0.12 1.0e-05 5.3e-04 Homo sapiens Ran GTPase activating protein 1 (RANGAP1), mRNA.
OSBPL7 -0.13 1.1e-05 5.3e-04 Homo sapiens oxysterol binding protein-like 7 (OSBPL7), transcript variant 1,
mRNA.
WDR23 -0.11 1.2e-05 5.6e-04 Homo sapiens WD repeat domain 23 (WDR23), transcript variant 1, mRNA.
FBXO46 -0.16 1.2e-05 5.6e-04 PREDICTED: Homo sapiens F-box protein 46, transcript variant 5 (FBXO46),
mRNA.
PRKD2 -0.14 1.2e-05 5.6e-04 Homo sapiens protein kinase D2 (PRKD2), mRNA.
VAMP2 -0.11 1.3e-05 5.7e-04 Homo sapiens vesicle-associated membrane protein 2 (synaptobrevin 2)
(VAMP2), mRNA.
NUMA1 -0.12 1.3e-05 5.8e-04 Homo sapiens nuclear mitotic apparatus protein 1 (NUMA1), mRNA.
ST3GAL1 -0.13 1.4e-05 5.9e-04 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1),
transcript variant 1, mRNA.
EDC4 -0.1 1.4e-05 5.9e-04 Homo sapiens enhancer of mRNA decapping 4 (EDC4), mRNA.
SIK3 -0.11 1.6e-05 6.5e-04 Homo sapiens SIK family kinase 3 (SIK3), mRNA.
CD97 -0.16 1.7e-05 6.6e-04 Homo sapiens CD97 molecule (CD97), transcript variant 1, mRNA.
TLN1 -0.2 1.7e-05 6.8e-04 Homo sapiens talin 1 (TLN1), mRNA.
STIP1 -0.13 1.8e-05 6.8e-04 Homo sapiens stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing pro-
tein) (STIP1), mRNA.
ITPKB -0.12 1.8e-05 6.9e-04 Homo sapiens inositol 1,4,5-trisphosphate 3-kinase B (ITPKB), mRNA.
RAB35 -0.1 1.9e-05 7.0e-04 Homo sapiens RAB35, member RAS oncogene family (RAB35), mRNA.
RAB11FIP1 -0.13 2.0e-05 7.0e-04 Homo sapiens RAB11 family interacting protein 1 (class I) (RAB11FIP1), tran-
script variant 3, mRNA.
RASAL3 -0.11 2.0e-05 7.0e-04 Homo sapiens RAS protein activator like 3 (RASAL3), mRNA.
WASF2 -0.17 2.1e-05 7.0e-04 Homo sapiens WAS protein family, member 2 (WASF2), mRNA.
PHRF1 -0.11 2.1e-05 7.0e-04 Homo sapiens PHD and ring finger domains 1 (PHRF1), mRNA.
Continued on next page
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ICAM2 -0.1 2.3e-05 7.3e-04 Homo sapiens intercellular adhesion molecule 2 (ICAM2), transcript variant 1,
mRNA.
HGS -0.1 2.3e-05 7.3e-04 Homo sapiens hepatocyte growth factor-regulated tyrosine kinase substrate
(HGS), mRNA.
MEF2D -0.11 2.4e-05 7.3e-04 Homo sapiens myocyte enhancer factor 2D (MEF2D), mRNA.
SPG7 -0.1 2.8e-05 7.6e-04 Homo sapiens spastic paraplegia 7 (pure and complicated autosomal reces-
sive) (SPG7), nuclear gene encoding mitochondrial protein, transcript variant
1, mRNA.
XRCC6 -0.12 2.9e-05 7.7e-04 Homo sapiens X-ray repair complementing defective repair in Chinese hamster
cells 6 (XRCC6), mRNA.
FYN -0.1 3.0e-05 7.8e-04 Homo sapiens FYN oncogene related to SRC, FGR, YES (FYN), transcript vari-
ant 2, mRNA.
PDPR -0.2 3.0e-05 7.8e-04 PREDICTED: Homo sapiens pyruvate dehydrogenase phosphatase regulatory
subunit (PDPR), mRNA.
TRIM28 -0.13 3.2e-05 8.1e-04 Homo sapiens tripartite motif-containing 28 (TRIM28), mRNA.
AKAP13 -0.11 3.4e-05 8.4e-04 Homo sapiens A kinase (PRKA) anchor protein 13 (AKAP13), transcript variant
2, mRNA.
AP1G2 -0.1 3.5e-05 8.4e-04 Homo sapiens adaptor-related protein complex 1, gamma 2 subunit (AP1G2),
mRNA.
MED25 -0.2 3.5e-05 8.5e-04 Homo sapiens mediator complex subunit 25 (MED25), mRNA.
3.3.3 Enrichment of Differentially Expressed Genes
Enrichment analysis on all differentially expressed (DE) (N=877) genes revealed 97 cate-
gories at a p-value threshold of 0.05 (see Appendix A: Table 2). A total of 29 categories
remained significant using a bonferroni adjusted p-value threshold of 0.05 (see Table 3.4).
Enriched pathways (after accounting for multiple testing) included the Ribosome, Translation,
RNA processing, Viral infections, protein transport and membrane targeting. The pathways
contained between 23 and 83 probes and these overlapped significantly across categories,
with most probes being members of the cytosolic or mitochondrial ribosome. Two of the
significantly enriched categories (identified as Nucleus and Ribosome) are brain expressed
modules that have been supplied by the WGCNA UserListEnrichment function.
Out of the remaining 68 categories that passed the p-value threshold of 0.05, but failed
to reach a q-value threshold of 0.05, most fall into the above mentioned categories (see
Appendix A: Table 2). The ones that did not included Innate immunity, glutamatergic
synaptic function, the ubiquitin system, blood platelets, Parkinson’s disease, exocytosis,
learning or memory, nervous system development, the Amygdala, mir-137 and response to
ethanol.
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Table 3.4 Enriched Pathways for Differential Expression
Enriched Category Library Overlap p-value adj.p.val
Ribosome_Homo sapiens_hsa03010 KEGG_2016 43 0.0001 0.0001
SRP-dependent cotranslational protein targeting to mem-
brane (GO:0006614)
GO_BP 43 0.0001 0.0001
viral transcription (GO:0019083) GO_BP 36 0.0001 0.0001
cotranslational protein targeting to membrane
(GO:0006613)
GO_BP 43 0.0001 0.0001
turquoise_M14_Nucleus_HumanMeta Brain 83 0.0001 0.0001
protein targeting to membrane (GO:0006612) GO_BP 48 0.0001 0.0001
establishment of protein localization to endoplasmic retic-
ulum (GO:0072599)
GO_BP 44 0.0001 0.0001
protein targeting to ER (GO:0045047) GO_BP 43 0.0001 0.0001
ribosomal subunit (GO:0044391) GO_CC 42 0.0001 0.0001
translational termination (GO:0006415) GO_BP 36 0.0001 0.0003
protein localization to endoplasmic reticulum
(GO:0070972)
GO_BP 43 0.0001 0.0004
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay (GO:0000184)
GO_BP 41 0.0001 0.0006
structural constituent of ribosome (GO:0003735) GO_MF 42 0.0001 0.0013
translational elongation (GO:0006414) GO_BP 37 0.0001 0.0016
macromolecular complex disassembly (GO:0032984) GO_BP 41 0.0001 0.0026
cellular protein complex disassembly (GO:0043624) GO_BP 36 0.0001 0.0035
cytosolic large ribosomal subunit (GO:0022625) GO_CC 23 0.0001 0.0042
large ribosomal subunit (GO:0015934) GO_CC 25 0.0001 0.0052
protein complex disassembly (GO:0043241) GO_BP 39 0.0001 0.0081
mRNA catabolic process (GO:0006402) GO_BP 48 0.0001 0.0084
protein localization to membrane (GO:0072657) GO_BP 54 0.0001 0.0093
establishment of protein localization to membrane
(GO:0090150)
GO_BP 53 0.0001 0.0105
viral life cycle (GO:0019058) GO_BP 38 0.0001 0.0121
nuclear-transcribed mRNA catabolic process
(GO:0000956)
GO_BP 47 0.0001 0.0123
ribosome (GO:0005840) GO_CC 40 0.0001 0.0139
translational initiation (GO:0006413) GO_BP 41 0.0001 0.0301
RNA catabolic process (GO:0006401) GO_BP 50 0.0001 0.0308
protein targeting (GO:0006605) GO_BP 53 0.0001 0.0426
salmon_M12_Ribosome_HumanMeta Brain 32 0.0001 0.0499
Table of results for gene enrichment analysis of different expressed genes between Controls and First Episode
Psychosis. A total of 877 probes were differentially expressed. Results show categories that had a bonferroni
adjusted p value below 0.05. (See Appendix A: Table 2 for full results)
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3.3.4 Weighted Gene Co-Expression Network Analysis Results
WGCNA resulted in 14 modules after merging initial modules based on eigengene distance
(Figure 3.2c). Network dendrograms of probes and module assignment before and after
merging is shown in figure 3.2d.
Module eigengenes were tested for their correlation with traits including case control
status, BMI and Tobacco use. Correlations between controls status and three patient sub-
groups based on medication was also included. These were antipsychotic-free (AF) patients
and patients on either Risperidone or Olanzapine. Figure 3.3 depicts a heatmap of these
relationships, for each trait and module. Out of the 14 modules 7 were found to be statistically
significant for the binary comparison between case and control. These were, in order of
lowest to highest p-value the Blue (R2 =0.26, p-value= 1x10-5, Size = 781 probes), Turquoise
(R2 =-0.24, p-value= 7x10-5, Size = 1663 probes), Cyan (R2 =-0.22, p-value= 2x10-4, Size
= 46 probes), Yellow (R2 =-0.2, p-value= 6x10-4, Size = 338 probes), Green (R2 =-0.2,
p-value= 9x10-4, Size = 364 probes), Pink (R2 =-0.15, p-value= 1x10-2, Size = 349 probes)
and Tan (R2 =-14, p-value= 2x10-2, Size = 69 probes) modules.
BMI was highly associated with the Pink, Purple, Magenta and Turquoise modules.
Tobacco use was most significantly associated with the Cyan module. When comparing
controls with three subsets of the FEP samples, namely just antipsychotic-free samples
(AF vs HC), the antipsychotics Risperidone (Ris vs Con) or Olanzapine (Ola vs Con), we
observed differences in several modules. Notably the Blue, Tan, Green and Turquoise
modules. While the direction of the correlations stayed the same in all cases, the correlation
for Risperidone was reduced in the Blue and Turquoise modules compared to antipsychotic-
free and Olanzapine samples. No significant correlations were found between the Green
module and Controls with Risperidone (p-value = 0.1) or Olanzapine (p-value = 0.03), but
a significant negative correlation with the antipsychotic-free group was found compared to
controls (R2 = -0.23 p-value = 1x10-4). The Tan module showed the opposite pattern with the
correlation being increased for Risperidone and Olanzapine compared to the antipsychotic-
free group.
3.3.5 Enrichment analysis of WGCNA modules
For pathway analysis of the identified WGCNA modules, genes with above average module
membership were used. The Grey module was excluded, due to being an aggregate of
unassigned probes.
Enrichment analysis identified pathways in 8 of the 14 modules, using a q-value threshold
of 0.05 and a minimum of 5 probes (see Table 3.5. The Pink, Purple, Midnightblue, Cyan,
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(a) Clustering of samples and variables (b) Scale independence and connectivity
(c) Clustering of Eigengenes (d) Clustering of Probes
Figure 3.2 WGCNA Module Construction
(a) Hierarchical clustering of samples with (b) Scale free independence (c) Module eigengene hierar-
chical clustering with red line indicating height below which modules are merged. (d) hierarchical
clustering of modules before and after merge with module membership indicated by colors.
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Figure 3.3 Module-trait Relationships
Heatmap of WGCNA modules and medication subgroups. The 5 categorical columns are coded as
binary in correlations, with Control being 0. They are FEP vs. Control (Phenotype), Antipsychotic
Free, Risperidone, Olanzapine. BMI is the body mass index, and Tobacco represents smoking status.
Red signifies a positive correlation with the trait, while Blue represents a negative correlation. The
top value is the correlation coefficient, while the bottom value is the p-value.
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Green and Lightcyan modules did not contain modules that passed the multiple testing burden.
Of the remaining modules, the Turquoise, Yellow, Blue and Green all had a correlation for
case-control status above 0.2 and p-value below 0.001.
The most significant categories for the Turquoise Module was the Schizophrenia com-
posite gene list adapted from Purcell et al. (2009b) “Scz-composite” (p-value = 4.52x10-18,
q-value = 1.09x10-13), followed by ”UpWithAlzheimers_Blalock” (p-value = 1.15x10-11,
q-value = 2.76x-7). For the Yellow module they were ”nucleolus” (p-value = 3.95x10-10,
q-value = 9.52x10-6) and “Autism_Associated_Module_Vonieagu” (p-value = 1.1x10-6, q-
value = 0.026). For the Blue module all 10 categories that passed the q-value threshold
were brain derived modules. These included ”Glutamatergic Synaptic Function” (p-value =
2.06x10-7, q-value = 0.0049) and “DownWithAlzheimers_Blalock” (p-value = 3.01x10-7,
q-value = 0.0072).
The Green module did not contain any enriched categories that passed the q-value
threshold. The most significant category was “GlutatmatergicSynapse_Mouse” (p-value =
0.000186, q-value = 1).
3.3.6 WGCNA module relationship with Symptom Severity
PANSS scores were correlated with significantly differentially expressed probe and WGCNA
modules (see Figure 3.4). The Greenyellow module was the most strongly associated module
with Positive Symptoms (R2 =0.29, p-value= 9x10-7). the correlation with negative symptoms
was less significant and reversed (R2 = -0.17, p-value= 5x10-3).
Positive Symptoms were also positively correlated with the brown (R2 =0.15, p-value=
1x10-2), and blue modules (R2 =0.17, p-value= 4x10-3), and negatively correlated with the
black (R2 = -0.19, p-value= 1x10-3), tan (R2 = -0.2, p-value= 7x10-4), yellow (R2 = -0.19,
p-value= 2x10-3), green (R2 = -0.18, p-value= 1x10-3) and grey (R2 = -0.19, p-value= 1x10-3)
modules.
The strongest association with negative symptoms was with the pink module (R2 = -0.22,
p-value= 2x10-4).
For the general psychopathology subscale associations were less significant, although
there was a negative association with the green and tan modules. The strongest association
for the overall PANSS was with the tan module (R2 = -0.21, p-value= 6x10-4).
The probes in the Greenyellow module had expression levels scaled and centred and
were stratified into four groups based on Positive (Figure 3.5) and Negative Symptoms
scales (Figure 3.6). The low positive symptom group (PANSS = 15-20) had a general
downregulation of almost all probe and high positive symptoms (PANSS = 20-49) correlated
with increased expression. The reverse was true for Negative Symptoms.
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Table 3.5 Enriched Pathways for WGCNA modules
Module Library Enriched Categories
Blue* Brain turquoise M14 Nucleus HumanMeta; turquoise M14 Nucleus MouseMeta;
Brain yellow M18 CTX; blue M16 Neuron CTX; brown pyramidalNeurons
Layer5/basolateralAmygdala Sugino/Winden; turquoise Cerebellum Hu-
manChimp
Black Brain salmon M12 Ribosome HumanMeta
Transcription GO BP viral transcription (GO:0019083); translational termination (GO:0006415);
cellular protein complex disassembly (GO:0043624); translational elonga-
tion (GO:0006414); translational initiation (GO:0006413); viral life cycle
(GO:0019058)
KEGG 2016 Ribosome Homo sapiens hsa03010
GO CC ribosomal subunit (GO:0044391); ribosome (GO:0005840); cytosolic part
(GO:0044445)
GO MF structural constituent of ribosome (GO:0003735)
Tan* Blood Lymphcytes genesCorrelatedAcrossIndividuals Whitney
Yellow* GO CC nucleolus (GO:0005730); nucleoplasm (GO:0005654)
Brain Brain Autism associated module M12 Voineagu
Greenyellow Brain orange M5 Microglia(Type2) CTX
Brain HBA principal sensory nucleus of trigeminal nerve localMarker(top200) IN Pontine
Tegmentum; Supraoptic Nucleus localMarker(FC>2) IN Hypothalamus
GO BP cellular response to type I interferon (GO:0071357); type I interferon signaling
pathway (GO:0060337); response to type I interferon (GO:0034340); defense
response to virus (GO:0051607); response to virus (GO:0009615); cytokine-
mediated signaling pathway (GO:0019221)
KEGG 2016 Herpes simplex infection Homo sapiens hsa05168; Measles Homo sapiens
hsa05162; Hepatitis C Homo sapiens hsa05160; Influenza A Homo sapiens
hsa05164
Magenta Blood Reticulocytes genesCorrelatedAcrossIndividuals Whitney; RedBloodCell Ka-
banova
Brown Brain pink M10 Microglia(Type1) HumanMeta
Brain HBA Substantia Nigra, pars reticulata localMarker(FC>2) IN Mesencephalon; Sub-
stantia Nigra, pars reticulata localMarker(top200) IN Mesencephalon
Blood RedBloodCell Kabanova
GO CC plasma membrane region (GO:0098590)
GO BP phagosome maturation (GO:0090382); extracellular matrix organization
(GO:0030198); extracellular structure organization (GO:0043062)
KEGG 2016 Osteoclast differentiation Homo sapiens hsa04380; Tuberculosis Homo sapiens
hsa05152
Turquoise* Pirooznia Scz-composite; synaptome; neuronal PSD
Brain Brain UpWithAlzheimers Blalock ADvsCT inCA1; PostSynapticDensity proteins
Bayes; Up CD40 stimulation in MG AitGhezala MicrogialMarkers; pink M14
GlutamatergicSynapticFunction CTX; green M5 Mitochondria HumanMeta;
blue downAD metalIonTransport glycoprotein Blalock AD
GO BP actin filament-based process (GO:0030029); hemostasis (GO:0007599); blood
coagulation (GO:0007596); coagulation (GO:0050817); actin cytoskeleton
organization (GO:0030036); platelet activation (GO:0030168)
GO MF actin binding (GO:0003779); RNA polymerase II regulatory region DNA bind-
ing (GO:0001012)
GO CC extracellular vesicular exosome (GO:0070062); cell-cell junction
(GO:0005911); microtubule (GO:0005874)
KEGG 2016 Viral carcinogenesis Homo sapiens hsa05203; Endocytosis Homo sapiens
hsa04144; Focal adhesion Homo sapiens hsa04510
Table of WGCNA modules and corresponding gene enrichment results. Criteria for inclusion of Enrichment
Category were a q-value below 0.05 and a minimum of 5 probes overlapping with the pathway. Only 8 modules
contained any Pathways that passed the inclusion criteria. Only probes with above median module membership
were used for enrichment analysis. *Modules with an association to Psychosis status (p-value < 0.05)
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Figure 3.4 Module-trait Relationships PANSS
Heatmap of WGCNA modules and correlations with PANSS sub-scales. The first column represents
FEP vs. Control coded as binary in correlations as before. The PannsScore is the overall PANSS, while
PanssPositive, PanssNegative and PanssPsycho represent the 3 subscales. Red signifies a positive
correlation with the trait, while Blue represents a negative correlation. The top value is the correlation
coefficient, while the bottom value is the p-value.
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Figure 3.5 Heatmap of Expression Level in Greenyellow Module by Positive Symptoms
Heatmap of Probes in Greenyellow module based on positive symptoms. Rows correspond to
indicated probes. Columns represent average expression level across individuals in each group. The
groups were generated based on the score on the PANSS positive sub scale. Cases were split into low
(n = 45, PANSS score = 7-15), medium (n = 29, PANSS score = 15-20 ) and high (n = 29, PANSS
score = 20 - 49) positive symptom groups. Controls (n = 149 ) were used for comparison. Individuals
with no available PANSS score were excluded. Rows are clustered using complete-linkage clustering,
with the dendrogram indicating distance.
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Figure 3.6 Heatmap of Expression Level in Greenyellow Module by Negative Symptoms
Heatmap of Probes in Greenyellow module compared with Negative symptoms. Rows correspond to
indicated probes. Columns represent average expression level across individuals in each group. The
groups were generated based on the score on the PANSS Negative sub scale. Cases were split into low
(n = 45, PANSS score = 7-15), medium (n = 29, PANSS score = 15-20 ) and high (n = 29, PANSS
score = 20 - 49) negative symptom groups. Controls (n = 149 ) were used for comparison. Individuals
with no available PANSS score were excluded. Rows are clustered using complete-linkage clustering,
with the dendrogram indicating distance.
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3.3.7 Medication
To characterise the effect of antipsychotics in our sample, we used probes that were previously
shown to be differentially expressed and performed secondary differential expression analysis
on four subsets of the data based on medication. Healthy controls were compared with
all samples with known medication (n=100), Olanzapine (n=46), Risperidone (n=27) and
antipsychotic Free (n=18) groups (see Appendix A: Figures A.1 to A.4). No significant
probes were found in the Risperidone group. All medication groups had a reduced log fold
change across probes, while log fold change for probes were amplified when the antipsychotic
free group was compared to controls.
3.4 Discussion
3.4.1 Differential Expression Pathways associated with Innate Immu-
nity
When visualising differential expression, we notably see upregulation of Alpha Defensin
probes in psychosis patients (Figure 3.1a), which include the three highest upregulated probes
in FEP patients in this study (DEFA1, DEFA1B, DEFA3). This is consistent with a previous
microarray study of similar size looking at schizophrenia patients (Gardiner et al., 2013)
as well as two proteomic studies of Schizophrenia (Plasma) and Bipolar (Saliva) patients
(Craddock et al., 2008; Iavarone et al., 2014). More recently they were also identified in a
transcriptome meta-analysis by Hess et al. (2016), in a core module. Alpha Defensins are
primarily involved in the innate immune system specifically in viral opsonisation. Upregula-
tion of innate immune genes has been a consistent finding in the schizophrenia literature, and
viral infections have been linked to increased schizophrenia risk, especially during pregnancy.
In line with this, we also found the Cathelicidin Antimicrobial Peptide (CAMP) to be the
second most upregulated probe in psychosis (logFC = 0.63, q-value = 7.36x10-05). These
probes were not assigned to any module but were highly correlated among themselves.
The enrichment results overwhelmingly show changes in translation/transcription and
mitochondrial function, in addition to the immune system, in line with previous results found
by Hess et al. (2016) and others. Interestingly there is much overlap in the probes linked
to viral replication and the above categories in our gene lists, which might point towards
immune deregulation in psychosis patients. However such changes in the expression of
innate immunity are also seen in chronic stress and sleep disorders which are well-known
factors in schizophrenia and psychosis (Anderson and Maes, 2012). This is also consistent
with cortisol deregulation via the HPA axis, which has been found in first episode psychosis
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(Karanikas et al., 2014), and individuals at high risk of developing psychosis (Perkins et al.,
2005).
While not passing the multiple testing thresholds, several of the categories that passed a
p-value threshold of 0.05 were related to brain function. These included learning and memory,
Parkinson’s disease and glutamatergic synapses. Since only a subset of genes is expressed in
both blood and brain tissues, brain-related pathways have a lower prior probability of being
enriched in this analysis and are thus mentioned. They may provide insights, since Pathways
that are deregulated in one blood may also be disrupted in the brain, either due to medication,
drugs, hormones, sleep or genetic vulnerability.
3.4.2 Modules associated with Psychosis and Psychosis Severity
Using WGCNA several modules were identified that were significantly correlated with
first-episode psychosis. These were the Blue, Yellow, Cyan, Green and Turquoise modules
(see Figure 3.3). The Blue, Yellow and Turquoise modules were significantly enriched for
multiple pathways, using a q-value threshold of 0.05, and are discussed further in this section.
While neither the Cyan or Green modules showed significant enrichment for any pathways
using a q-value threshold, the Green module was enriched for pathways at a p-value threshold
of 0.05, with the top category being related to glutamatergic neuron function. The Green
module was therefore also included for discussion below.
Correlation with PANSS further highlighted the Greenyellow module, where an associ-
ation with positive symptoms and was found (Figure 3.4). It was also highly enriched for
brain-expressed genes and is discussed below.
Blue module
The Blue module was highly enriched for pathways from the Brain library of pathways (see
UserListEnrichment documentation), with overlap for Amygdala and Cerebellum modules.
This module was the only one that was positively correlated to psychosis. Interestingly when
the Risperidone group was compared to controls, no significant correlation was observed,
which stood in contrast to Olanzapine and antipsychotic-free patients.
Differential expression analysis, comparing these patient groups with controls, identified
no significant probes for Risperidone, suggesting that Risperidone may have a major role
in normalising gene expression patterns in blood, even after a short period of treatment.
Olanzapine may be more specific to the brain or simply act on other pathways.
The Amygdala is involved in emotion regulation, and facial recognition and has been
linked to schizophrenia as well as a series of other neuropsychiatric disorders. If this pathway
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can be normalised using Risperidone identifying patients with deregulation in it, may be
useful for targeted treatment.
However, we cannot exclude the possibility that this signal discrepancy may be due to
differences in how Risperidone and Olanzapine are prescribed.
Turquoise module
The Turquoise module was enriched for brain pathways and schizophrenia risk genes. Using
gene enrichment the category most strongly associated with this module was the previously
curated list of genes by Purcell et al. (2014) of plausible schizophrenia genes. This represented
the single most significantly enriched category across all modules.
The Hub gene with the highest absolute module membership for this module was Histidine
Triad Nucleotide Binding Protein 1 (HINT1) (-0.95). HINT1 has previously been shown to
interact with the Cannabinoid-1 Receptor (CNR1) to negatively regulate NMDAR activity
(Vicente-Sánchez et al., 2013), and research by Di Forti et al. (2009) has provided evidence
that cannabis increases the risk of developing schizophrenia sevenfold in at-risk populations.
The Turquoise module was also enriched for pathways associated with Actin processes,
coagulation, vesicle transport and CNS associated pathways such as Glutamate, the Synap-
tome and Alzheimers Disease. Interestingly the module was most strongly correlated to the
Olanzapine subset and BMI. Olanzapine is associated with significant weight gain, which
can produce significant changes in gene expression. Correlation with Risperidone was again
non-existent, indicating a potential Risperidone mediated effect in normalising gene expres-
sion levels to those of controls. This is especially interesting when taking into consideration
the enrichment of schizophrenia genes.
However, since this module was by far the largest in the analysis with 1663 probes results
should be regarded with caution.
Green Module
The Green module was also the only module that showed an increased correlation between
antipsychotic-free samples and controls, compared to both medication subsets, or the overall
case-control correlation.
Interestingly the two medication categories had no significant correlation with this module
when compared to controls, indicating the module was similar in medicated patients and
control individuals. This may mean that both Risperidone and Olanzapine act on this module.
This module also contained the only “GRIN” probe, namely Glutamate Ionotropic
Receptor NMDA Type Subunit Associated Protein 1 (GRINA). These genes either are part
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of Glutamate receptors or are associated with them. From our data in isolation, it seems
like the Green module is upregulated in response to antipsychotics. The hub gene with the
highest membership for this module was CLK2, a kinase that plays a role in gluconeogenesis
and AKT1 dephosphorylation via PPP2R5B.
Further investigation with gene enrichment analysis revealed 6 of the top 10 modules
to be associated with Protein signalling and degradation via the ubiquitin system, while the
remaining four modules related to the nervous system. Of these two specifically mapped
to Glutamate related pathways. While these passed the p-value threshold, non passed the
q-value threshold. Also, the signal was based on less than 20 probes, and the green module is
among the larger ones we identified, with 364 members. Nonetheless, I feel it is appropriate
to highlight this module since pathway analysis is itself somewhat limited in that its based on
characterised lists of genes. It is therefore conceivable that pathways associated with this
module have not been defined in the literature, and given the prior probability of glutamate’s
role in schizophrenia, it is important to highlight this module.
Yellow modules
A previous study by de Jong et al. (2012) generated WGCNA modules and identified one
(Tan) that was associated with chronic schizophrenia patients and replicated in non-medicated
samples. It contains 129 probes, 108 of which were present in our dataset. The Yellow
module (338 probes) presented here contains 40 of the 108 probes which are in the Tan
module generated by de Jong et al. (2012). This supports the assertion of the authors that
the overall pathway is robust and preserved. Interestingly the Yellow module is enriched
for brain-expressed probes and genes previously associated with schizophrenia (Pirooznia
et al., 2016), as well as an autism pathway. de Jong et al. (2012), found ABCF1 to be the
HUB gene of the tan module they identified, and this is mirrored in our results were ABCF1
is a hub gene in the Yellow module. Also, a series of other genes specifically discussed
by de Jong et al. (2012) were assigned to the yellow module including TUBB, RING1 and
HSP90AB1 which the authors suggest are all linked to the MHC locus.
Greenyellow Module
Correlation of PANSS with WGCNA modules highlighted the greenyellow module. The
highest correlation was with positive symptoms (0.29, p-value < 0.001), but the correlation
with negative symptoms was also significant (-0.17, p-value = 0.005).
The Greenyellow module was enriched for pathways such as type I interferon signalling,
viruses (including herpes) and three brain modules relating to Microglia, Principle sen-
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sory nucleus of the trigeminal nerve (Pontine Tegmentum) and the Supraoptic Nucleus
(Hypothalamus).
The herpes simplex virus, type 1 (HSV-1) is the primary cause of cold sores, and is
known to hijack the trigeminal nerve and copy itself into DNA of the pontine tegmentum.
The Hypothalamus is adjacent to this region, and they play an important role in REM sleep.
HSV-1 has been associated with worse schizophrenia outcomes, by causing encephalitis
in rare cases and attacking the temporal lobe which can lead to psychosis, problems with
memory, behavioural changes and sleep problems (Prasad et al., 2012; Yolken, 2004). The
Hypothalamus is also deeply involved in stress responses, via the HPA axis and cortisol.
Activation of this axis can occur through psychological and physiological stress.
Surprisingly, individuals with low positive PANSS scores were related to the most
significant signature, with expression being lower than for controls across almost all probes,
while high scores on the positive symptom scale increased expression over controls. This
was probably related to the negative correlation between positive and negative symptoms, as
negative symptoms severity decreased global expression levels for the module.
The most strongly downregulated probe in high negative symptoms was Adenosine
Deaminase, RNA Specific (ADAR), which was also, to a lesser extent downregulated in
high positive symptoms when compared to controls. ADAR is a ubiquitously expressed
gene, with an important role in RNA editing, the primary function of which is marking and
differentiating host RNA from viral RNA. It is also linked disorders of the innate immune
system, cancer and neurological disorders (Mannion et al., 2015).
ADAR mutations can cause severe autoimmune reactions and Aicardi-Goutieres syn-
drome, a neurodevelopmental disorder (Rice et al., 2012). In addition ADAR is located on
chromosome 1q21.1, which was identified by the International Schizophrenia Consortium
as a rare deletion increasing Schizophrenia risk (International Schizophrenia Consortium,
2008). It has been suggested that this may in part be due to its role in sleep regulation via the
Glutamate system (Robinson et al., 2016), and due to its role in editing the serotonin receptor
5-HT2C mRNA (Yang et al., 2004). This is due to intracellular pattern recognition receptors
for RNA stimulating the immune response via interferon signalling.
ADAR has been proposed to be required to suppress the innate immune systems interferon
pathway from targeting internal RNA, by modifying host RNA to avoid an autoimmune
responses. If this function breaks down, intracellular receptors like RIG-1 and IFIH1 (also
known as MDA5), become activated and start their signalling cascades leading to transcription
of Interferons, IL-6, iNOS and TNF-α via TRAF3, TBK1 and IRF-3/7 signalling (Wang
et al., 2017). IRF-7 and IFIH1 are in both members of the greenyellow module, and they
most strongly upregulated in strong positive symptoms. These results were also largely
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mirrored by Hess et al. (2016) who found significant upregulation of TNF-α , Interferon,
TLR, STAT, NF-κB and IL-6 related pathways. In addition to cellular stress responses such
as Hypoxia, RNA metabolism, and Apoptosis. In reality, the distinction between the innate
immune and cellular stress responses is arbitrary, as they are both involved in the stress
response via HPA-axis activation. and similar findings were reported for gene expression
studies in schizophrenia, depression and PTSD (Breen et al., 2017; Gardiner et al., 2013;
Jansen et al., 2016).
Most of the genes in the greenyellow module were not differentially expressed between
cases and controls. However, more than half of them were correlated above 0.25 with positive
PANSS score. This indicates that this module may play a role in positive and negative
symptoms as they are negatively correlated.
To test if a medication was the primary driver of this effect, an further analysis was
performed looking at the correlation of positive symptoms in antipsychotic-free individuals
(n= 13). The most significant probe in the greenyellow module became ADAR with a
correlation of 0.72 with positive symptoms and -0.35 with negative symptoms.
The Greenyellow module provides evidence for HPA-axis deregulation, most likely due
to increased stress, either by an increased exposure to life stressors (be they psychological, or
mediated by pattern recognition receptors) or an increased sensitivity to stress. Either results
in upregulation of the innate immune system and can cause an inflammatory response that is
also transmitted to the brain. Pro-inflammatory cytokines such as Interferon type 1, and TNF
can then affect behaviour by disturbing the serotonin and dopamine systems among others
(Miller and Raison, 2016). This can also lead to microglia activation and oxidative stress in
the brain, leading to behavioural changes, such as hyper-vigilance and anxiety. Accumulating
damage to neurons and social rejection during disease progression, could in this way lead to
paranoia and delusional thinking.
3.4.3 Effects of Medication
Differences were found in correlations between the three medication subgroups, especially
when comparing Risperidone (N=27) to controls. This was evident from differential ex-
pression results which indicated a reduction in log fold change and identified no significant
probes (see Appendix A: Figure A.3). It is possible that differences simply failed to reach
statistical significance. However, almost all probes in the antipsychotic-free group were
significantly differentially expressed, despite the smaller sample size (N = 18) (see Appendix
A: Figure A.4). The Olanzapine (N = 46) comparison also identified many significantly
differentially expressed probes, although the log fold change was much lower than for probes
in antipsychotic-free samples (see Appendix A: Figure A.2).
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The WGCNA results also suggested changes for the Risperidone vs control comparison
in multiple modules in contrast with Olanzapine, antipsychotic-free and the overall FEP
group comparisons with controls. A reduction in correlation for Risperidone was identified
in the blue, pink, purple, yellow, cyan, green and turquoise modules.
This might be due to differences in demographics of the sub-populations, prescription
tendencies or the time scale of effect of the drugs. Some studies have indicated that Olanzap-
ine has a more tolerable side effect profile, and is more effective in the treatment of negative
symptoms (Shoja Shafti and Gilanipoor, 2014), which may explain the more pronounced ef-
fect of Risperidone. The difference might also be due to individuals with negative symptoms
receiving more Olanzapine. There was moderate evidence for this, with the average negative
symptom score for the Olanzapine group being 17.5, while it is 15.3 for the Risperidone
group.
Given the changes in log fold change in differential expression and the WGCNA data, it
seems reasonable to conclude that the effect of antipsychotics is likely to change expression
in the direction of the control group, meaning that any differentially expressed probes have a
low likelihood of being significant purely because of medication.
Overall, these results are exploratory, and in need of further validation, unless they have
prior support from other studies.
3.4.4 Conclusion
This chapter presented the results of the GAP gene expression data for the first time. Dif-
ferential expression, WGCNA and gene enrichment analysis were used. Symptom severity
and medication were explored in relation to WGCNA modules, and potential confounding
variables such as Age, Gender, Ethnicity, Smoking and BMI were included when possible.
I found evidence for differential expression of probes involved in innate immunity, the
viral response, metabolism and translation/transcription. Two of the significant pathways
were expressed in brain. In addition I found subthreshold pathways relating to memory, the
glutamate system and Parkinson’s disease. While these pathways are worth pointing out they
should be viewed with scepticism.
Using the WGCNA package, 15 modules were generated. Five of these have been
discussed in detail. These are the blue, turquoise, yellow, green and greenyellow modules.
All of these are enriched for brain-expressed genes. The results suggested that the blue and
turquoise modules were affected by Risperidone, normalising expression towards controls.
The turquoise module was highly enriched for schizophrenia risk genes. The yellow module
partially replicated previous results in chronic schizophrenia.
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The green module was the only module that correlated more strongly with the antipsychotic-
free group than both Risperidone and Olanzapine groups, indicating it may be mechanically
involved in antipsychotic function. The most significantly enriched pathway was related to
glutamatergic neuronal functions, at a p-value threshold, but not a q-value threshold.
The greenyellow module was associated with positive and negative symptoms in opposite
directions and was highly enriched for interferon gamma 1 signalling pathways. This
supports previous literature showing links with the immune system in schizophrenia and
other psychiatric disorders. This is discussed in the context of the Greenyellow module, and
the hub gene ADAR.
We report that our differential expression analysis partially replicates and expands on
previous findings of a series of psychiatric studies. The strongest signal is in association
with the innate immune signal, transcriptional changes and mitochondrial perturbations.
All of this is consistent with chronic stress via activation of the HPA axis, which leads to
over-activation of the innate immune system, and ultimately changes to behaviour and brain
function. This highlights the importance of taking stress responses more seriously. Especially
since outcomes for mental health in developed countries have lagged behind those in the
developing world, and genetic and molecular strategies have been at best been disappointing.
Despite this we show evidence of plausible gene expression signatures for psychosis in
blood, and while these results need to be replicated they are highly encouraging for follow
up studies.
Chapter 4
Predictive Modelling using the GAP data
4.1 Introduction
Accurate diagnosis is crucial to facilitate better patient care. Currently, in the case of
psychosis, diagnosis is performed by clinical assessment and is somewhat subjective. There
is a broad range of causal factors for psychosis ranging from drugs, sleep deprivation, physical
diseases to schizophrenia and other psychiatric conditions. This requires identification of the
underlying cause of psychosis for treatment to be most effective. Diagnostic concordance
between the ICD-10 and DSM (III, IIIR, IV) categorisations lies between 71% and 93%
of the DSM diagnoses showing higher concordance with the ICD-10, primarily due to
Schizophreniform disorder and other subtypes, that fall under Schizophrenia within the
ICD-10 (Jakobsen et al., 2006). In addition to this, diagnostic assessment of the same
individuals using the same classification system also shows high discordance. This pattern is
similar for other psychiatric conditions that feature psychotic symptoms, and newer versions
of the DSM have radically increased diagnostic categories, largely for practical clinical
purposes, rather than for distinct underlying biological, social or psychological reasons.
While there are certain cases of Psychosis in which the optimal treatment can be identified
with relative ease, (for example drug abuse, NMDAR encephalitis) the majority of cases do
not fall into a clear diagnostic category, and often go through several diagnoses, or receive
additional ones during their lifetime. As such, finding biomarkers and other predictive clinical
variables could potentially provide value by ruling out or identifying psychosis subtypes
more readily. This could help guide treatment plans by identifying contributing causal factors
of psychosis. In addition finding early markers of psychosis could help prevent relapse,
predict response to medication or reduce the chance of developing psychosis to begin with,
by allowing early intervention. The GAP study has multiple data-streams available, including
genetic, transcriptomic, demographic and clinical data. As such it provides an opportunity to
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evaluate the individual and combined predictive power of these data sources, in first episode
psychosis and in ICD or DSM based subtypes.
4.1.1 Aims
In order evaluate the predictive power of these data-streams, we had 4 core aims:
1. The first was to build Lasso and Elastic-Net Regularized Generalized Linear Models
(GLMNET) using various combinations of Gene expression data, polygenic risk scores
and demographic information.
2. The second aim was to compare performance across models in first episode psychosis.
3. The third aim was to investigate feature importance for various models.
4. The fourth aim was to investigate how often samples were accurately classified, using
bootstrapping and how diagnosis and symptom severity (PANSS) correlated with this.
4.2 Methods
4.2.1 Gene Expression Data
Available data consisted of 280 samples, with 149 controls and 131 first episode cases. We
used four types of data in these experiments. The gene expression data was adjusted for cell
type using CellMix (Gaujoux and Seoighe, 2013), as described in chapter 2 This full set of
features was used as the Gx set. We also used the 1311 probe subset, consisting of genes with
a hypothesized connection with schizophrenia. These genes were sourced from Pirooznia
et al. (2016). We further made use of demographic variables. In this case, they consisted of
Age, Sex and Ethnicity, and they are referred to as demographics or demo.
4.2.2 Polygenic Risk Score (PRS)
The polygenic risk scores (PRS) and principal components were calculated by Evangelos
Vassos as described in (Vassos et al., 2017). PRS was available for 243 of the 280 samples.
The first 10 principal components were used to adjust PRS. Imputation was performed using
the caret k-Nearest Neighbours (KNN) imputation (knnImpute) (Kuhn, 2008).
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4.2.3 Machine Learning Model for Classification
For classification purposes Generalised Linear Models were used. This was implemented
with the R package caret (Kuhn and Johnson, 2013) using the glmnet package (Friedman
et al., 2010) or the GLM R core package, in the case of the PRS only condition (where
only a single predictor was used). Binary classification was performed using controls and
first-episode psychosis.
Bootstrapping was used to generate 10,000 training datasets, with a sample size of 280
each. In each case, the samples not used for training were dedicated for testing. Caret was set
up to use three values for the two tunable hyperparameters, alpha and lambda. This resulted
in 9 hyper-parameter combinations. For each of these nine combinations, 10,000 were built
on the training data and tested on the corresponding test set. This resulted in 90,000 models
in total or 10,000 per hyperparameter combination. The average accuracy of all models for
each of the nine parameter combinations was used to select the best settings.
Using the optimal hyperparameters, we created a final model on the full 280 samples.
We saved test predictions of each of the 10,000 models and used the aggregate of these to
estimate the accuracy and cohen’s kappa of each model (referred to as kappa in the text).
The kappa statistic compares observed accuracy with the expected accuracy of a random
classifier, taking into account class imbalances. Kappa values can fall between -1 and 1, with
a positive value suggesting better than random classification and 0 indicating performance
equal to random predictions.
This process was repeated for each of the eight predictor combinations (Gx, Gx_Scz,
PRS, Demo, PRS+Demo, Gx+PRS, Gx+Demo, Gx+Demo+PRS). Before creating bootstrap
datasets for each predictor combination, the seed was set to 7, before training each model.
The DoMC package in R to allow the use of 8 cores during model training was used.
4.2.4 Classification accuracy
Percentage of correct classification was calculated for each model, by pooling the results
of all 10,000 bootstrap iteration predictions. Samples had a 37.5 % chance of being pre-
dicted in each iteration (Kuhn and Johnson, 2013), meaning each sample was predicted in
approximately 3750 models (each bootstrap iteration built a new GLMNET model). Since
assignment to the train and test data set is random at each iteration, there is slight variation
in the number of predictions for each sample. A simple percentage was calculated for each
sample, based on the instances each sample was assigned to their correct class and the exact
number of models used to predict it. A value of 50% correct classifications for a given
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sample thus means correct classification in 1875 models, while 100% would mean correct
classification in all 3750 models.
4.3 Results
4.3.1 Polygenic Risk Score Imputation
Since Polygenic Risk Scores were only available for 243 out of 280 samples in the cohort,
we decided to use imputation to avoid discarding samples for the machine learning models.
We performed a simple KNN imputation, using only two predictors. This was based on a
previous GAP study by Vassos et al. (2017), which demonstrated a strong effect between
ethnicities, and identified differences in PRS between psychosis patients with a schizophrenia
diagnosis, compared to other diagnoses or controls. The predictors chosen were, therefore,
ethnicity and diagnosis. Ethnicity was stratified into Black, White, Asian and Other, while
the diagnoses were stratified into Schizophrenia, Other Psychoses and Controls.
4.3.2 Performance of Classification Models
Eight GLMNET models were trained (see Table 4.1). The Estimated accuracy was highest
for models using the entire gene expression data (Accuracy = 61%, Kappa = 0.22-0.23),
with models 7 and 8 which incorporated Demographics performing marginally better as
judged by their Kappa value (Table 4.1). PRS did not provide a noticeable benefit and was
not selected by the GLMNET algorithm for any of the final models except models 3 and 5,
which consisted of PRS alone and PRS in combination with demographics. The performance
range across bootstrap iterations for all 8 models is visualised in Figure 4.1.
4.3.3 Classification accuracy across Bootstrap Iterations
The percentage of correct classification was calculated based on approximately 3750 pre-
dictions, per sample, during bootstrapping. Density plots of samples were plotted based
on this percentage (see Figure 4.2). The density plots were stratified by case-control status
(Figure 4.2a) (FEP, Control), and by Diagnosis (Figure 4.2b) (SCZ, OP, Control). Models
incorporating the full Gx data (1,2,6,7 and 8) had similar classification distributions. Controls
were more accurately classified. When stratified by diagnosis, the Schizophrenia samples
fell into a roughly bimodal distribution, with the larger peak at 90%, meaning these samples
were misclassified in 10% of the bootstrap models (Figure 4.2b).
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Table 4.1 List of models with estimated overall Accuracy and Kappa
Model Features Accuracy Kappa
1 Gx 0.61 0.22
2 Gx_Scz 0.61 0.22
3 PRS 0.52 0.04
4 Demographics 0.54 0.07
5 PRS + Demo 0.54 0.07
6 Gx + PRS 0.61 0.22
7 Gx + Demo 0.61 0.23
8 Gx + Demo + PRS 0.61 0.23
Table of Machine Learning models used. Accuracy and Kappa for final model, incorporating all
280 samples, was estimated based on 10,000 bootstrap iteration. Models with Gx use the full gene
expression data, Gx_Scz uses schizophrenia risk genes taken from Pirooznia et al. (2016). Demo
refers to Demographics (Ethnicity, Age, Gender), while PRS is Polygenic Risk Score.
Across all bootstrap iterations Other Psychoses samples reached the highest density at
45% meaning they were classed as controls more regularly than Schizophrenia samples. This
is illustrated further in Figure 4.3, where data from model 1 is visualised using boxplots
stratified by Control and FEP (Figure 4.3a), or Diagnosis (Figure 4.3b). This shows that





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.4 Psychosis severity correlated with classification accuracy
Full Positive and Negative Syndrome Scale scores were available for 49 out of 68 SCZ
patients, and 47 out of 63 OP patients. The two populations were split into quantiles based on
Classification accuracy from bootstrap iterations in model 1. The quantile splits were made
to create 4 groups of equal size, and fell at 0%-25%, 25%- 58%, 58%-85% and 85%-100%.
Figure 4.5 shows full PANSS and subscales plotted against accuracy quantiles.
Median PANSS was lowest for Schizophrenia samples in the first quantile (0%-25%
correct classification), for all subscales with the exception of the Negative symptom subscale
(see Figure 4.5c), where the highest median score was observed. Similarly the highest median
PANSS score in the schizophrenia samples was observed in the last quantile containing the
most accurately classified samples across all iterations (85% - 100% correct classification).
This was, again, on all but the negative symptom subscale. Correlations between PANSS and
classification accuracy in schizophrenia was 0.3 for positive symptoms (p-value = 0.03), 0.25
for overall PANSS (p-value = 0.08), 0.22 for general psychopathology (p-value = 0.11) and
0.01 for negative symptoms (p-value = 0.96).
For schizophrenia samples there was therefore an overall trend of higher scores on the
Positive subscale that was significant. The trend was also observed for the Psychopathology
subscales for samples that were more accurately classified, however this was not significant.
This increase in median PANSS was observed for schizophrenia but not for other psychoses,
where the highest correlation of 0.1 was seen with negative symptoms, but this failed to
reached significance (p-value = 0.49). Schizophrenia patients with high PANSS scores on the
positive subscale were more accurately classified, while that was not true for other psychoses.
4.4 Discussion
4.4.1 Classification Accuracy was highest for Schizophrenia linked Psy-
chosis
The predictive power of the models was lower than previous studies, with none reaching an
estimated accuracy above 61%. In contrast, a recent study by Hess et al. (2016) achieved an
estimated accuracy above 90% and another study by Lee et al. (2012) had similar results in
blood. However, these result in came from more homogeneous dataset consisting of chronic
schizophrenia patients. GAP is a multi-ethnic cohort, and only about half the patients qualify
for a Schizophrenia diagnosis according to the Operational Criteria Checklist for Psychotic
Illness and Affective Illness (OPCRIT) system (Rucker et al., 2011). The discrepancy in
predictive power could be due to confounding with medication in other studies or different
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Figure 4.4 Heatmap of top 20 features of Gene Expression Model 1:
The top 20 predictive genes from Model 1 (all gene expression) are plotted. Gene expression
values were centred and scaled for each feature, and averaged across each subcategory. Samples
are stratified by Control, Other Psychosis and Schizophrenia as before, with the exception that the
schizophrenia category was split into Schizophrenia and Schizophreniform disorder according to
the DSMIV diagnosis. Rows are clustered using complete-linkage clustering, with the dendrogram
indicating distance.
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(a) Full PANSS (b) Positive subscale
(c) Negative subscale (d) Psychopathology subscale
Figure 4.5 Boxplots of PANSS plotted against binned levels of classification accuracy:
Classification accuracy was split into quantiles, resulting in accuracy categories 0%-25%, 25-58%,
58%-85% and 85%-100%. Patients with Schizophrenia (n = 49) are on the right and Other psychoses
(n = 47) are on the left. (a) Shows overall PANSS (b) Shows the Positive PANSS subscale (c) Shows
the Negative PANSS subscale (d) Shows the general Psychopathology PANSS subscale.
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computational approaches. An interesting possibility is that Schizophrenia has a more
consistent phenotype, or that the blood signature in other psychosis is more heterogeneous.
The highest accuracy was achieved by model 8 which uses Gene Expression, Demograph-
ics and PRS. However, this constituted a minimal improvement over any model that included
Gene expression data, with accuracy increases far below 1%, meaning that neither PRS or
demographic variables provided a benefit over Gx alone.
When examining the density plots of models using just gene expression data (Model
1), the highest density of control samples was observed at approximately 95% accurate
classification across all bootstrap iterations, with a sharp drop as accuracy decreases. First
episode psychosis cases, on the other hand, have a largely flat distribution, with a small peak
at 95% (see Figure 4.2b), suggesting a highly heterogeneous gene expression signature that
is distinct from controls for only a subset of samples. Interestingly when the data is split
into diagnostic categories, the schizophrenia distribution forms two peaks, one at 90%, and a
smaller one at 10%. This suggests that the GLMNET can identify a distinct and accurate gene
expression signature for a small majority of schizophrenia samples, while a large minority is
consistently misclassified.
Samples with diagnoses of other Psychoses on the other hand peak at 50%, meaning most
Other Psychosis samples are essentially classified at random. This indicates a heterogeneity
between Schizophrenia and Other Psychosis within their gene expression signature.
4.4.2 Polygenic Risk Score provided no improvement in predictive power
The polygenic risk score model achieved an estimated accuracy of 0.52 which provided
little benefit in classification. None of the models using gene expression data selected PRS
as a predictive variable. While PRS has been shown to have some power to distinguish
schizophrenia samples from controls, it has limited power in populations of African descent
(Lu et al., 2014) due to the allele frequencies being more diverse in those populations.
Since this cohort is multi-ethnic and first-episode, with only half the patients receiving a
schizophrenia diagnosis, any predictive power is likely significantly reduced. As the PGC
(Ripke et al., 2014) increases its sample size PRS predictive power is presumed to increase.
This may lead to better predictions in the future when combined with expression data.
4.4.3 Schizophrenia and Schizophreniform disorder comparison
Since our Schizophrenia category uses the OPCRIT system which synthesises ICD-10 and
DSM-IV criteria, approximately half the samples categories as Schizophrenic suffer from
Schizophreniform disorder under the DSM-IV criteria. Schizophreniform disorder is a less
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severe form of Schizophrenia, with a better outcome. Diagnosis occurs when patients have
not met the full diagnostic criteria for schizophrenia. This usually means symptoms have
developed no more than six months before diagnosis.
As such, I hypothesised that misclassified samples in the Schizophrenia group may
correlate with schizophreniform disorder under the DSM-IV, under the assumption that gene
expression signature may not have been as prominent in these samples. No evidence for
this was found, in fact, the trend was slightly reversed, with the median schizophreniform
patient being more accurately predicted. Since outcome for schizophreniform disorder tends
to be better, despite the symptom overlap, this may suggest that schizophreniform is more
strongly influenced by environmental factors in the first episode when compared to long-term
symptoms in schizophrenia, and a gene expression signature may be more prominent in these
individuals. Reduction in stressful life events and provision of care could conceivably be
consistent with higher rates of recovery, while genetic vulnerability and structural changes
in the brain would presumably play a more significant role in schizophrenia and lead to the
worse long-term outcomes. This is speculative however and would need to be investigated in
a larger sample size.
4.4.4 Genes Important for Model Performance are linked to Immune
System
The gene expression heatmap of the top 20 predictors in model 1 (Figure 4.4), showed slight
expression changes between controls and other psychosis. The strongest signals, however,
were between schizophreniform disorder, and to a lesser extent schizophrenia and controls.
In model 1, which used the full gene expression data, we note Lipocalin 2 (LCN2) and
Cathelicidin Antimicrobial Peptide (CAMP) upregulation, especially in Schizophreniform
disorder. These probes cluster most closely with SUMO3, ATP5H, IDH1, TFRC, SLC44A1,
LDHA and FUCA1 which altogether forms a signal of upregulation in all three groups
compared to controls.
CAMP is a member of a class of proteins involved in innate immunity, primarily in
macrophages. CAMP expression is also mediated by vitamin D, which has been studied
extensively in regard to schizophrenia, depression, the immune system and sleep (Anderson
and Maes, 2012; Aranow, 2011; Brown and Roffman, 2014; McCarty et al., 2014; Moylan
et al., 2014; Penckofer et al., 2010). It also is correlated with Defensin expression, which
forms the most upregulated proteins in our study (see Chapter 3). They are markers of
inflammation, stress and upregulation of the innate immune system.
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LCN2 (also known as NGAL) and Transferrin receptor 1 (TFRC) have also been shown
to play a role in the innate immune system (Ganz, 2009; Goetz et al., 2002), notably in an IL-6
mediated sequestering of iron, which impedes the survival of many pathogens (Parrow et al.,
2013). Interestingly, intracellular pathogens also make use of this mechanism to increase
iron available within the cell (Parrow et al., 2013). Both LCN2 and TFRC are up-regulated
(logfc 0.58 and 0.17 respectively) in the FEP patients (Chapter 3), which suggests iron uptake
from the serum. Chronic stress is known to significantly reduce serum iron levels (Wei
et al., 2008). Iron deficiency is more common in psychiatric patients, with 35% of psychosis
patients being affected according to one study (Korkmaz et al., 2015). In addition increased
accumulation of iron in the basal ganglia (in which TFRC plays a role) is linked to a range of
neurodegenerative disorders such as Huntington’s and Alzheimer’s (Wong and Duce, 2014).
SUMO3 much like ubiquitin can act as a protein-based post-translational modification
and plays a vital role in numerous pathways, including NF-κB signalling (Frank et al., 2013).
The role of SUMO is complex and multifaceted, but one study found SUMO3 knock-downs
increased NF-κB signalling following TNF-α stimulation (Frank et al., 2013). SUMO3 is the
most significant differentially expressed (see chapter 3), although not the most up-regulated.
A stress hypothesis, via the HPA-axis would suggest NF-κB up-regulation at the protein level,
and the differential expression results in chapter 3 did show enrichment of pro-inflammatory
pathways.
ATP5H and IDH1 are involved in mitochondrial function. Studies have also identified
SUMO3 and NF-κB upregulation following glucose and oxygen deprivation (Sirabella et al.,
2009; Yang et al., 2012). Since mitochondria play a core role in oxidative stress pathways,
and these pathways are enriched in psychosis expression studies (Hess et al., 2016), the
above-mentioned genes may be plausible biomarkers linked to schizophrenia pathology.
The probes selected by the model, in combination with differential expression evidence
previously laid out, point to a signal rooted in innate immunity, glucose metabolism, oxygen
deprivation and iron depletion. The signal is consistent with a pattern found in Stress,
which can be mediated by a variety of factors including psychological ones, chronic sleep
deprivation, infections, oxygen and glucose deprivation, environmental exposure and genetic
vulnerabilities. Of interest are differences between Schizophreniform disorder, Schizophrenia
and Other Psychosis in this context. The strongest signal was found for LCN2 and CAMP
between controls and schizophreniform disorder. These genes were also upregulated in
schizophrenia, but to a lesser extent, while they showed a slight downregulation in other
psychosis. Both LCN2 and CAMP may be useful as biomarkers for schizophreniform
disorder and identify patients who have a higher chance of recovery. This would need to be
replicated however.
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4.4.5 Classification Accuracy was associated with Positive Symptom
Severity
The four PANSS groups were correlated with the classification accuracy of Schizophrenia
and other psychosis samples separately. Classification accuracy’s were taken from model
1. The results indicated a significant correlation between positive symptoms and accurate
classification of schizophrenia samples, but not for other psychoses. None of the other
PANSS subscales achieved significance at a p-value threshold of 0.05. This suggests that the
most prominent blood signature that the classifier is using is related to positive symptoms,
specifically in schizophrenia. This mirrors results from chapter 3 indicating a correlation of
positive symptoms with innate immunity.
The overall low accuracy of the binary FEP vs Control classifier might thus be related
to the heterogeneity between schizophrenia and other psychoses. What these results show
however is that the GLMNET classifiers preferentially identify schizophrenia samples with
more severe symptoms, which indicates a common underlying gene expression signature.
These result may be an artefact of confounding with medication or drugs, but since samples
with known drug induced psychosis were excluded and little evidence of a medication effect
was identified in chapter 3 this seems unlikely.
The probes selected by the model are involved in innate immunity and the stress re-
sponses, and are up or down regulated in a manner that is consistent with the schizophrenia
literature. While immune deregulation also plays a role in disorders like depression and bipo-
lar disorder, the magnitude and precise molecular signature may be different. Alternatively it
is possible that less prominent features in the model provide the necessary specificity for the
schizophrenia signature.
While the DSM and ICD categorisations have been criticised for their lack of biological
support, this may provide evidence that schizophrenia is at least more coherent than general
non-pharmaceutically induced psychoses, in terms of the gene expression signature.
4.5 Conclusion and Future Directions
Overall our results achieve much lower accuracy than has been previously reported for blood
gene expression models. This is likely due to greater heterogeneity in the sample, both in
terms of demographics and diagnosis.
I found no evidence that genetic information in the form of PRS significantly increased
model performance. Again, this may be due to the high percentage of patients of African
ancestry. Alternatively, genetic risk may already be captured by gene expression. The
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features that were selected are consistent with a stress model of psychosis, based on HPA axis
arousal. A positive and significant correlation between classification accuracy and positive
symptoms in schizophrenia samples, but not in other FEP samples was found. As it stands,
this supports the idea that more severe positive symptoms are related to stress signals and
are primarily responsible for distinguishing cases from controls. In future work, it may be
useful to include adverse and traumatic life events in the models, which was not possible in
this case. It would also be valuable to test the hypothesis that the gene expression signature
in Scz is more coherent than in other psychoses, by building models in other psychiatric
datasets (especially affective disorders) and apply them to this cohort.
While these results have limited clinical value, further dissection of gene expression
signatures in Psychosis may provide valuable insights into the underlying nature of a patients
psychosis. The current evidence shows consistent but non-specific disruption of pathways
across multiple psychiatric disorders. Using gene expression data from chronic stress,
autoimmunity, pathogenic infections, sleep deprivation, drug use, and other stressors, it might
be possible to identify biomarkers that indicate a more subtle disruption in gene expression.
This could theoretically allow gene expression signatures to determine if pathway disruptions
are related to psychological stress, infections or genetics, which might ultimately help guide
treatment decisions.
Chapter 5
Predictive Modelling using the Dejong
data
5.1 Introduction
First Episode Psychosis has serious clinical implications and presents a challenge for physi-
cians in terms of selecting an appropriate treatment from a range of pharmacological and
therapy options. Psychotic symptoms range from hallucinations and delusions to thought
disorder and catatonia and have a wide variety of contributing factors including genetic,
neurological, environmental and substance abuse. Complicating this is that subdivision
of psychotic disorders in either the International Classification of Diseases 10 (ICD-10),
or the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), are still deeply
rooted in Kraepelin notions, stemming from the early 20th century. While the definitions
of Psychotic disorders such as Schizophrenia, Bipolar Disorder and others, have evolved,
current diagnostic techniques are still quite subjective.
Outside of substance-induced psychosis, perhaps the clearest examples of progress in
classifying psychosis, is the recent realisation that a small percentage of apparent schizophre-
nia cases are suffering from NMDAR antibody Encephalitis (Zandi et al., 2011), a disease
characterised by antibodies with glutamate receptor reactivity. This represents a significant
step towards a more individualised and targeted treatment approach.
Genetic studies have become more sophisticated in identifying genes linked to schizophre-
nia risk (Ripke et al., 2014). However these markers as of yet are of limited clinical use, and
physicians often have little option, but to cycle through a series of interventions, by trial and
error, until one is found that is tolerable for the patient. Due to the heterogeneous nature
of psychosis, gene expression studies can potentially provide a resource of biomarkers that
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sit at the intersection of environmental and biological factors. Ideally, this would help in
identifying diagnostic subdivisions and help with patient care in the clinic, by moving beyond
symptom-based diagnostic and treatment approaches. While attempts have been made to use
blood gene expression data to distinguish psychosis patients from controls in the past (Lee
et al., 2012), the literature is lacking in replication and often suffers from a lack of samples.
A notable exception to this is the schizophrenia mega-analysis by Hess et al. (2016) which
pooled available transcriptomic data from 8 studies (including de Jong et al. (2012)) and used
SVM and Random forest approaches to build classifiers designed to distinguish case-control
status. Their study design trained on data from Illumina chips and used Affymetrix data for
validation. They managed to achieve an AUC of above 0.9 in the training data and above 0.7
in the test data.
Due to the heterogeneous nature of the GAP data available to us, in addition to our
previous results showing poor predictive performance within GAP and for schizophrenia
datasets (chapter 4), we wanted to investigate if predictive models built on schizophrenia
would perform better. Our previous results indicated differences between schizophrenia
and psychosis samples with other diagnoses, but since the models were built on FEP as a
single category, and without test data for final models, it is necessary to create additional
classifiers on external data. This is important to verify the assumption that schizophrenia is a
more homogeneous group and to provide insight into the molecular signature of other FEP
cases. For this purpose, a previously published de Jong et al. (2012), and well define chronic
schizophrenia cohort was identified, consisting of 239 northern European individuals. A 202
sample subset was chosen to build a Schizophrenia classifier and to test it on the GAP data.
We hypothesised that the low predictive power of machine learning models trained on first
episode psychosis is related to the heterogeneous nature of FEP. To support this hypothesis,
we aimed to build classification model on DeJong data and test the performance on the
GAP dataset. We hypothesised that a robust model would more accurately classify first
episode psychosis patients, who are of European ancestry, have higher symptom severity,
ultimately got a diagnosis of schizophrenia, and took anti-psychotic medication. Finally, we
hypothesised that individuals with disorders thought to be closely related to schizophrenia,
based on genetic studies, heritability, and overall clinical presentation, would be classified
more accurately. Roughly speaking, the assumption was that accuracy would decrease
progressively across the spectrum from schizoaffective disorder, delusional disorders, bipolar
disorder to depression.
5.1.1 Aims
In order to test this hypothesis we had 4 core aims.
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1. The first was to train a series of predictive models, including ensemble models using
the dejong data, and to provide evidence that these models are robust and accurate
using internal validation in the form of training sets and cross-validation.
2. The second aim of this project was to validate the models in GAP and report the
performance.
3. The third aim was to investigate differences in classification confidence and probability
for GAP patients who later got a diagnosis of schizophrenia and those who were
diagnosed with other psychoses. We aimed to investigate any signal further by looking
for consistency across all trained machine learning models.
4. The fourth aim was to identify potential clinical or biological confounding factors that
may mask or generate a signal. Of special concern here was anti-psychotic medication
and ethnicity.
5.2 Methods
5.2.1 Gene Expression Datasets
For training Machine Learning models in this chapter we used the DeJong Chronic Schizophre-
nia cohort (referred to as Dejong after this point) as described in de Jong et al. (2012). The
239 samples used in the study came from 2 platforms, 202 from Illumina H-12 and 37 from
Illumina H-8. To simplify the process the 37 samples from the Illumina H-8 chip were not
incorporated in this analysis. The full data for the other samples is freely available at the Ar-
rayExpress Archive (https://www.ebi.ac.uk/arrayexpress) with the identifier E-GEOD-38484.
The E-GEOD-38484 gene expression data was obtained using the ArrayExpress R package
(Rustici et al., 2013). The same subset of the GAP data was used as in chapters 3 and 4
namely 280 samples (149 controls, 131 FEP).
5.2.2 Processing
All datasets were subset to probes that overlap with Gene Symbols identified in the GAP
dataset as described in the preprocessing chapter. This was achieved in the DeJong Chronic
Schizophrenia cohort (Dejong) dataset by using illuminaHumanv3.db package (Dunning
et al., 2015) to translate Illumina ProbeIDs to nuIDs. Probes in the GAP dataset that did not
have any direct nuID matches in the DeJong dataset were examined again using nuIDs, which
correspond to the same Gene Symbol. All remaining probes were dropped in all datasets.
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Probes with LOC or HS. Prefixes were also removed. We used Cellmix (Gaujoux and
Seoighe, 2013) and Surrogate Variable Analysis Leek et al. (2012) to identify any potential
additional confounding factors. All datasets were centred and scaled before any further
analysis.
5.2.3 Machine Learning
The machine learning process involved multiple steps. External data was randomly split
into train and test data 10 times. The training data sets were reduced to relevant features,
by predefined cut-offs, and random forest based recursive feature elimination (RFE). The
remaining features were used to build models with 6 machine learning algorithms of different
families. The models were pooled for each of the 10 splits and an ensemble was created
using stochastic gradient boosting (GBM). Models were validated in test data, and finally
used to predict GAP data. This process is described in detail below and in figure 5.1.
Train and Test data
Ten sets of Train and Test data were randomly generated. This was done using the "createDat-
aPartition" function from the caret package Kuhn (2008), by selecting 80% of samples for the
training data and using the remaining 20% as test data for that set. The ratio of Schizophrenia
samples to Controls was kept constant in all datasets. Down-sampling was performed at later
stages during the model building process.
Feature Selection
Feature selection was performed on each of the 10 Training data sets separately. This was
done in 3 steps. The first step was the removal of highly correlated features; these were
defined as features with a Pearson correlation coefficient above 0.75. The second step was
the removal of features with a variance across samples below 0.25. The third step was an
implementation of RFE incorporating re-sampling from the caret package Kuhn (2008), by
using the rfe function, with slight modification (Algorithm 1). The training data was centred
and scaled, and the RFE algorithm was run using 30 bootstrap iterations, with downsampling.
A predefined list of 30 feature sizes (750, 725, 700 ... 25) was passed on to the function. a
Random Forest algorithm (with OOB settings), was used to build models. Features were
ranked by importance internal to the caret package. The top-performing feature size was
selected, and in situations where the number of selected features exceeded the number of
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3. Feature Selection = rf
4. CaretStack = nb, rf
svmPoly, svmLinear2
glmnet, pcaNNet




Figure 5.1 Machine Learning Ensemble Flowchart
Flowchart of steps in Machine Learning Ensemble process. 1. cleaned Chronic Schizophrenia data
de Jong et al. (2012) was randomly split 10 times into training and testing data. 2. Feature reduction
was performed on each of the 10 training datasets, which included removal of highly correlated
and low variance probes. 3. Recursive feature selection using Random Forest, with 30 bootstrap
iterations, was implemented. 4. Six machine learning algorithms (nb, rf, smvPoly, svmLinear2,
glmnet, pcaNNet) were implemented with 25 bootstrap iterations on each of the 10 training datasets.
All bootstrap iterations used the same sample indices. 5. Caret Ensemble was implemented using
Stochastic Gradient Boosting. An Ensemble was built on the 6 models from step 4, for each training
set, using 25 bootstrap iterations. All classification models from steps 4 and 5 were used to predict
the GAP data and corresponding test data, set aside in step 1.
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samples, only the N most important features were taken forward, where N is the number of
samples in the training set.
Data: 10 Dejong Training Data sets
Result: 10 Training Data sets with reduced features
1 for each Training Data set do
2 for each resampling iteration do
3 Generate train and test data using bootstrapping;
4 Train model on train data with Random Forest using all P predictors;
5 Calculate model performance;
6 Calculate variable importance;
7 for Each subset size Si (750, 725,700 ... 25) do
8 Keep the Si most important variables ;
9 Train model on train data with Random Forest using all Si predictors;
10 Calculate model performance;
11 Calculate variable importance;
12 end
13 end
14 Calculate performance over Si on test data;
15 Determine top performance model;
16 Rank predictors of model;
17 if P predictors > N Sample Size then
18 Select N top predictors;
19 end
20 end
21 Save Predictor lists for downstream model building;
Algorithm 1: Recursive Feature Selection
Training of Models
The Training data were subset to the features selected previously and was scaled and centred
again. Machine learning models were trained following this using the caretList function,
from the caretEnsemble package (developer version, 24th may 2017, tinyurl.com/cEnsemble
) in R. The structure of the process can be seen in Algorithm 2. In short, six machine learning
algorithms were selected (see Table 5.1) and individually passed from caretList to the train
function from the caret package. Random hyperparameter search was implemented via caret
Kuhn (2008) , using the tuneLength command. The search was performed across ten values
per hyperparameters, except in Random Forest and Naive Bayes, where the search was across
5.2 Methods 94
30 and five values respectively. For Random Forest only the mTry parameter was searched,
and this was manually done across all values from 1 to 30. In the case of Naive Bayes, the
tunable hyperparameter space was fully explored.
All models used bootstrapping for purposes. Twenty-Five Intermediate Train and Test
data sets were generated and used in the generation of all models and for all hyperparameter
combinations. The optimal model was selected using the receiver operating characteristic
(ROC), and the final model was trained on the initial training data using the same settings.
Data: Dejong Training Data
Result: Machine Learning Models
1 Generate 25 bootstrapping train and test data indices;
2 for each machine learning algorithm a do
3 for each hyperparameter combination h in a do
4 Generate train and test data using bootstrap index i;
5 for each resampling iteration i do
6 Train model a on train data i using hyperparameters h ;
7 Calculate model performance in test data i;
8 end
9 Find top performing hyperparameters;
10 end
11 Train model a on full input training data using final hyperparameters;
12 Add model a to list of final models;
13 end
14 Save list of final models
Algorithm 2: Machine Learning using caretList
Training of Ensemble Model
The ensemble model was trained using the 6 models generated previously. This was achieved
using the caretStack function from the caretEnsemble package. GBM was used to produce an
ensemble model from the 6 constituent models. This was implemented via the gbm package.
AUC derived from ROC was used as the evaluation metric, we used bootstrapping ( n = 25)
for resampling, and a random parameter search (tuneLength = 10) to identify the optimal
hyper-parameters.
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Table 5.1 List of Machine Learning Algorithms used
Algorithm Algorithm Full Name R Library Tunelength
svmLinear2 SVM with Linear kernel e1071 10
svmPoly SVM with Polynomial kernel kernlab 10
glmnet GLM with Lasso or Elastic-Net glmnet 10
pcaNNet ANNs with Principle Component Step nnet 10
nb Naive Bayes klaR 5
rf Random Forrest randomForest 30
gbm Stochastic Gradient Boosting gbm 10
Table of Machine Learning algorithms used and the names of corresponding R libraries called by the
caret package. Tunelength refers to the number of values used for each tunable hyperparameter. SVM
stands for Support Vector Machines, GLM stands for Generalised Linear Models, ANNs stands for
Artifical Neural Networks. Stochastic Gradient Boosting was used for the ensemble model.
5.2.4 Testing performance in external data
To test performance GAP and all other external datasets were scaled and centred individually.
Following this, the final models for all 7 algorithms (6 caretStack, 1 ensemble) were used to
predict class probabilities for all samples within the current dataset. The predict function
from the caret package was used for this.
5.2.5 Testing of variables associated with classification accuracy
Following prediction, GAP FEP cases were split into Schizophrenia and Other_Psychosis
based on ICD-10 and DSM-IV diagnostic criteria. If either criterion labelled the patient as
schizophrenic, they were put into the schizophrenia group. Otherwise, they were classed as
Other_Psychosis. Subsets were evaluated separately for predictive performance. Additional
tests were performed to identify variables correlated with predictive confidence for the
ensemble model predictions in GAP data. The variables tested were Ethnicity, Gender,
Tobacco use, Medication, PANSS and Diagnosis (ICD-10 and DSMIV). Variables were
tested independently, and samples were excluded in each instance based on the available




The demographic data available for participants in the deJong study was limited. We had
access to information on Gender and Age (see Table 5.2). There was a statistical difference
in gender between Schizophrenia patients and controls. The GAP cohort was identical to
previous chapters, FEP patients were split up into Other Psychosis and Schizophrenia for
some analysis, as in chapter 4. Demographic data for all 3 groups can be found in Chapter 2,
Table 2.1.
Table 5.2 Dejong Chronic Schizophrenia Demographics
Control Schizophrenia (SCZ) p-value
n 96 106
Gender = male (%) 42 (43.8) 76 (71.7) <0.001
Age (mean (sd)) 39.31 (14.19) 39.58 (10.74) 0.877
Table of demographics for the subset of data used from de Jong et al. (2012). Data is split by control
and schizophrenia. Only information for gender and age was available. A significant difference was
found for gender between groups. P-values were calculated using the chi-square test for Gender, and
t-test for age.
5.3.2 Machine Leaning classifiers built in Chronic Schizophrenia
After comparing GAP and Dejong data, 3918 genes were found to be expressed in both.
The machine learning pipeline was implemented as described in figure 5.1. First, a cross
validation algorithm was used to generate 10 sets of training, and 10 corresponding sets of
test data. At each iteration 80% of samples (n = 162) were assigned to the training data, and
the remaining 20% (n = 40) to the test data. Seven machine learning models were trained for
each data split, six on the training data and one ensemble model built on six initial models
(See Table 5.1), resulting in a total of 70 models.
Estimated accuracy during the feature selection approach varied between 67.5% and 75%
(Figure 5.2). The biggest increase in accuracy was seen by increasing features from 25 and
200 features. Datasets 5, 6 and 9 showed the highest performance above 73% while dataset
10 showed the lowest at 67%. Datasets 2 and 3 were most consistent in estimated accuracy
across all features at 70% - 72% accuracy. Dataset 2 is the only one that showed the highest











































































































































The performance of the seven models across each of the 10 data splits was tested using
corresponding test sets. This can be seen in Figure 5.3. The lowest AUC is observed in the
9th split (see Table 5.3) with an average AUC of 0.67 while the highest average AUC was
found in split 10 with 0.88. The 5th data split failed to generate a pcaNNet.
Since the above analysis did not indicate that models in split 1 were outliers in any of
the mentioned metrics, they were considered representative regarding overall performance.
Models from split 1 were therefore used in further analysis, and features were examined. The
top probe for the RF model was RBCK1, and the top probe for the GLMNET model was
















































































































































































































































































































Table 5.3 AUC for all 70 algorithms in Dejong test data
Dejong Test Data
Machine Learning Model
svmLinear2 svmPoly glmnet nb pcaNNet rf ensemble
Split_1 0.82 0.87 0.87 0.86 0.84 0.84 0.84
Split_2 0.78 0.82 0.82 0.75 0.77 0.78 0.8
Split_3 0.86 0.85 0.83 0.82 0.84 0.84 0.85
Split_4 0.73 0.82 0.79 0.74 0.76 0.75 0.79
Split_5 0.83 0.84 0.8 0.74 NA 0.75 0.81
Split_6 0.78 0.82 0.82 0.77 0.81 0.79 0.86
Split_7 0.89 0.9 0.93 0.8 0.88 0.82 0.89
Split_8 0.82 0.75 0.82 0.71 0.83 0.75 0.76
Split_9 0.66 0.71 0.76 0.55 0.71 0.62 0.71
Split_10 0.87 0.84 0.92 0.87 0.87 0.9 0.85
Table of AUC for models tested on internal dejong test data. All rows correspond to AUC results of
models trained on different initial splits of dejong data and tested on corresponding training data (n=
40).
Table 5.4 AUC for all 70 algorithms tested in GAP data
GAP Test Data
Machine Learning Model
svmLinear2 svmPoly glmnet nb pcaNNet rf ensemble
Split_1 0.67 0.69 0.69 0.66 0.68 0.66 0.68
Split_2 0.67 0.67 0.68 0.66 0.69 0.65 0.67
Split_3 0.64 0.67 0.67 0.66 0.67 0.66 0.66
Split_4 0.68 0.67 0.67 0.65 0.67 0.64 0.67
Split_5 0.66 0.68 0.65 0.66 NA 0.66 0.66
Split_6 0.68 0.66 0.69 0.66 0.68 0.66 0.67
Split_7 0.64 0.67 0.67 0.67 0.67 0.66 0.65
Split_8 0.67 0.68 0.67 0.66 0.66 0.66 0.67
Split_9 0.67 0.66 0.7 0.67 0.68 0.66 0.68
Split_10 0.65 0.68 0.68 0.67 0.65 0.67 0.67
Table of AUC for models tested on GAP data. All rows correspond to AUC results of models trained
on different initial splits of dejong data and tested on corresponding GAP data (n= 280).
5.3.3 Predicting FEP using Chronic Schizophrenia classifiers
GAP first-episode psychosis samples were predicted using all 70 models, with the AUC
ranging from 0.65 to 0.7 across all splits and model types (see Table 5.4). Split 1 was used
for analysis after this point for multiple reasons, since the results were robust across all splits.
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Balanced Accuracy was calculated for all seven models in Split 1, for the full data, the
schizophrenia samples and other psychosis samples (see Table 5.5). The highest balanced
accuracy for schizophrenia was 67% (GLMNET model). The Ensemble model performed
best for the full dataset and the other psychosis subset, with balanced accuracies of 64% and
61% respectively.
All models predicted class based on schizophrenia probability between 0 and 1. The
cut-off for classification was 0.5, meaning all samples with a probability between 0.5 and 1
were assigned to the schizophrenia group, while all other samples were classed as controls.
A perfect classifier would assign all controls a probability close to 0 and all FEP a probability
close to 1. Density plots of all models showing the distribution probability for schizophrenia
samples, other psychoses, controls and FEP can be found in (Appendix B: Figure B.1).
Boxplots of the final Ensemble model can be seen in Figure 5.4 where samples groups
are compared based on diagnosis. For the Control-FEP comparison (Figure 5.4a) the median
predicted probability (of belonging into the schizophrenia group) for FEP samples is 0.61
while for control samples it is 0.37. The difference between Control and FEP is statistically
significant (p-value = 6.5e-07). For the Schizophrenia vs. Other Psychosis vs. Control
comparison (Figure 5.4b) the median probability of schizophrenia assignment, as determined
by the ensemble mode, is 0.74 for Schizophrenia samples, while it is 0.56 for other psychosis
samples. ANOVA on the 3 sample groups identified a significant differences between the
probabilities of Control and Schizophrenia samples (adj. p-value = 7e-07), Control and Other
Psychosis (adj. p-value = 0.012), but not between Schizophrenia and Other Psychosis (adj.
p-value = 0.12).
As such an ensemble model built on chronic schizophrenia, showed a significant differ-
ence in predictions for the control group compared to the FEP schizophrenia group, and the
FEP other psychosis group. No significant difference was found between the Schizophrenia




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To look at misclassification in more detail, we looked at three main factors, Ethnicity, Gender
and Medication. Ethnicity, Gender and Medication did not have a statistically significant
effect on predictive confidence in the ensemble model. Boxplots showing the ensemble
model stratified by the above factors can be seen in Appendix B: Figure B.2. Gender was
close to being significant (p-value = 0.06), and this might be due to the Gender difference
found in the training data (p-value < 0.001, see Table 5.2).
In addition we also tested PANSS subscales for significant correlation with predictive
confidence in the ensemble model. This was done separately for Schizophrenia and Other
Psychosis. None reached statistical significant, although the lowest p-value was for the
positive subscale in schizophrenia samples (cor = 0.25, p-value = 0.07, n = 49).
Full stratification of DSM-IV and ICD-10 Diagnoses
Full stratification of DSM-IV and ICD-10 criteria was also performed for the FEP group (see
Appendix B: Figure B.3). While the groups become to small for statistical analysis, they are
noted for completeness. Thee categories had a median above 0.75 are Schizophrenia (median
= 0.86, n = 32), Psychotic Disorder NOS (median = 0.77, n = 13), and Schizoaffective
Disorder Depressed (median = 0.84, n = 9). The other categories include Mania with
Psychosis (median = 0.56, n= 20), Schizophreniform Disorder (median = 0.56, n=27),
followed by Schizoaffective Disorder Bipolar (median = 0.51, n = 7), and delusional disorder
(median = 0.30, n= 7). The two patients with a diagnosis of Major Depression were both
classed as Schizophrenic.
Out of the 68 patients classed as schizophrenic in either ICD10 or DSMIV, only 32 were
diagnosed as Schizophrenic in the DSM-IV, while 25 were diagnosed with schizophreniform
disorder, a diagnosis that is given to patients who do not meet the full criteria for schizophrenia
according to the DSMIV. Interestingly, Schizophreniform samples show a wider range of
predictions with a median predictive probability of 0.60 and a sensitivity of 0.64 (n = 25),
while the 30 Schizophrenia cases have a median predictive probability of 0.86 and a sensitivity
of 0.81 (n = 32). While a substantial amount of Schizophreniform diagnosed patients develop




5.4.1 Model Creation and Robustness
After model creation, we looked at all 70 models in internal test sets of DeJong. The
ensemble models outperformed the strongest constitute model in just one data split. However
the sample size for test samples in all cases was n= 40, and single outliers are bound to have
a large impact at this point. Despite this, the average AUC for the Dejong training data was
found to be 0.8. Which is in line with the results from other studies (Hess et al., 2016; Perkins
et al., 2015; Takahashi et al., 2010), where an estimated AUC of 70%-86% was common.
5.4.2 Validation of Classifiers in GAP
The accuracy of chronic schizophrenia models, when applied to the GAP data was compara-
tively low. It was found that overall balanced accuracy was between 0.61 (svmLinear2 and
rf) and 0.641 (ensemble). Even though the models were trained on Chronic Schizophrenia
and not first episode psychosis, the accuracy is comparable and even outperforms (in the
case of the ensemble model) the highest median estimates of bootstrapped GLMNET models
(61% accuracy) constructed on GAP expression data (Chapter 4). It is important to keep in
mind that GAP is both multi-ethnic and first episode cohort, while other studies have usually
focused on chronic schizophrenia in a homogeneous population. One exception is the study
by Hess et al. (2016), which included the Dejong dataset when training the machine learning
algorithms. They achieved an AUC of 0.7 in testing data, which is comparable to the AUC of
0.64-0.7 achieved here.
5.4.3 Comparison of Schizophrenia and Other Psychoses
It may seem obvious that a classifier built on schizophrenia data would more accurately
predict Schizophrenia in a second dataset, but the concept of Schizophrenia as a singular
category is not as straightforward. Recent work shows considerable genetic overlap with
conditions such as bipolar disorder and schizoaffective disorder (Cross-Disorder Group of
the Psychiatric Genomics Consortium, 2013).
We found that predictive accuracy was greatest for Schizophrenia, followed by controls.
While accuracy was lowest for Other Psychosis, they had a higher chance of being classed as
Schizophrenic than controls. No significant difference in predictive confidence was found
between Schizophrenia and Other Psychosis for the ensemble model. Also, but both groups
revealed a statistically significant difference when compared with controls. This indicates,
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in contrast with our hypothesis, and results from chapter 4, that a chronic schizophrenia
signature classification model does show some predictive power in other psychoses.
These results show that it is possible to build a predictive model based on a white European
chronic schizophrenia cohort and achieve significant predictive power in an ethnically mixed
first episode psychosis population. While these models are not accurate enough to guide
physicians in the clinic, they open the possibility of building more complex clinical models,
by targeting subgroups, and integrating additional biomarkers.
5.4.4 Further diagnostic comparisons in First Episode Psychosis
Since schizophreniform is a less severe form of schizophrenia with better outcome, we
compared the predictive power in patients with both diagnoses, according to DSM-IV records
(see Appendix B: Figure B.3). The median predictive probability for Schizopreniform was
of 0.60 (n = 25), while the Schizophrenia median predictive probability was 0.86 (n = 32).
Since the classifier is based on chronic schizophrenia it makes sense that Schizophrenia
patients would be more accurately predicted, and this might indicate that the classifier is
using a signature in blood that is related to disease progression. However it might also be
related to chronic medication use. Since this sample size is small, future analysis with more
schizophreniform and schizophrenia patients would be necessary.
It is also interesting to note that the Schizoaffective disorder patients with depressed
subtype were identified with higher confidence, than those with bipolar subtype. While the
numbers are small for these groups, ICD-10 subgroups also show more accurate classification
in line with more severe depressive symptoms. Delusions, Mania and the Schizoaffective
Bipolar subtypes being predicted less accurately may be due to these disorders having more
prominent elements of grandiosity, high self esteem and delusions of power.
It is possible that the some of this effect can be explained by stress that is common in
depressive rumination, and schizophrenia and has a suppressive effect on the immune system
in addition to numerous other long term consequences. Manic and Grandiose behaviour
in delusional disorders if accompanied by a positive self perception may be objectivity
damaging to the patient, but might not be perceived as such by them. This may also explain
lower predictive power for patients with schizophreniform disorder as symptoms that have
persisted for a shorter time period may not have had the same damaging effects and biological
changes as would be caused by chronic stress. Including Duration of untreated Psychosis as
a variable may be helpful in elucidating this further (Perkins et al., 2005).
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5.4.5 Symptom Severity was not associated with Classification Accu-
racy
We did not find any significant relationship between PANSS and classification in either the
Schizophrenia or other psychosis subsets. The most significant correlation was between
positive symptoms and schizophrenia (cor = 0.25, p-value = 0.07, n = 49).
In our previous results we found that in a bootstrapped GLMNET model, the positive
PANSS score correlated positively with the GAP Schizophrenia subset, but not with other
other psychoses (Chapter 4). Recent research has identified a blood based gene expression
signature (Jansen et al., 2016) in depression that shows immune suppression and activation
in Major depression, and increased levels of IL-6. This mirrors the schizophrenia gene
expression literature (Gardiner et al., 2013) and our own results (Chapter 3), were immune
deregulation has been consistently identified.
While the results here are not significant, this may be related to low power due to
small sample size. In addition positive symptoms in chronic schizophrenia are likely less
severe (we did not have PANSS available for chronic patients at the time blood was taken),
since they have been in treatment for a longer period. As such the blood signature related
to positive symptoms, if it exists, would be reduced. From that perspective these results
may be consistent with results from previous chapters, however this possibility has to be
independently investigated.
5.4.6 Predictive probes are related to immunity and protein transport
GLMNET and Random Forest models provided a list of features used for predictions. The
most significant of these for the GLMNET model was Fucosidase, Alpha-L- 1 (FUCA1) a
protein implicated in lysosomal storage disease and glycoprotein metabolism. Lysosomal
disruption has been observed previously in gene expression studies linking Schizophrenia
and Bipolar disorder (Hess et al., 2016). This is of particular interest since lysosomal protein
pathways play a role in signal transduction and regulation by virtue of up or downregulating
receptors on the cell membrane.
The top probe for the random forest model was RBCK1, which is part of the LUBAC
complex and plays a pivotal role in linear ubiquitination, all throughout the body. LUBAC is
an essential protein in apoptosis and nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) signalling, by ubiquitinating upstream proteins facilitating their activation
by phosporylation (Stieglitz et al., 2012; Tokunaga and Iwai, 2012). It plays an integral role
in normal immune function.
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Studies of schizophrenia and psychosis have found numerous links to genes apparently
involved in immune signalling, cancer, metabolism and the cytoskeleten. While these path-
ways appear unrelated to psychiatric disorders, proteins in these pathways can have numerous
roles, since endocytosis, exocytosis, apoptosis, cell migration and glucose metabolism are
fundamental processes in normal neuronal functioning. These results further strengthen
previous findings, albeit weakly.
5.4.7 Ensemble Model did not improve predictive power
Our ensemble model showed a modest improvement in classification , based on balanced
accuracy, for first episode in general. Upon close examination this was due to a slight
increase in sensitivity for non schizophrenia cases, from 0.603 to 0.619. Highest sensitivity
for schizophrenia and overall balanced accuracy for schizophrenia cases was achieved by the
glmnet model.
Further improvements may be achievable for the ensemble by increasing bootstrap
iterations for the GBM based ensemble, using a different combinations of models and
refining the feature selection process. In addition, GBM may not be ideal for a classification
problem of this complexity. Boosting algorithms often perform poorly in datasets with a
substantial amount of mislabeling, due to a high risk of overfitting. Since schizophrenia and
psychosis are categories that primarily exist for historic and practical medical purposes, it is
very likely that the best prediction approaches will need to take into account relatively high
rates of misdiagnosis and mislabeling. One way of addressing this would be to use machine
learning algorithms, that are more adept at handling mislabelled data.
Another option would be to train models on subsets that form more coherent sub cat-
egories, in this case data was trained on schizophrenia, but our data suggests that in first
episode psychosis classification based on positive symptoms at least in schizophrenia may be
useful.
To explore any of these questions with confidence, while avoiding the risk of over-fitting
would require including additional data of comparable quality.
5.4.8 Clinical Application
Our results show similar performance to the recent large schizophrenia blood expression
study by Hess et al. (2016). They report ROC of 0.9 - 0.99 in training data and ROC of
0.7-0.75 in test data. While our overall GAP dataset achieves an AUC of between 0.66
and 0.68, this is, as mentioned before, for the entire multi-ethnic First Episode Psychosis
data. Performance increased for patients with a DSM-IV schizophrenia diagnosis, and also
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patients with more depressed symptoms vs manic symptoms. We did not find any significant
correlations between Schizophrenia samples and PANSS scores, in future studies it may be
interesting to specifically contrast predictive power with patients who have bipolar disorder
and specifically manic episodes.
5.4.9 Limitations
There is the possibility that our models simply identified unrelated markers that may correlate
with some sort of stress rather than be directly associated with psychosis, something that has
happened in the past. In order to address this, it would be important to test the model on gene
expression data from other diseases, that are unrelated to psychosis. However even a signal
that merely predicts general ill health, may in combination with other predictors such as PRS
or family history, prove useful in a clinical setting.
5.4.10 Future work
Since psychosis is highly heterogeneous, and our results seem to indicate that Schizophrenia
is more coherent than psychosis in general, finding clusters within psychosis seems like a
more promising approach than treating first episode psychosis as a singular category. For this
purpose Schizophrenia and perhaps schizo-affective disorder would form a category. Our
results seem to indicate similar predictive accuracies for the schizo-affective subset as for
schizophrenia. We also note a better prediction for patients with more severe diagnoses of
depression. In both cases our sample size is limited and these results should be interpreted
with extreme caution, but validation in gene expression data from depressed patients and
patients with schizo-affective disorder, would be a natural progression. Previous findings
have identified a gene expression signature for depression, that disappears in remission
(Jansen et al., 2016).
This may simply indicate that patients with severe mental illness have a gene expression
signature that is more related to metabolism and activity levels. This could explain why
patients with manic symptoms are less likely to be classified correctly. In order to address
this, drawing in additional clinical information about lifestyle and activity prior and during
admission may be useful. In addition comparing results to those of patients with diseases,
that produce similar changes in lifestyles, would help with establishing how specific the
models are to mental health rather than general physical ill health.
As mentioned before further addition of genetic, metabolic and clinical data, should be
incorporated in future work to investigate potential increases in performance. Unfortunately
datasets of this complexity are difficult generate. However, several large scale project are
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in the early stages of collecting data from thousands of participants, and will cover a range
of biological omics data, activity data and clinical data long time periods. These include
"the human project" in New York and "project baseline" at Duke University, which are both
aiming to recruit 10,000 participants. When these projects mature they will provide the
possibility of testing these models on a more general population.
Chapter 6
Discussion and Conclusions
6.1 Overview of the Thesis
In this thesis, I characterised the GAP gene expression data for the first time, to identify
biomarkers and to work towards an empirical classification of first episode psychosis.
Chapter 1 introduced the complexity in diagnosing and treating psychosis sufferers
appropriately, due to the multifaceted presentation, and the range of risk factors. I critically
reviewed the literature on genetic and environmental factors and discussed findings in
the context of a potential stress response model, which can account for gene-environment
interactions. I introduced the concepts of transcriptomics and machine learning and examined
the potential of these approaches in contributing to a more individualised medical approach.
Chapter 2 discusses methods and datasets used in this thesis. I introduced the GAP
study and characterised the transcriptomic, clinical, demographic and genetic data used
in this thesis. I described the methods employed in the preprocessing pipeline for the
transcriptomic data, which represents the backbone of this thesis. Finally, I gave an overview
of the approaches and algorithms relating to the machine learning aspects of this work and
described how I implemented them.
Chapter 3 detailed the differential expression and network analysis experiments. The
aim was to identify biomarkers and pathways to distinguish psychosis and control individu-
als. Enrichment of differentially expressed probes identified a significant association with
pathways associated with transcription and viral infection. Further analysis using network
approaches identified four modules related to first episode psychosis, all of which were highly
enriched for brain-expressed genes and pathways. By including PANSS scores, I identified
one additional module, which was associated with the severity of positive symptoms. This
module was highly enriched for interferon gamma 1, viral and brain pathways.
6.2 Implications of key findings 112
Chapter 4 used bootstrapping and machine learning to generate a series of classification
models and classification frequencies for samples, based on combinations of gene expression
data, PRS and demographic variables. The aim was to estimate classification accuracy and
characterise misclassification for future experiments. The classification accuracy was best
for models using gene expression data but was limited to 0.61%. Examination of the data
found that FEP samples with a later recorded schizophrenia diagnosis were more likely to be
accurately classified than individuals who received other psychosis diagnoses. I also found a
positive correlation between the positive sub-scale score of the PANSS and correct classifica-
tion for people with a schizophrenia diagnosis, but again not for other psychoses. Transcripts
chosen by the model were involved in immune function, iron regulation, mitochondrial
function.
Chapter 5 details a machine learning based classification approach using an external
gene expression dataset, first published by de Jong et al. (2012). The data was composed of
samples taken from chronic schizophrenia patients and controls in the Netherlands. The aim
was to build an ensemble model, based on multiple algorithms, to achieve higher classification
accuracy and to examine the performance in the GAP FEP data. The accuracy of models
was 80% in the Dutch cohort. The accuracy of FEP-control classification was 64% which
was a small improvement over models trained on GAP. Sensitivity was found to be higher in
GAP schizophrenia patients (0.65-0.75) than in other psychoses (0.59-0.62). The data also
suggested that in other psychosis, depressive symptoms were classified more accurately than
manic symptoms. Transcripts used in these models were again related to immune function.
In the remainder of this chapter, the implications and limitations of key findings of the
work are discussed, before examining potential future directions.
6.2 Implications of key findings
6.2.1 Gene expression differences are consistent with a Stress response
Analysis of the GAP gene expression data, using differential expression and network ap-
proaches, to contrast FEP and controls, showed deregulation in pathways related to gene
expression, viral infection, oxidative stress and innate immunity. These findings mirror the
results from multiple other transcriptomic studies both in the case of schizophrenia (Gardiner
et al., 2013; Hess et al., 2016) and Major depressive disorder (Jansen et al., 2016). These
pathways and the direction of gene expression is consistent with a heightened stress response.
The activation of the stress response can be modulated by a wide variety of biological, social,
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and cultural factors, such as genetics, pathogen infections, physical injury, discrimination or
neglect.
While the findings of this study are agnostic regarding the cause of the disruption of
this pathway, it seems likely that all of the above-mentioned factors play a role to varying
extents. Recent studies have implicated the importance of the HPA-axis in first episode
psychosis, identifying associations between increased levels of cortisol and hippocampal
volume (Mondelli et al., 2010b), as well as childhood trauma (Mondelli et al., 2010a). The
findings presented here, are consistent with HPA-axis activation, and while this is not entirely
novel, it strengthens existing literature, by providing further gene expression evidence in a
large multi-ethnic first episode cohort.
6.2.2 Psychosis associated module is enriched for Schizophrenia risk
genes
Following construction of modules using WGCNA, I performed enrichment analysis and
included previously identified schizophrenia risk genes. I identified a large module highly
enriched for several categories of schizophrenia risk genes. The categories used for enrich-
ment were based on data compiled by Pirooznia et al. (2016), and included the genes from
the psychiatric genetics consortium, rare copy-number variants, denovo mutations identified
in sequencing studies, as well candidate genes and neuronal pathways determined to have a
prior probability for schizophrenia risk.
While no evidence was found for an enrichment of the genes implicated by the recent
PGC schizophrenia consortium, they were included in the composite list of all schizophrenia
risk genes, which was the single most significant finding across all modules, and mapped
to the Turquoise module. This module was also enriched for Postsynaptic density pro-
teins, synaptome proteins, microglial markers, metal ion transport, mitochondrial function,
Alzheimer’s disease and glutamatergic synaptic function, as well as viral infections, platelet
activation, vesicle transport and actin organisation.
While these pathways may seem fundamentally disconnected, they make sense in the
context of HPA-axis activation. The release of cortisol suppresses the innate immune system
and platelet activity, which use a lot of the same molecular machinery for endo and exocytosis
that is required for neurotransmitter release. This relies in part on the actin cytoskeleton for
vesicle transport. The stress response also suppresses the release of iron and other metals,
to starve potential pathogens. Mitochondrial function is connected to apoptosis, nutrient
starvation and oxidative stress. These perturbations are also found in Alzheimer’s disease,
where patients can also suffer from psychosis.
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Glutamateterig synapses have been shown to play a major role in schizophrenia, high-
lighted by ketamine use and findings related to NMDAR autoimmunity, which both cause
psychosis symptoms. Since this work is based on blood-based gene expression, these results
are maybe better understood to affect pathways used in multiple systems, rather than indicat-
ing a glutamate system signature that can be detected in peripheral tissue. A high polygenic
risk may sensitise both the glutamate system and pathways downstream of HPA-axis activa-
tion, by affecting the same genes used in both systems, which may explain differences in
symptom presentation despite similar traumatic experiences. Alternatively, activation of the
HPA axis may cause global changes in epigenetics that also affect brain expression.
It is important to note that this module was also correlated with BMI and Olanzap-
ine (but not Risperidone). While no evidence was found for a significant contribution of
antipsychotics, these results should be viewed with caution.
6.2.3 Positive Symptoms correlate with innate immune modules
I used available data from patients who had completed the Positive and Negative Syndrome
Scale to identify WGCNA modules associated with symptom severity. The "greenyellow"
module was the most significant finding, and was found to be positively correlated with
positive symptoms, and negatively correlated with negative symptoms. The module was not
correlated with the overall PANSS, psychosomatic symptoms, or case-control status.
After performing Gene enrichment analysis, I found significant enrichment for pathways
related to type I interferon signalling, virus infections, as well as brain regions like the Hy-
pothalamus. Expression differences correlated with severity of positive symptoms. Negative
and positive symptoms are negatively correlated, and this may point towards a molecular
mechanism that is different in the two dimensions.
One notable finding was that ADAR expression was negatively correlated with negative
symptom severity in the greenyellow module. To account for a potential confounding effect
of antipsychotic medication, I analysed medication free samples and found that ADAR was
the most significantly correlated probe, in the greenyellow module, for positive symptoms,
and was among the most highly correlated ones in negative symptoms.
ADAR is a ubiquitously expressed gene, with a variety of functions in innate immunity,
cancer and neurological disorders (Mannion et al., 2015). It codes for an RNA editing protein
with the primary function of marking and differentiating host RNA from viral RNA.
Deletion of ADAR is lethal, and downregulation causes severe autoimmunity as a ubiq-
uitous antiviral response is induced via the Interferon I pathway, leading to upregulation
of TNF-α and IL-6 among others. This upregulation has been consistently shown in gene
expression studies for depression (Jansen et al., 2016) and schizophrenia (Gardiner et al.,
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2013; Hess et al., 2016) and a large study looking at PTSD also recently found upregulation
of the Interferon I pathway (Breen et al., 2017).
ADAR is located on chromosome 1 in the q21.1, which was identified by the International
Schizophrenia Consortium as a rare deletion increasing Schizophrenia risk (International
Schizophrenia Consortium, 2008).
As mentioned ADAR has also been implicated in various cancers (Mannion et al., 2015).
Schizophrenia patients notably have lower rates of certain cancers (Ji et al., 2013) particularly
prostate cancer, and ADAR suppression interestingly reduces prostate cancer proliferation in
vitro and in vivo, (Salameh et al., 2015). Risk of cancer according to one study rises after
successful treatment for patients (Ji et al., 2013). This may represent a selective advantage
under certain circumstances, and partially explain differences in cancer rates.
The blood signature also shows a clearer correlation with positive symptoms than negative
ones, which is supported by the machine learning results in chapter 3, that show a higher
classification accuracy for schizophrenia patients as positive symptom severity increases.
One interpretation of this might be that Positive symptoms are more likely to activate or be
modulated by the HPA-axis and thus show a clearer signature in blood.
Overall these results show an interesting divergence between the Interferon I signature in
positive and negative symptom severity, that may be worth exploring further. These findings
are also consistent with a psychosis model that is influenced by environmental stressors.
6.2.4 Schizophrenia is more accurately predicted than other psychoses
The machine learning models I built, achieved comparably low accuracy between 61% and
64%. It was however notable that patients who received a schizophrenia diagnosis were
more accurately identified compared to patients with other diagnoses. Interestingly I found
that patients with affective disorders tend to show better classification accuracies if they had
depressive symptoms rather than mania. In schizophrenia, high positive symptom severity
increased classification accuracy as mentioned above. Evidence in the literature suggests
that Schizophrenia and Bipolar disorder share a close genetic relationship, perhaps this is
modulated more via depressive symptoms than manic ones.
This information may be useful in building future machine learning models for classifica-
tion purposes and may help in identifying patient subgroups. Of note is that both machine
learning approaches that relied on internal and external data, relied on probes that are deeply
rooted in pathways associated with innate immunity, stress and the HPA-axis. This further
strengthens the idea that HPA-axis activation is related to psychosis, at least in schizophrenia
patients with positive symptoms.
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While these results are not currently interesting from a clinical perspective, they may
contribute in guiding a more targeted approach in the future. A simple binary classification
approach was used, and this data suggests that using positive symptom scores rather than
case-control status, might lead to better results.
6.3 Limitations
The GAP gene expression data is complex, including patients from different ethnic back-
grounds, on different anti-psychotic medications and with a range of symptoms and diagnoses
of varying degrees of severity.
As such the work presented in this thesis has multiple limitations. Since all chapters
rely heavily on gene expression data in blood, there is a possibility of confounding with an
endless number of variables. While attempts were made to account for unknown variables, the
heterogeneous nature of the FEP sample could plausibly interfere in finding such signatures.
In addition anti-psychotic medication and smoking status likely need to be controlled for
in a more comprehensive manner. Posthoc analyses, and correlations with modules were
performed and compared with anti-psychotic free patients. However, only 17 of the FEP
patients did not use antipsychotics, as such any lack of association should be viewed with
appropriate scepticism.
Such subset analysis, was also performed when using PANSS scores and Diagnosis.
This is subject to a lot of researchers degrees of freedom, and can introduce significant bias
by testing many hypotheses and reporting only significant ones. To avoid this I aimed for
transparency regarding analysis that was performed posthoc. No attempt was made to adjust
for the number alternative hypotheses tested, but in many cases methods this would results
in inadequate statistical hypothesis testing and would need to be independently verified in
separate datasets regardless. This does highlight the requirement for cautious interpretation
of these results. However analysis on subsets of potential confounding factors, that could not
be included in the main analysis, are known a priori. As such they should be viewed less
critically.
The weak findings in regard to PRS should be seen as preliminary since one third of
samples came from individuals of African descent, where PRS has little to no predictive
power. In addition imputation was used to predict PRS for 37 individuals, which further
complicates interpretation. Combining this data with other datasets will be necessary to
address this issue.
Another key limitation is that processing the data can introduce biases. Processing was
performed from a perspective of Controls and First Episode Psychosis as distinct groups,
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this was done to simplify analysis, but the results of the work presented here suggest that it
might be important to conduct further analysis by separating groups by symptom severity
and symptom type in the future. This is a limitation that is not unique to this work, and the
fact that the data here suggests such a subdivision is useful in itself.
6.4 Future Directions
To address the issues discussed above, and test hypotheses generated, it would be important to
include additional transcriptomic datasets. Hess et al. (2016) recently performed a large mega
analysis of all publicly available expression data for schizophrenia, which largely mirrors
the findings presented here. Since findings in Depression (Jansen et al., 2016) and PTSD
mirror these results (Breen et al., 2017), incorporating all publicly available gene expression
datasets from a range of psychiatric disorders in a comprehensive analysis would be natural
progression to elucidate commonalities and differences. Unfortunately few datasets have the
breadth of available data that is found in the GAP study.
As such further work internal to the GAP study is extensive. Additional biological
data that includes mass spectrometry based proteomics, methylation and neuroimaging, as
well to 3 and 12 month followup data for transcriptomics and neuroimaging in a subset
of participants can be incorporated in the future. This would allow the testing of a series
of hypothesis discussed in this thesis. It would also allow for more complex classification
models. Finally it would allow for the generation of expression and protein quantitative trait
loci (eQTL and pQTL) which could also be incorporated into potential classifiers.
An important step would be to incorporate data on trauma, drug use and other risk factors,
that may help with generating better predictive models and exploring a potential link with
the HPA-axis.
6.5 Concluding Remarks
The results of this thesis add to the existing literature which strongly implicates innate
immunity and stress in its broadest definition as a contributing factor to the development of
psychosis. While this is likely a very non-specific indicator of psychosis risk at the molecular
level, further studies may identify a more specific "sub-signature" in certain patient groups.
The results presented here showed some indication that positive symptom severity was linked
to the strength of interferon I pathway deregulation for example, and predictive modelling
approaches indicated a more coherent blood based expression signature for schizophrenia
suffers.
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Taking this further, it may be possible to ultimately identify a gene expression signature
in blood that specifically points towards high HPA-axis activation via rumination or anxiety,
or identify changes that are more closely linked to a stress response mediated by the NF-κB
pathway, due to environmental exposures or pathogens. Genetics, Epigenetic, patient history
and living conditions would likely help elucidate this further, allowing for a more targeted
and personalised intervention as is seen in the case of Anti-NMDAR encephalitis.
The renowned author and neuroscientist Robert Sapolsky, in his best-selling book "Why
Zebras don’t get ulcers", once explained that a Zebra leads a very relaxing social live in
a herd, punctuated only by short bursts of stress when fleeing from a predator, before
succumbing to being eaten or returning to a presumably satisfying existence of eating grass.
The human stress response evolved in same context, not predicting that we would leave our
distant cousins behind, to build cities and societies; filled with inequality, discrimination and
sleepless nights in front of excel spreadsheets, which one cannot outrun.
In this context, an easily stimulated stress response, whether it is caused by genetic or
environmental factors, can quickly become maladaptive. Future study of how the stress
response behaves in modern society, for individuals of varying genetic backgrounds, can
perhaps help in shaping social policies and interventions that allow people to thrive despite
our long outdated biology.
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Appendix A
Supplementary Material: Chapter 3
Full List of differentially Expressed probes.
Table A.1 Top differentially expressed probes (Complete)
Gene logFC p-value q-value CHR Definition
Up-regulated
SUMO3 0.1 2.37E-08 0.0000736 21 Homo sapiens SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae)
(SUMO3), mRNA.
CAMP 0.63 3.11E-08 0.0000736 3 Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA.
DEFA1B 0.91 0.000000209 0.000206 8 Homo sapiens defensin, alpha 1B (DEFA1B), mRNA.
DEFA1 0.82 0.000000323 0.000206 8 Homo sapiens defensin, alpha 1 (DEFA1), mRNA.
DEFA3 0.9 0.000000353 0.000206 8 Homo sapiens defensin, alpha 3, neutrophil-specific (DEFA3), mRNA.
IDH1 0.13 0.000000375 0.000206 2 Homo sapiens isocitrate dehydrogenase 1 (NADP+), soluble (IDH1),
mRNA.
TMEM170B 0.29 0.000000391 0.000206 6 Homo sapiens transmembrane protein 170B (TMEM170B), mRNA.
LDHA 0.1 0.000000562 0.000239 11 Homo sapiens lactate dehydrogenase A (LDHA), transcript variant 2,
mRNA.
LCN2 0.58 0.000000607 0.000239 9 Homo sapiens lipocalin 2 (LCN2), mRNA.
C9ORF72 0.23 0.000000871 0.000276 9 Homo sapiens chromosome 9 open reading frame 72 (C9orf72), tran-
script variant 1, mRNA.
LYPLAL1 0.17 0.000000905 0.000276 1 Homo sapiens lysophospholipase-like 1 (LYPLAL1), mRNA.
TFRC 0.17 0.00000104 0.000276 3 Homo sapiens transferrin receptor (p90, CD71) (TFRC), mRNA.
S100A8 0.35 0.00000105 0.000276 1 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA.
PCMT1 0.13 0.00000114 0.000284 6 Homo sapiens protein-L-isoaspartate (D-aspartate) O-
methyltransferase (PCMT1), mRNA.
BNIP2 0.17 0.0000013 0.000307 15 Homo sapiens BCL2/adenovirus E1B 19kDa interacting protein 2
(BNIP2), mRNA.
SLC30A9 0.17 0.00000137 0.000307 4 Homo sapiens solute carrier family 30 (zinc transporter), member 9
(SLC30A9), mRNA.
SLC44A1 0.17 0.00000169 0.000348 9 Homo sapiens solute carrier family 44, member 1 (SLC44A1), mRNA.
TCEB1 0.13 0.00000191 0.000362 8 Homo sapiens transcription elongation factor B (SIII), polypeptide 1
(15kDa, elongin C) (TCEB1), mRNA.
VAMP7 0.14 0.00000191 0.000362 XY Homo sapiens vesicle-associated membrane protein 7 (VAMP7),
mRNA.
GLRX 0.22 0.00000224 0.000367 5 Homo sapiens glutaredoxin (thioltransferase) (GLRX), mRNA.
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CLNS1A 0.17 0.00000237 0.000367 11 Homo sapiens chloride channel, nucleotide-sensitive, 1A (CLNS1A),
mRNA.
FAM96A 0.23 0.00000239 0.000367 15 Homo sapiens family with sequence similarity 96, member A
(FAM96A), transcript variant 1, mRNA.
H2AFZ 0.1 0.00000242 0.000367 4 Homo sapiens H2A histone family, member Z (H2AFZ), mRNA.
SENP7 0.25 0.00000271 0.000367 3 Homo sapiens SUMO1/sentrin specific peptidase 7 (SENP7), transcript
variant 2, mRNA.
COX7A2L 0.18 0.00000271 0.000367 2 Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 like
(COX7A2L), nuclear gene encoding mitochondrial protein, mRNA.
C14ORF100 0.14 0.00000286 0.000367 14 Homo sapiens chromosome 14 open reading frame 100 (C14orf100),
mRNA.
TAF7 0.19 0.00000288 0.000367 5 Homo sapiens TAF7 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 55kDa (TAF7), mRNA.
PSMC2 0.14 0.00000299 0.000367 7 Homo sapiens proteasome (prosome, macropain) 26S subunit, ATPase,
2 (PSMC2), mRNA.
S100A12 0.3 0.00000303 0.000367 1 Homo sapiens S100 calcium binding protein A12 (S100A12), mRNA.
MED28 0.12 0.00000329 0.00038 4 Homo sapiens mediator complex subunit 28 (MED28), mRNA.
ARL6IP5 0.13 0.0000035 0.000394 3 Homo sapiens ADP-ribosylation-like factor 6 interacting protein 5
(ARL6IP5), mRNA.
IFNGR1 0.15 0.0000043 0.000433 6 Homo sapiens interferon gamma receptor 1 (IFNGR1), mRNA.
SRP9 0.19 0.00000457 0.000434 1 Homo sapiens signal recognition particle 9kDa (SRP9), mRNA.
PRDX3 0.12 0.00000459 0.000434 10 Homo sapiens peroxiredoxin 3 (PRDX3), nuclear gene encoding mito-
chondrial protein, transcript variant 1, mRNA.
ATG3 0.14 0.00000495 0.000436 3 Homo sapiens ATG3 autophagy related 3 homolog (S. cerevisiae)
(ATG3), mRNA.
CRLS1 0.2 0.00000507 0.000436 20 Homo sapiens cardiolipin synthase 1 (CRLS1), mRNA.
CCPG1 0.16 0.00000543 0.000445 15 Homo sapiens cell cycle progression 1 (CCPG1), transcript variant 2,
mRNA.
CLDND1 0.18 0.00000545 0.000445 3 Homo sapiens claudin domain containing 1 (CLDND1), transcript vari-
ant 1, mRNA.
ANXA3 0.34 0.00000571 0.000458 4 Homo sapiens annexin A3 (ANXA3), mRNA.
TM2D1 0.11 0.00000633 0.000466 1 Homo sapiens TM2 domain containing 1 (TM2D1), mRNA.
MAP2K1IP1 0.2 0.00000657 0.000466 4 Homo sapiens mitogen-activated protein kinase kinase 1 interacting pro-
tein 1 (MAP2K1IP1), mRNA.
COX7A2 0.21 0.0000067 0.000466 6 Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 2 (liver)
(COX7A2), mRNA.
FAM45A 0.13 0.00000696 0.000477 10 Homo sapiens family with sequence similarity 45, member A
(FAM45A), mRNA.
ATP5C1 0.23 0.00000764 0.000509 10 Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 com-
plex, gamma polypeptide 1 (ATP5C1), nuclear gene encoding mito-
chondrial protein, transcript variant 2, mRNA.
CDC40 0.11 0.000008 0.00052 6 Homo sapiens cell division cycle 40 homolog (S. cerevisiae) (CDC40),
mRNA.
VBP1 0.21 0.00000802 0.00052 X Homo sapiens von Hippel-Lindau binding protein 1 (VBP1), mRNA.
PHF5A 0.19 0.00000872 0.000529 22 Homo sapiens PHD finger protein 5A (PHF5A), mRNA.
GNG10 0.3 0.00000901 0.000533 9 Homo sapiens guanine nucleotide binding protein (G protein), gamma
10 (GNG10), mRNA.
PSMD10 0.15 0.00000935 0.000533 X Homo sapiens proteasome (prosome, macropain) 26S subunit, non-
ATPase, 10 (PSMD10), transcript variant 1, mRNA.
HEXB 0.1 0.00000953 0.000533 5 Homo sapiens hexosaminidase B (beta polypeptide) (HEXB), mRNA.
YPEL5 0.13 0.00000973 0.000533 2 Homo sapiens yippee-like 5 (Drosophila) (YPEL5), mRNA.
WDR61 0.13 0.00000973 0.000533 15 Homo sapiens WD repeat domain 61 (WDR61), mRNA.
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COX17 0.13 0.00001 0.000533 3 Homo sapiens COX17 cytochrome c oxidase assembly homolog (S.
cerevisiae) (COX17), nuclear gene encoding mitochondrial protein,
mRNA.
UQCRQ 0.26 0.0000102 0.000533 5 Homo sapiens ubiquinol-cytochrome c reductase, complex III subunit
VII, 9.5kDa (UQCRQ), nuclear gene encoding mitochondrial protein,
mRNA.
PHF20L1 0.16 0.0000104 0.000533 8 Homo sapiens PHD finger protein 20-like 1 (PHF20L1), transcript vari-
ant 1, mRNA.
KLHDC2 0.15 0.0000114 0.000558 14 Homo sapiens kelch domain containing 2 (KLHDC2), mRNA.
CD24 0.27 0.0000117 0.000558 Y Homo sapiens CD24 molecule (CD24), mRNA.
TANK 0.12 0.0000117 0.000558 2 Homo sapiens TRAF family member-associated NFKB activator
(TANK), transcript variant 1, mRNA.
LYST 0.13 0.0000118 0.000558 1 Homo sapiens lysosomal trafficking regulator (LYST), mRNA.
FBXL5 0.12 0.0000122 0.000563 4 Homo sapiens F-box and leucine-rich repeat protein 5 (FBXL5), tran-
script variant 1, mRNA.
PIGY 0.17 0.0000124 0.000565 4 Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class Y
(PIGY), transcript variant 2, mRNA.
ENY2 0.19 0.0000131 0.000579 8 Homo sapiens enhancer of yellow 2 homolog (Drosophila) (ENY2),
mRNA.
TBK1 0.15 0.0000132 0.000579 12 Homo sapiens TANK-binding kinase 1 (TBK1), mRNA.
ORMDL1 0.14 0.0000137 0.000587 2 Homo sapiens ORM1-like 1 (S. cerevisiae) (ORMDL1), mRNA.
ASNSD1 0.19 0.0000141 0.000597 2 Homo sapiens asparagine synthetase domain containing 1 (ASNSD1),
mRNA.
CYB5R4 0.13 0.0000147 0.000617 6 Homo sapiens cytochrome b5 reductase 4 (CYB5R4), mRNA.
TXNDC17 0.19 0.0000152 0.000632 17 Homo sapiens thioredoxin domain containing 17 (TXNDC17), mRNA.
SRGN 0.12 0.0000163 0.000658 10 Homo sapiens serglycin (SRGN), mRNA.
TMX1 0.24 0.0000165 0.000658 14 Homo sapiens thioredoxin-related transmembrane protein 1 (TMX1),
mRNA.
TXN 0.17 0.0000167 0.000659 9 Homo sapiens thioredoxin (TXN), mRNA.
RNF7 0.14 0.0000174 0.000676 3 Homo sapiens ring finger protein 7 (RNF7), transcript variant 3, mRNA.
COMMD3 0.16 0.0000189 0.000696 10 Homo sapiens COMM domain containing 3 (COMMD3), mRNA.
KIAA1600 0.18 0.0000193 0.000696 10 Homo sapiens KIAA1600 (KIAA1600), mRNA.
UBL3 0.17 0.0000197 0.000696 13 Homo sapiens ubiquitin-like 3 (UBL3), mRNA.
MTMR6 0.17 0.0000199 0.000696 13 Homo sapiens myotubularin related protein 6 (MTMR6), mRNA.
OSBPL8 0.22 0.00002 0.000696 12 Homo sapiens oxysterol binding protein-like 8 (OSBPL8), transcript
variant 2, mRNA.
MARCH7 0.15 0.0000205 0.000703 2 Homo sapiens membrane-associated ring finger (C3HC4) 7
(MARCH7), mRNA.
CNIH4 0.26 0.0000211 0.000706 1 Homo sapiens cornichon homolog 4 (Drosophila) (CNIH4), mRNA.
SLC35A1 0.18 0.0000212 0.000706 6 Homo sapiens solute carrier family 35 (CMP-sialic acid transporter),
member A1 (SLC35A1), mRNA.
COPS5 0.13 0.0000212 0.000706 8 Homo sapiens COP9 constitutive photomorphogenic homolog subunit
5 (Arabidopsis) (COPS5), mRNA.
TMED7 0.16 0.0000214 0.000706 5 Homo sapiens transmembrane emp24 protein transport domain contain-
ing 7 (TMED7), mRNA.
KBTBD11 0.15 0.0000216 0.000708 8 Homo sapiens kelch repeat and BTB (POZ) domain containing 11
(KBTBD11), mRNA.
MRPL3 0.2 0.0000221 0.000717 3 Homo sapiens mitochondrial ribosomal protein L3 (MRPL3), nuclear
gene encoding mitochondrial protein, mRNA.
MRPL33 0.11 0.0000223 0.000717 2 Homo sapiens mitochondrial ribosomal protein L33 (MRPL33), nuclear
gene encoding mitochondrial protein, transcript variant 2, mRNA.
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PPP3CB 0.1 0.000023 0.000726 10 Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit,
beta isoform (PPP3CB), mRNA.
AGL 0.23 0.0000241 0.000726 1 Homo sapiens amylo-1, 6-glucosidase, 4-alpha-glucanotransferase
(AGL), transcript variant 5, mRNA.
TOMM20 0.11 0.0000245 0.000726 1 Homo sapiens translocase of outer mitochondrial membrane 20 ho-
molog (yeast) (TOMM20), nuclear gene encoding mitochondrial pro-
tein, mRNA.
LY96 0.42 0.0000249 0.000726 8 Homo sapiens lymphocyte antigen 96 (LY96), mRNA.
CNOT8 0.12 0.000025 0.000726 5 Homo sapiens CCR4-NOT transcription complex, subunit 8 (CNOT8),
mRNA.
MYL6 0.12 0.0000251 0.000726 12 Homo sapiens myosin, light chain 6, alkali, smooth muscle and non-
muscle (MYL6), transcript variant 1, mRNA.
RPSA 0.15 0.0000252 0.000726 3 Homo sapiens ribosomal protein SA (RPSA), transcript variant 1,
mRNA.
RCBTB2 0.14 0.0000252 0.000726 13 Homo sapiens regulator of chromosome condensation (RCC1) and BTB
(POZ) domain containing protein 2 (RCBTB2), mRNA.
AGTPBP1 0.11 0.0000261 0.000738 9 Homo sapiens ATP/GTP binding protein 1 (AGTPBP1), mRNA.
UBLCP1 0.11 0.0000263 0.000742 5 Homo sapiens ubiquitin-like domain containing CTD phosphatase 1
(UBLCP1), mRNA.
MRPL32 0.19 0.0000271 0.000754 7 Homo sapiens mitochondrial ribosomal protein L32 (MRPL32), nuclear
gene encoding mitochondrial protein, mRNA.
TMEM14B 0.15 0.0000278 0.000759 6 Homo sapiens transmembrane protein 14B (TMEM14B), mRNA.
AZIN1 0.14 0.0000282 0.000763 8 Homo sapiens antizyme inhibitor 1 (AZIN1), transcript variant 1,
mRNA.
SF3B14 0.2 0.0000288 0.000771 2 Homo sapiens splicing factor 3B, 14 kDa subunit (SF3B14), mRNA.
TPK1 0.11 0.0000297 0.000777 7 Homo sapiens thiamin pyrophosphokinase 1 (TPK1), transcript variant
2, mRNA.
STK17B 0.16 0.0000306 0.000784 2 Homo sapiens serine/threonine kinase 17b (STK17B), mRNA.
CKLF 0.14 0.0000306 0.000784 16 Homo sapiens chemokine-like factor (CKLF), transcript variant 5,
mRNA.
ANGEL2 0.12 0.0000309 0.000785 1 Homo sapiens angel homolog 2 (Drosophila) (ANGEL2), mRNA.
SUMO1P3 0.1 0.0000325 0.000818 1 Homo sapiens SUMO1 pseudogene 3 (SUMO1P3), non-coding RNA.
GGPS1 0.1 0.0000332 0.000826 1 Homo sapiens geranylgeranyl diphosphate synthase 1 (GGPS1), tran-
script variant 2, mRNA.
HIGD1A 0.18 0.0000334 0.000826 3 Homo sapiens HIG1 hypoxia inducible domain family, member 1A
(HIGD1A), transcript variant 1, mRNA.
UBE2E1 0.12 0.0000336 0.000829 3 Homo sapiens ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog,
yeast) (UBE2E1), transcript variant 2, mRNA.
ANKIB1 0.15 0.0000361 0.000846 7 Homo sapiens ankyrin repeat and IBR domain containing 1 (ANKIB1),
mRNA.
SRP19 0.14 0.0000362 0.000846 5 Homo sapiens signal recognition particle 19kDa (SRP19), mRNA.
DUSP12 0.12 0.0000362 0.000846 1 Homo sapiens dual specificity phosphatase 12 (DUSP12), mRNA.
DPM1 0.19 0.0000372 0.000846 20 Homo sapiens dolichyl-phosphate mannosyltransferase polypeptide 1,
catalytic subunit (DPM1), mRNA.
VPS29 0.17 0.0000373 0.000846 12 Homo sapiens vacuolar protein sorting 29 homolog (S. cerevisiae)
(VPS29), transcript variant 1, mRNA.
MRLC2 0.1 0.0000374 0.000846 18 Homo sapiens myosin regulatory light chain MRLC2 (MRLC2),
mRNA.
FUCA1 0.14 0.0000374 0.000846 1 Homo sapiens fucosidase, alpha-L- 1, tissue (FUCA1), mRNA.
DPY30 0.18 0.0000379 0.000846 2 Homo sapiens dpy-30 homolog (C. elegans) (DPY30), mRNA.
SRP72 0.11 0.0000381 0.000846 4 Homo sapiens signal recognition particle 72kDa (SRP72), mRNA.
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C14ORF138 0.17 0.0000383 0.000846 14 Homo sapiens chromosome 14 open reading frame 138 (C14orf138),
transcript variant 1, mRNA.
UBE2N 0.14 0.0000383 0.000846 12 Homo sapiens ubiquitin-conjugating enzyme E2N (UBC13 homolog,
yeast) (UBE2N), mRNA.
RSL24D1 0.42 0.0000388 0.000846 15 Homo sapiens ribosomal L24 domain containing 1 (RSL24D1), mRNA.
DSE 0.15 0.0000396 0.000853 6 Homo sapiens dermatan sulfate epimerase (DSE), transcript variant 1,
mRNA.
RAB5A 0.1 0.0000397 0.000853 3 Homo sapiens RAB5A, member RAS oncogene family (RAB5A),
mRNA.
RWDD1 0.21 0.0000404 0.000861 6 Homo sapiens RWD domain containing 1 (RWDD1), transcript variant
3, mRNA.
PPM1B 0.14 0.0000404 0.000861 2 Homo sapiens protein phosphatase 1B (formerly 2C), magnesium-
dependent, beta isoform (PPM1B), transcript variant 2, mRNA.
TMED10P 0.1 0.0000412 0.000868 8 Homo sapiens transmembrane emp24-like trafficking protein 10 (yeast)
pseudogene (TMED10P), non-coding RNA.
EFHA1 0.15 0.0000416 0.000868 13 Homo sapiens EF-hand domain family, member A1 (EFHA1), mRNA.
RHOT1 0.13 0.0000419 0.000868 17 Homo sapiens ras homolog gene family, member T1 (RHOT1), tran-
script variant 2, mRNA.
IRF2BP2 0.12 0.000042 0.000868 1 Homo sapiens interferon regulatory factor 2 binding protein 2
(IRF2BP2), transcript variant 1, mRNA.
ACADM 0.19 0.0000428 0.00088 1 Homo sapiens acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight
chain (ACADM), nuclear gene encoding mitochondrial protein, mRNA.
KLHL5 0.1 0.0000446 0.000897 4 Homo sapiens kelch-like 5 (Drosophila) (KLHL5), transcript variant 3,
mRNA.
SERP1 0.15 0.0000446 0.000897 3 Homo sapiens stress-associated endoplasmic reticulum protein 1
(SERP1), mRNA.
ATP5O 0.14 0.0000468 0.000929 21 Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 com-
plex, O subunit (ATP5O), nuclear gene encoding mitochondrial protein,
mRNA.
MDH1 0.1 0.0000474 0.000933 2 Homo sapiens malate dehydrogenase 1, NAD (soluble) (MDH1),
mRNA.
PPP1R2 0.16 0.0000475 0.000933 3 Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 2
(PPP1R2), mRNA.
SS18L2 0.14 0.0000475 0.000933 3 Homo sapiens synovial sarcoma translocation gene on chromosome 18-
like 2 (SS18L2), mRNA.
RPLP0 0.16 0.00005 0.000943 12 Homo sapiens ribosomal protein, large, P0 (RPLP0), transcript variant
1, mRNA.
NIF3L1 0.11 0.00005 0.000943 2 Homo sapiens NIF3 NGG1 interacting factor 3-like 1 (S. pombe)
(NIF3L1), mRNA.
PSMB7 0.13 0.0000501 0.000943 9 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 7
(PSMB7), mRNA.
PSMA3 0.17 0.0000502 0.000943 14 Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 3
(PSMA3), transcript variant 2, mRNA.
ZFR 0.13 0.0000502 0.000943 5 Homo sapiens zinc finger RNA binding protein (ZFR), mRNA.
FOXN2 0.17 0.0000524 0.000964 2 Homo sapiens forkhead box N2 (FOXN2), mRNA.
FAR1 0.18 0.0000555 0.00101 11 Homo sapiens fatty acyl CoA reductase 1 (FAR1), mRNA.
EIF4E3 0.12 0.0000564 0.00101 3 Homo sapiens eukaryotic translation initiation factor 4E family member
3 (EIF4E3), mRNA.
RAB3GAP2 0.14 0.0000581 0.00103 1 Homo sapiens RAB3 GTPase activating protein subunit 2 (non-
catalytic) (RAB3GAP2), mRNA.
KIAA1370 0.14 0.0000602 0.00104 15 Homo sapiens KIAA1370 (KIAA1370), mRNA.
SLMAP 0.13 0.0000602 0.00104 3 Homo sapiens sarcolemma associated protein (SLMAP), mRNA.
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OXR1 0.24 0.0000613 0.00105 8 Homo sapiens oxidation resistance 1 (OXR1), mRNA.
RCOR3 0.17 0.0000615 0.00105 1 Homo sapiens REST corepressor 3 (RCOR3), mRNA.
FAM49B 0.1 0.0000643 0.00107 8 Homo sapiens family with sequence similarity 49, member B
(FAM49B), mRNA.
RASA1 0.13 0.0000669 0.00111 5 Homo sapiens RAS p21 protein activator (GTPase activating protein) 1
(RASA1), transcript variant 1, mRNA.
ZNHIT3 0.23 0.0000678 0.00111 17 Homo sapiens zinc finger, HIT type 3 (ZNHIT3), mRNA.
C8ORF59 0.22 0.0000684 0.00111 8 Homo sapiens chromosome 8 open reading frame 59 (C8orf59), tran-
script variant 3, mRNA.
ATP5L 0.14 0.00007 0.00112 11 Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 com-
plex, subunit G (ATP5L), nuclear gene encoding mitochondrial protein,
mRNA.
SP3 0.18 0.0000701 0.00112 2 Homo sapiens Sp3 transcription factor (SP3), transcript variant 2,
mRNA.
GAPT 0.17 0.0000709 0.00113 5 Homo sapiens GRB2-binding adaptor protein, transmembrane (GAPT),
mRNA.
CD302 0.16 0.0000715 0.00114 2 Homo sapiens CD302 molecule (CD302), mRNA.
SERPINB1 0.12 0.0000731 0.00114 6 Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member
1 (SERPINB1), mRNA.
NIN 0.12 0.0000739 0.00115 14 Homo sapiens ninein (GSK3B interacting protein) (NIN), transcript
variant 2, mRNA.
RPL7 0.36 0.0000757 0.00117 8 Homo sapiens ribosomal protein L7 (RPL7), mRNA.
NDUFA4 0.3 0.0000782 0.0012 7 Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 4, 9kDa (NDUFA4), nuclear gene encoding mitochondrial protein,
mRNA.
PCNP 0.19 0.0000794 0.0012 3 Homo sapiens PEST proteolytic signal containing nuclear protein
(PCNP), mRNA.
PSIP1 0.16 0.0000797 0.0012 9 Homo sapiens PC4 and SFRS1 interacting protein 1 (PSIP1), transcript
variant 2, mRNA.
TMCO1 0.19 0.0000805 0.00121 1 Homo sapiens transmembrane and coiled-coil domains 1 (TMCO1),
mRNA.
SRP14P1 0.15 0.0000822 0.00123 12 Homo sapiens signal recognition particle 14kDa (homologous Alu RNA
binding protein) pseudogene 1 (SRP14P1), non-coding RNA.
RHEB 0.12 0.000083 0.00124 7 Homo sapiens Ras homolog enriched in brain (RHEB), mRNA.
SCAMP1 0.14 0.0000838 0.00124 5 Homo sapiens secretory carrier membrane protein 1 (SCAMP1),
mRNA.
ATP5J 0.18 0.0000848 0.00125 21 Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 com-
plex, subunit F6 (ATP5J), nuclear gene encoding mitochondrial protein,
transcript variant 3, mRNA.
UQCRH 0.14 0.0000858 0.00125 1 Homo sapiens ubiquinol-cytochrome c reductase hinge protein
(UQCRH), mRNA.
RPL24 0.13 0.0000888 0.00128 3 Homo sapiens ribosomal protein L24 (RPL24), mRNA.
HINT1 0.34 0.0000901 0.00129 5 Homo sapiens histidine triad nucleotide binding protein 1 (HINT1),
mRNA.
TMEM126B 0.21 0.0000901 0.00129 11 Homo sapiens transmembrane protein 126B (TMEM126B), mRNA.
TMED5 0.18 0.0000914 0.0013 1 Homo sapiens transmembrane emp24 protein transport domain contain-
ing 5 (TMED5), mRNA.
RPS9 0.13 0.0000918 0.0013 19 Homo sapiens ribosomal protein S9 (RPS9), mRNA.
STAG2 0.16 0.0000922 0.0013 X Homo sapiens stromal antigen 2 (STAG2), transcript variant 2, mRNA.
PAPD4 0.1 0.000094 0.00131 5 Homo sapiens PAP associated domain containing 4 (PAPD4), mRNA.
ACSL4 0.17 0.0000969 0.00134 X Homo sapiens acyl-CoA synthetase long-chain family member 4
(ACSL4), transcript variant 1, mRNA.
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LYRM5 0.14 0.0000971 0.00134 12 Homo sapiens LYR motif containing 5 (LYRM5), mRNA.
GMFG 0.12 0.0000988 0.00135 19 Homo sapiens glia maturation factor, gamma (GMFG), mRNA.
ANKRD12 0.19 0.000102 0.00138 18 Homo sapiens ankyrin repeat domain 12 (ANKRD12), transcript vari-
ant 1, mRNA.
CAPZA2 0.21 0.000103 0.00139 7 Homo sapiens capping protein (actin filament) muscle Z-line, alpha 2
(CAPZA2), mRNA.
SLC40A1 0.13 0.000106 0.0014 2 Homo sapiens solute carrier family 40 (iron-regulated transporter),
member 1 (SLC40A1), mRNA.
SRP14 0.14 0.000107 0.00141 15 Homo sapiens signal recognition particle 14kDa (homologous Alu RNA
binding protein) (SRP14), mRNA.
FAM160B1 0.16 0.000107 0.00141 10 Homo sapiens family with sequence similarity 160, member B1
(FAM160B1), transcript variant 1, mRNA.
S100A9 0.1 0.000114 0.00146 1 Homo sapiens S100 calcium binding protein A9 (calgranulin B)
(S100A9), mRNA.
FEM1C 0.15 0.000115 0.00147 5 Homo sapiens fem-1 homolog c (C. elegans) (FEM1C), mRNA.
KLF9 0.17 0.000118 0.0015 9 Homo sapiens Kruppel-like factor 9 (KLF9), mRNA.
GALC 0.1 0.000119 0.0015 14 Homo sapiens galactosylceramidase (GALC), transcript variant 1,
mRNA.
COX7C 0.33 0.00012 0.0015 5 Homo sapiens cytochrome c oxidase subunit VIIc (COX7C), nuclear
gene encoding mitochondrial protein, mRNA.
PNRC2 0.15 0.00012 0.0015 1 Homo sapiens proline-rich nuclear receptor coactivator 2 (PNRC2),
mRNA.
RPS15A 0.34 0.000122 0.00151 16 Homo sapiens ribosomal protein S15a (RPS15A), transcript variant 1,
mRNA.
ACN9 0.13 0.000124 0.00153 7 Homo sapiens ACN9 homolog (S. cerevisiae) (ACN9), mRNA.
ZRANB2 0.19 0.000124 0.00153 1 Homo sapiens zinc finger, RAN-binding domain containing 2
(ZRANB2), transcript variant 2, mRNA.
GLO1 0.11 0.000131 0.0016 6 Homo sapiens glyoxalase I (GLO1), mRNA.
PSMA6 0.23 0.000131 0.0016 14 Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 6
(PSMA6), mRNA.
HMGN4 0.12 0.000132 0.0016 6 Homo sapiens high mobility group nucleosomal binding domain 4
(HMGN4), mRNA.
UBL5 0.15 0.000134 0.00161 19 Homo sapiens ubiquitin-like 5 (UBL5), transcript variant 2, mRNA.
CHD1 0.11 0.000136 0.00163 5 Homo sapiens chromodomain helicase DNA binding protein 1 (CHD1),
mRNA.
TBCA 0.14 0.000137 0.00163 5 Homo sapiens tubulin folding cofactor A (TBCA), mRNA.
FBXO33 0.11 0.000137 0.00163 14 Homo sapiens F-box protein 33 (FBXO33), mRNA.
TRIM33 0.1 0.000141 0.00164 1 Homo sapiens tripartite motif-containing 33 (TRIM33), transcript vari-
ant a, mRNA.
PPP1CB 0.17 0.000141 0.00164 2 Homo sapiens protein phosphatase 1, catalytic subunit, beta isoform
(PPP1CB), transcript variant 3, mRNA.
LSM1 0.15 0.000141 0.00164 8 Homo sapiens LSM1 homolog, U6 small nuclear RNA associated (S.
cerevisiae) (LSM1), mRNA.
RPL15 0.11 0.000144 0.00166 3 Homo sapiens ribosomal protein L15 (RPL15), mRNA.
POLE4 0.12 0.000145 0.00167 2 Homo sapiens polymerase (DNA-directed), epsilon 4 (p12 subunit)
(POLE4), mRNA.
MITD1 0.12 0.000148 0.00168 2 Homo sapiens MIT, microtubule interacting and transport, domain con-
taining 1 (MITD1), mRNA.
STX7 0.13 0.000153 0.00173 6 Homo sapiens syntaxin 7 (STX7), mRNA.
NCK1 0.12 0.000153 0.00173 3 Homo sapiens NCK adaptor protein 1 (NCK1), mRNA.
DCP2 0.14 0.000154 0.00173 5 Homo sapiens DCP2 decapping enzyme homolog (S. cerevisiae)
(DCP2), mRNA.
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MGST3 0.12 0.000155 0.00173 1 Homo sapiens microsomal glutathione S-transferase 3 (MGST3),
mRNA.
C2ORF64 0.12 0.000156 0.00173 2 Homo sapiens chromosome 2 open reading frame 64 (C2orf64),
mRNA.
C20ORF52 0.13 0.000158 0.00175 20 Homo sapiens chromosome 20 open reading frame 52 (C20orf52),
mRNA.
C17ORF61 0.13 0.000159 0.00175 17 Homo sapiens chromosome 17 open reading frame 61 (C17orf61),
mRNA.
ZBED5 0.14 0.000159 0.00175 11 Homo sapiens zinc finger, BED-type containing 5 (ZBED5), mRNA.
MRPL11 0.12 0.000161 0.00177 11 Homo sapiens mitochondrial ribosomal protein L11 (MRPL11), nuclear
gene encoding mitochondrial protein, transcript variant 1, mRNA.
PFAAP5 0.16 0.000162 0.00177 13 Homo sapiens phosphonoformate immuno-associated protein 5
(PFAAP5), mRNA.
PDCD10 0.27 0.000168 0.00182 3 Homo sapiens programmed cell death 10 (PDCD10), transcript variant
2, mRNA.
DDX59 0.11 0.00017 0.00183 1 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 59
(DDX59), transcript variant 1, mRNA.
CRBN 0.18 0.00017 0.00183 3 Homo sapiens cereblon (CRBN), mRNA.
MTDH 0.11 0.000174 0.00186 8 Homo sapiens metadherin (MTDH), mRNA.
DEK 0.16 0.000176 0.00186 6 Homo sapiens DEK oncogene (DNA binding) (DEK), mRNA.
RBX1 0.23 0.000177 0.00187 22 Homo sapiens ring-box 1 (RBX1), mRNA.
NAT5 0.1 0.000179 0.00188 20 Homo sapiens N-acetyltransferase 5 (GCN5-related, putative) (NAT5),
transcript variant 3, mRNA.
DBI 0.23 0.000192 0.00195 2 Homo sapiens diazepam binding inhibitor (GABA receptor modulator,
acyl-Coenzyme A binding protein) (DBI), transcript variant 2, mRNA.
RPS6KB1 0.15 0.000194 0.00196 17 Homo sapiens ribosomal protein S6 kinase, 70kDa, polypeptide 1
(RPS6KB1), mRNA.
ATP5EP2 0.1 0.000198 0.00199 13 Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 com-
plex, epsilon subunit pseudogene 2 (ATP5EP2), transcript variant 6,
non-coding RNA.
NSL1 0.11 0.0002 0.002 1 Homo sapiens NSL1, MIND kinetochore complex component, ho-
molog (S. cerevisiae) (NSL1), transcript variant 2, mRNA.
NME1-NME2 0.1 0.0002 0.002 17 Homo sapiens NME1-NME2 readthrough (NME1-NME2), mRNA.
PAIP2 0.1 0.000202 0.002 5 Homo sapiens poly(A) binding protein interacting protein 2 (PAIP2),
transcript variant 1, mRNA.
EVI2A 0.34 0.000203 0.00201 17 Homo sapiens ecotropic viral integration site 2A (EVI2A), transcript
variant 2, mRNA.
CHMP5 0.24 0.000206 0.00202 9 Homo sapiens chromatin modifying protein 5 (CHMP5), mRNA.
TMEM167B 0.1 0.000206 0.00202 1 Homo sapiens transmembrane protein 167B (TMEM167B), mRNA.
GCA 0.12 0.000208 0.00202 2 Homo sapiens grancalcin, EF-hand calcium binding protein (GCA),
mRNA.
ZMPSTE24 0.1 0.000208 0.00202 1 Homo sapiens zinc metallopeptidase (STE24 homolog, S. cerevisiae)
(ZMPSTE24), mRNA.
AP1S2 0.2 0.000209 0.00203 X Homo sapiens adaptor-related protein complex 1, sigma 2 subunit
(AP1S2), mRNA.
OBFC2A 0.12 0.000211 0.00203 2 Homo sapiens oligonucleotide/oligosaccharide-binding fold containing
2A (OBFC2A), mRNA.
EFR3A 0.14 0.000211 0.00203 8 Homo sapiens EFR3 homolog A (S. cerevisiae) (EFR3A), mRNA.
REEP5 0.13 0.000219 0.00208 5 Homo sapiens receptor accessory protein 5 (REEP5), mRNA.
RGS18 0.21 0.000221 0.0021 1 Homo sapiens regulator of G-protein signaling 18 (RGS18), mRNA.
CCDC53 0.12 0.000227 0.00214 12 Homo sapiens coiled-coil domain containing 53 (CCDC53), mRNA.
ADD3 0.11 0.000228 0.00214 10 Homo sapiens adducin 3 (gamma) (ADD3), transcript variant 3, mRNA.
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COQ10B 0.1 0.000229 0.00214 2 Homo sapiens coenzyme Q10 homolog B (S. cerevisiae) (COQ10B),
mRNA.
MRPS22 0.12 0.000229 0.00214 3 Homo sapiens mitochondrial ribosomal protein S22 (MRPS22), nuclear
gene encoding mitochondrial protein, mRNA.
OSTC 0.14 0.000229 0.00214 4 Homo sapiens oligosaccharyltransferase complex subunit (OSTC),
mRNA.
BTAF1 0.15 0.000232 0.00216 10 Homo sapiens BTAF1 RNA polymerase II, B-TFIID transcription
factor-associated, 170kDa (Mot1 homolog, S. cerevisiae) (BTAF1),
mRNA.
RPS3 0.1 0.000233 0.00216 11 Homo sapiens ribosomal protein S3 (RPS3), mRNA.
SNRPG 0.23 0.000237 0.00218 2 Homo sapiens small nuclear ribonucleoprotein polypeptide G (SNRPG),
mRNA.
USP15 0.17 0.000247 0.00224 12 Homo sapiens ubiquitin specific peptidase 15 (USP15), mRNA.
MBNL1 0.16 0.000252 0.00228 3 Homo sapiens muscleblind-like (Drosophila) (MBNL1), transcript vari-
ant 6, mRNA.
PSMA4 0.2 0.000252 0.00228 15 Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 4
(PSMA4), mRNA.
CBFB 0.12 0.000258 0.00232 16 Homo sapiens core-binding factor, beta subunit (CBFB), transcript vari-
ant 2, mRNA.
VPS36 0.15 0.000267 0.00237 13 Homo sapiens vacuolar protein sorting 36 homolog (S. cerevisiae)
(VPS36), mRNA.
RPL17 0.34 0.000268 0.00237 18 Homo sapiens ribosomal protein L17 (RPL17), transcript variant 2,
mRNA.
COX6C 0.21 0.000271 0.00237 8 Homo sapiens cytochrome c oxidase subunit VIc (COX6C), mRNA.
RPL9 0.37 0.000275 0.0024 4 Homo sapiens ribosomal protein L9 (RPL9), transcript variant 2,
mRNA.
CMPK1 0.17 0.000283 0.00245 1 Homo sapiens cytidine monophosphate (UMP-CMP) kinase 1, cytoso-
lic (CMPK1), mRNA.
ZSWIM6 0.11 0.000288 0.00247 5 PREDICTED: Homo sapiens zinc finger, SWIM-type containing 6
(ZSWIM6), mRNA.
RPL35 0.17 0.000288 0.00247 9 Homo sapiens ribosomal protein L35 (RPL35), mRNA.
ERH 0.16 0.000299 0.00252 14 Homo sapiens enhancer of rudimentary homolog (Drosophila) (ERH),
mRNA.
FAM116A 0.12 0.000306 0.00258 PREDICTED: Homo sapiens family with sequence similarity 116,
member A (FAM116A), mRNA.
ATP11B 0.11 0.000311 0.0026 3 Homo sapiens ATPase, class VI, type 11B (ATP11B), mRNA.
FAM60A 0.12 0.000316 0.00263 12 Homo sapiens family with sequence similarity 60, member A
(FAM60A), transcript variant 1, mRNA.
SEC11C 0.18 0.000325 0.00269 18 Homo sapiens SEC11 homolog C (S. cerevisiae) (SEC11C), mRNA.
RSBN1 0.14 0.000331 0.00274 1 Homo sapiens round spermatid basic protein 1 (RSBN1), mRNA.
PTEN 0.1 0.000337 0.00276 10 Homo sapiens phosphatase and tensin homolog (PTEN), mRNA.
LACTB 0.1 0.000337 0.00276 15 Homo sapiens lactamase, beta (LACTB), nuclear gene encoding mito-
chondrial protein, transcript variant 1, mRNA.
PPA1 0.12 0.000341 0.00279 10 Homo sapiens pyrophosphatase (inorganic) 1 (PPA1), mRNA.
RPS27 0.22 0.000345 0.0028 1 Homo sapiens ribosomal protein S27 (metallopanstimulin 1) (RPS27),
mRNA.
CGGBP1 0.14 0.000353 0.00282 3 Homo sapiens CGG triplet repeat binding protein 1 (CGGBP1), tran-
script variant 1, mRNA.
SEC11A 0.11 0.000353 0.00282 15 Homo sapiens SEC11 homolog A (S. cerevisiae) (SEC11A), mRNA.
RPS24 0.25 0.000359 0.00286 10 Homo sapiens ribosomal protein S24 (RPS24), transcript variant 1,
mRNA.
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C14ORF156 0.23 0.00037 0.00291 14 Homo sapiens chromosome 14 open reading frame 156 (C14orf156),
mRNA.
TDG 0.1 0.00037 0.00291 12 Homo sapiens thymine-DNA glycosylase (TDG), mRNA.
GMFB 0.16 0.000385 0.00299 14 Homo sapiens glia maturation factor, beta (GMFB), mRNA.
NAE1 0.11 0.000386 0.00299 16 Homo sapiens NEDD8 activating enzyme E1 subunit 1 (NAE1), tran-
script variant 3, mRNA.
PRICKLE4 0.12 0.00039 0.003 6 Homo sapiens prickle homolog 4 (Drosophila) (PRICKLE4), mRNA.
RPL31 0.34 0.00039 0.003 2 Homo sapiens ribosomal protein L31 (RPL31), transcript variant 1,
mRNA.
GPR65 0.17 0.000397 0.00303 14 Homo sapiens G protein-coupled receptor 65 (GPR65), mRNA.
IFRD1 0.15 0.00041 0.0031 7 Homo sapiens interferon-related developmental regulator 1 (IFRD1),
transcript variant 1, mRNA.
C12ORF47 0.1 0.000415 0.00312 PREDICTED: Homo sapiens chromosome 12 open reading frame 47
(C12orf47), misc RNA.
CD48 0.13 0.00042 0.00312 1 Homo sapiens CD48 molecule (CD48), mRNA.
THOC7 0.1 0.000422 0.00312 3 Homo sapiens THO complex 7 homolog (Drosophila) (THOC7),
mRNA.
CHMP1B 0.1 0.000424 0.00312 18 Homo sapiens chromatin modifying protein 1B (CHMP1B), mRNA.
TMEM123 0.18 0.000427 0.00312 11 Homo sapiens transmembrane protein 123 (TMEM123), mRNA.
SF3B1 0.1 0.00044 0.00319 2 Homo sapiens splicing factor 3b, subunit 1, 155kDa (SF3B1), transcript
variant 1, mRNA.
TMEM14D 0.14 0.000444 0.00321 10 PREDICTED: Homo sapiens transmembrane protein 14D
(TMEM14D), mRNA.
PRDM1 0.12 0.000456 0.00326 6 Homo sapiens PR domain containing 1, with ZNF domain (PRDM1),
transcript variant 1, mRNA.
CTSH 0.1 0.00046 0.00327 15 Homo sapiens cathepsin H (CTSH), transcript variant 1, mRNA.
CD47 0.11 0.000505 0.00346 3 Homo sapiens CD47 molecule (CD47), transcript variant 2, mRNA.
UBE2J1 0.12 0.00051 0.00348 6 Homo sapiens ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog,
yeast) (UBE2J1), mRNA.
AKAP11 0.16 0.000518 0.00352 13 Homo sapiens A kinase (PRKA) anchor protein 11 (AKAP11), mRNA.
RPS18 0.18 0.00052 0.00352 6 Homo sapiens ribosomal protein S18 (RPS18), mRNA.
CASP1 0.12 0.000538 0.0036 11 Homo sapiens caspase 1, apoptosis-related cysteine peptidase (inter-
leukin 1, beta, convertase) (CASP1), transcript variant delta, mRNA.
CCDC72 0.27 0.000547 0.00362 3 Homo sapiens coiled-coil domain containing 72 (CCDC72), mRNA.
UBE3A 0.11 0.000557 0.00365 15 Homo sapiens ubiquitin protein ligase E3A (UBE3A), transcript variant
2, mRNA.
CMTM6 0.1 0.000567 0.00369 3 Homo sapiens CKLF-like MARVEL transmembrane domain contain-
ing 6 (CMTM6), mRNA.
TAX1BP1 0.14 0.000568 0.00369 7 Homo sapiens Tax1 (human T-cell leukemia virus type I) binding pro-
tein 1 (TAX1BP1), transcript variant 2, mRNA.
SLC4A7 0.19 0.000571 0.0037 3 Homo sapiens solute carrier family 4, sodium bicarbonate cotransporter,
member 7 (SLC4A7), mRNA.
UQCRHL 0.11 0.000572 0.0037 1 Homo sapiens ubiquinol-cytochrome c reductase hinge protein-like
(UQCRHL), mRNA.
CLINT1 0.1 0.000582 0.00375 5 Homo sapiens clathrin interactor 1 (CLINT1), mRNA.
KRCC1 0.14 0.000586 0.00377 2 Homo sapiens lysine-rich coiled-coil 1 (KRCC1), mRNA.
RPL26 0.31 0.000587 0.00377 17 Homo sapiens ribosomal protein L26 (RPL26), mRNA.
ROMO1 0.13 0.000591 0.00377 20 Homo sapiens reactive oxygen species modulator 1 (ROMO1), nuclear
gene encoding mitochondrial protein, mRNA.
PCMTD1 0.17 0.000595 0.00378 8 Homo sapiens protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 1 (PCMTD1), mRNA.
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ATP5I 0.1 0.000603 0.00382 4 Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 com-
plex, subunit E (ATP5I), nuclear gene encoding mitochondrial protein,
mRNA.
WSB2 0.12 0.000607 0.00382 12 Homo sapiens WD repeat and SOCS box-containing 2 (WSB2),
mRNA.
SNRPD2 0.13 0.000614 0.00385 19 Homo sapiens small nuclear ribonucleoprotein D2 polypeptide 16.5kDa
(SNRPD2), transcript variant 1, mRNA.
USP16 0.11 0.000615 0.00385 21 Homo sapiens ubiquitin specific peptidase 16 (USP16), transcript vari-
ant 1, mRNA.
MTMR11 0.14 0.000619 0.00387 1 Homo sapiens myotubularin related protein 11 (MTMR11), mRNA.
RPL39 0.24 0.000621 0.00388 X Homo sapiens ribosomal protein L39 (RPL39), mRNA.
C7ORF23 0.15 0.000625 0.00388 7 Homo sapiens chromosome 7 open reading frame 23 (C7orf23),
mRNA.
HPRT1 0.1 0.000632 0.00392 X Homo sapiens hypoxanthine phosphoribosyltransferase 1 (Lesch-
Nyhan syndrome) (HPRT1), mRNA.
MTIF3 0.11 0.000641 0.00395 13 Homo sapiens mitochondrial translational initiation factor 3 (MTIF3),
nuclear gene encoding mitochondrial protein, mRNA.
BAZ2B 0.14 0.000659 0.00403 2 Homo sapiens bromodomain adjacent to zinc finger domain, 2B
(BAZ2B), mRNA.
NDUFS5 0.14 0.00066 0.00403 1 Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 5,
15kDa (NADH-coenzyme Q reductase) (NDUFS5), mRNA.
TOMM7 0.19 0.000662 0.00403 7 Homo sapiens translocase of outer mitochondrial membrane 7 ho-
molog (yeast) (TOMM7), nuclear gene encoding mitochondrial protein,
mRNA.
C18ORF25 0.11 0.000665 0.00405 18 Homo sapiens chromosome 18 open reading frame 25 (C18orf25), tran-
script variant 2, mRNA.
TMEM50B 0.13 0.000675 0.00409 21 Homo sapiens transmembrane protein 50B (TMEM50B), mRNA.
RPS17 0.23 0.000694 0.00418 15 Homo sapiens ribosomal protein S17 (RPS17), mRNA.
ITGAE 0.1 0.000708 0.00424 17 Homo sapiens integrin, alpha E (antigen CD103, human mucosal lym-
phocyte antigen 1; alpha polypeptide) (ITGAE), mRNA.
ATP6V1G1 0.14 0.000709 0.00424 9 Homo sapiens ATPase, H+ transporting, lysosomal 13kDa, V1 subunit
G1 (ATP6V1G1), mRNA.
C14ORF106 0.12 0.000711 0.00424 14 Homo sapiens chromosome 14 open reading frame 106 (C14orf106),
mRNA.
SMEK2 0.11 0.000716 0.00427 2 Homo sapiens SMEK homolog 2, suppressor of mek1 (Dictyostelium)
(SMEK2), mRNA.
RPL23 0.31 0.000717 0.00427 17 Homo sapiens ribosomal protein L23 (RPL23), mRNA.
RPS6P1 0.17 0.000726 0.00431 PREDICTED: Homo sapiens misc_RNA (RPS6P1), miscRNA.
RPL13A 0.13 0.000737 0.00435 19 Homo sapiens ribosomal protein L13a (RPL13A), mRNA.
MRPS21 0.14 0.000747 0.00438 1 Homo sapiens mitochondrial ribosomal protein S21 (MRPS21), nuclear
gene encoding mitochondrial protein, transcript variant 2, mRNA.
BIRC2 0.14 0.000756 0.00442 11 Homo sapiens baculoviral IAP repeat-containing 2 (BIRC2), mRNA.
SUZ12 0.12 0.000783 0.00451 17 Homo sapiens suppressor of zeste 12 homolog (Drosophila) (SUZ12),
mRNA.
RPL5 0.11 0.000799 0.00456 1 Homo sapiens ribosomal protein L5 (RPL5), mRNA.
TMED2 0.1 0.000806 0.0046 12 Homo sapiens transmembrane emp24 domain trafficking protein 2
(TMED2), mRNA.
RPS10 0.13 0.000808 0.0046 6 Homo sapiens ribosomal protein S10 (RPS10), mRNA.
CENTB2 0.1 0.000811 0.0046 3 Homo sapiens centaurin, beta 2 (CENTB2), mRNA.
SNX14 0.12 0.000816 0.00461 6 Homo sapiens sorting nexin 14 (SNX14), transcript variant 2, mRNA.
RAB8B 0.12 0.000829 0.00467 15 Homo sapiens RAB8B, member RAS oncogene family (RAB8B),
mRNA.
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SFRS2IP 0.1 0.000834 0.00467 12 Homo sapiens splicing factor, arginine/serine-rich 2, interacting protein
(SFRS2IP), mRNA.
CUL4A 0.12 0.000834 0.00467 13 Homo sapiens cullin 4A (CUL4A), transcript variant 2, mRNA.
COQ5 0.11 0.00084 0.00469 12 Homo sapiens coenzyme Q5 homolog, methyltransferase (S. cerevisiae)
(COQ5), mRNA.
MS4A6A 0.14 0.000845 0.00471 11 Homo sapiens membrane-spanning 4-domains, subfamily A, member
6A (MS4A6A), transcript variant 3, mRNA.
NDUFA1 0.1 0.000849 0.00472 X Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
1, 7.5kDa (NDUFA1), nuclear gene encoding mitochondrial protein,
mRNA.
MATR3 0.13 0.000851 0.00473 5 Homo sapiens matrin 3 (MATR3), transcript variant 1, mRNA.
RPS3A 0.31 0.000861 0.00475 4 Homo sapiens ribosomal protein S3A (RPS3A), mRNA.
PQLC3 0.11 0.000883 0.00483 2 Homo sapiens PQ loop repeat containing 3 (PQLC3), mRNA.
NDUFB3 0.15 0.000888 0.00483 2 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
3, 12kDa (NDUFB3), mRNA.
SAMD9 0.14 0.000896 0.00484 7 Homo sapiens sterile alpha motif domain containing 9 (SAMD9),
mRNA.
NDUFB5 0.11 0.000899 0.00484 3 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
5, 16kDa (NDUFB5), nuclear gene encoding mitochondrial protein,
mRNA.
RPS6 0.13 0.000901 0.00484 9 Homo sapiens ribosomal protein S6 (RPS6), mRNA.
GNAI3 0.12 0.000924 0.0049 1 Homo sapiens guanine nucleotide binding protein (G protein), alpha
inhibiting activity polypeptide 3 (GNAI3), mRNA.
NDUFB7 0.12 0.000927 0.0049 19 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
7, 18kDa (NDUFB7), nuclear gene encoding mitochondrial protein,
mRNA.
CXCR4 0.1 0.000928 0.0049 2 Homo sapiens chemokine (C-X-C motif) receptor 4 (CXCR4), tran-
script variant 1, mRNA.
LEMD3 0.15 0.000934 0.00491 12 Homo sapiens LEM domain containing 3 (LEMD3), mRNA.
TRAM1 0.11 0.000938 0.00492 8 Homo sapiens translocation associated membrane protein 1 (TRAM1),
mRNA.
HIF1A 0.11 0.00096 0.00499 14 Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-
loop-helix transcription factor) (HIF1A), transcript variant 2, mRNA.
C1ORF59 0.1 0.000989 0.00507 1 Homo sapiens chromosome 1 open reading frame 59 (C1orf59),
mRNA.
RPA3 0.11 0.00101 0.00517 7 Homo sapiens replication protein A3, 14kDa (RPA3), mRNA.
WDFY1 0.12 0.00104 0.00524 2 Homo sapiens WD repeat and FYVE domain containing 1 (WDFY1),
mRNA.
VPS26A 0.11 0.00104 0.00525 10 Homo sapiens vacuolar protein sorting 26 homolog A (S. pombe)
(VPS26A), transcript variant 2, mRNA.
RPL35A 0.15 0.00106 0.00533 3 Homo sapiens ribosomal protein L35a (RPL35A), mRNA.
RPL13 0.13 0.00109 0.00539 16 Homo sapiens ribosomal protein L13 (RPL13), transcript variant 2,
mRNA.
SNHG5 0.27 0.0011 0.00542 6 Homo sapiens small nucleolar RNA host gene (non-protein coding) 5
(SNHG5) on chromosome 6.
MRFAP1L1 0.1 0.0011 0.00542 4 Homo sapiens Morf4 family associated protein 1-like 1 (MRFAP1L1),
transcript variant 2, mRNA.
CLK1 0.15 0.00111 0.00544 2 Homo sapiens CDC-like kinase 1 (CLK1), mRNA.
CREG1 0.13 0.00113 0.0055 1 Homo sapiens cellular repressor of E1A-stimulated genes 1 (CREG1),
mRNA.
RDH14 0.12 0.00117 0.00559 2 Homo sapiens retinol dehydrogenase 14 (all-trans/9-cis/11-cis)
(RDH14), mRNA.
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PELI1 0.11 0.00121 0.00575 2 Homo sapiens pellino homolog 1 (Drosophila) (PELI1), mRNA.
RAP2C 0.12 0.00122 0.00577 X Homo sapiens RAP2C, member of RAS oncogene family (RAP2C),
mRNA.
TNFAIP8 0.12 0.00123 0.00579 5 Homo sapiens tumor necrosis factor, alpha-induced protein 8 (TN-
FAIP8), transcript variant 2, mRNA.
FAU 0.13 0.00123 0.00579 11 Homo sapiens Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)
ubiquitously expressed (FAU), mRNA.
SLC38A2 0.14 0.00127 0.00594 12 Homo sapiens solute carrier family 38, member 2 (SLC38A2), mRNA.
COPS8 0.1 0.00128 0.00595 2 Homo sapiens COP9 constitutive photomorphogenic homolog subunit
8 (Arabidopsis) (COPS8), transcript variant 2, mRNA.
TMEM188 0.1 0.00129 0.00599 16 Homo sapiens transmembrane protein 188 (TMEM188), mRNA.
DYNLT1 0.1 0.00134 0.00616 6 Homo sapiens dynein, light chain, Tctex-type 1 (DYNLT1), mRNA.
FLJ31306 0.11 0.00137 0.00627 14 PREDICTED: Homo sapiens hypothetical protein FLJ31306
(FLJ31306), mRNA.
NSA2 0.12 0.0014 0.00639 5 Homo sapiens NSA2 ribosome biogenesis homolog (S. cerevisiae)
(NSA2), mRNA.
PARK7 0.13 0.00145 0.00651 1 Homo sapiens Parkinson disease (autosomal recessive, early onset) 7
(PARK7), mRNA.
RPL27 0.19 0.00149 0.00665 17 Homo sapiens ribosomal protein L27 (RPL27), mRNA.
HMGB1L1 0.16 0.0015 0.00667 20 Homo sapiens high-mobility group box 1-like 1 (HMGB1L1), mRNA.
UBE2Q2 0.13 0.00156 0.00685 15 Homo sapiens ubiquitin-conjugating enzyme E2Q family member 2
(UBE2Q2), mRNA.
RPS29 0.12 0.00158 0.00692 14 Homo sapiens ribosomal protein S29 (RPS29), transcript variant 1,
mRNA.
CLEC12A 0.29 0.00159 0.00695 12 Homo sapiens C-type lectin domain family 12, member A (CLEC12A),
transcript variant 2, mRNA.
THUMPD1 0.12 0.0016 0.00697 16 Homo sapiens THUMP domain containing 1 (THUMPD1), mRNA.
C16ORF61 0.14 0.0016 0.00698 16 Homo sapiens chromosome 16 open reading frame 61 (C16orf61),
mRNA.
EEF1B2 0.19 0.00162 0.00702 2 Homo sapiens eukaryotic translation elongation factor 1 beta 2
(EEF1B2), transcript variant 3, mRNA.
NOP58 0.12 0.00165 0.0071 2 Homo sapiens NOP58 ribonucleoprotein homolog (yeast) (NOP58),
mRNA.
SNX10 0.12 0.00167 0.00718 7 Homo sapiens sorting nexin 10 (SNX10), mRNA.
RPL30 0.13 0.00171 0.0073 8 Homo sapiens ribosomal protein L30 (RPL30), mRNA.
NME1 0.11 0.00176 0.00747 17 Homo sapiens non-metastatic cells 1, protein (NM23A) expressed in
(NME1), transcript variant 2, mRNA.
PPIL3 0.14 0.00178 0.00753 2 Homo sapiens peptidylprolyl isomerase (cyclophilin)-like 3 (PPIL3),
transcript variant PPIL3b, mRNA.
LSM5 0.12 0.00182 0.00765 7 Homo sapiens LSM5 homolog, U6 small nuclear RNA associated (S.
cerevisiae) (LSM5), mRNA.
AIF1 0.1 0.00185 0.00773 6 Homo sapiens allograft inflammatory factor 1 (AIF1), transcript variant
1, mRNA.
RNASE2 0.27 0.00187 0.00777 14 Homo sapiens ribonuclease, RNase A family, 2 (liver, eosinophil-
derived neurotoxin) (RNASE2), mRNA.
DPYD 0.1 0.00191 0.00787 1 Homo sapiens dihydropyrimidine dehydrogenase (DPYD), transcript
variant 1, mRNA.
ACAP2 0.1 0.00192 0.00789 3 Homo sapiens ArfGAP with coiled-coil, ankyrin repeat and PH domains
2 (ACAP2), mRNA.
BNIP3L 0.2 0.00194 0.00795 8 Homo sapiens BCL2/adenovirus E1B 19kDa interacting protein 3-like
(BNIP3L), mRNA.
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NDUFB2 0.13 0.00195 0.00797 7 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
2, 8kDa (NDUFB2), nuclear gene encoding mitochondrial protein,
mRNA.
RFX7 0.13 0.00197 0.00801 15 Homo sapiens regulatory factor X, 7 (RFX7), mRNA.
CD36 0.21 0.00201 0.00812 7 Homo sapiens CD36 molecule (thrombospondin receptor) (CD36), tran-
script variant 3, mRNA.
CD46 0.11 0.00217 0.00859 1 Homo sapiens CD46 molecule, complement regulatory protein (CD46),
transcript variant m, mRNA.
CCDC14 0.11 0.0022 0.00867 3 Homo sapiens coiled-coil domain containing 14 (CCDC14), mRNA.
EEF1AL7 0.11 0.00222 0.00874 4 Homo sapiens eukaryotic translation elongation factor 1 alpha-like 7
(EEF1AL7), non-coding RNA.
ACP1 0.12 0.00223 0.00874 2 Homo sapiens acid phosphatase 1, soluble (ACP1), transcript variant 4,
mRNA.
PRDX4 0.11 0.00229 0.00888 X Homo sapiens peroxiredoxin 4 (PRDX4), mRNA.
RPS14 0.11 0.00232 0.00897 5 Homo sapiens ribosomal protein S14 (RPS14), transcript variant 2,
mRNA.
ARGLU1 0.13 0.00234 0.00901 13 Homo sapiens arginine and glutamate rich 1 (ARGLU1), mRNA.
RBM25 0.1 0.00239 0.00917 14 Homo sapiens RNA binding motif protein 25 (RBM25), mRNA.
C16ORF63 0.12 0.00244 0.00931 16 Homo sapiens chromosome 16 open reading frame 63 (C16orf63),
mRNA.
ITM2A 0.13 0.00244 0.00931 X Homo sapiens integral membrane protein 2A (ITM2A), mRNA.
ASGR1 0.12 0.00244 0.00932 17 Homo sapiens asialoglycoprotein receptor 1 (ASGR1), mRNA.
CD52 0.19 0.00246 0.00932 1 Homo sapiens CD52 molecule (CD52), mRNA.
BMI1 0.14 0.00261 0.00973 10 Homo sapiens BMI1 polycomb ring finger oncogene (BMI1), mRNA.
PSTPIP2 0.11 0.00263 0.00979 18 Homo sapiens proline-serine-threonine phosphatase interacting protein
2 (PSTPIP2), mRNA.
TINP1 0.12 0.00265 0.00983 5 Homo sapiens TGF beta-inducible nuclear protein 1 (TINP1), mRNA.
KAT2B 0.13 0.00269 0.00991 3 Homo sapiens K(lysine) acetyltransferase 2B (KAT2B), mRNA.
SNORA25 0.1 0.00282 0.0103 11 Homo sapiens small nucleolar RNA, H/ACA box 25 (SNORA25), small
nucleolar RNA.
SNRPF 0.1 0.00283 0.0103 12 Homo sapiens small nuclear ribonucleoprotein polypeptide F (SNRPF),
mRNA.
RPL41 0.14 0.00283 0.0103 12 Homo sapiens ribosomal protein L41 (RPL41), transcript variant 2,
mRNA.
JAZF1 0.11 0.00284 0.0103 7 Homo sapiens JAZF zinc finger 1 (JAZF1), mRNA.
NSMCE4A 0.1 0.00286 0.0104 10 Homo sapiens non-SMC element 4 homolog A (S. cerevisiae)
(NSMCE4A), mRNA.
RPL11 0.12 0.00292 0.0106 1 Homo sapiens ribosomal protein L11 (RPL11), mRNA.
CROP 0.12 0.00295 0.0106 17 Homo sapiens cisplatin resistance-associated overexpressed protein
(CROP), transcript variant 2, mRNA.
MST4 0.1 0.00303 0.0109 X Homo sapiens serine/threonine protein kinase MST4 (MST4), transcript
variant 1, mRNA.
ATP5E 0.14 0.0031 0.0111 20 Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 com-
plex, epsilon subunit (ATP5E), nuclear gene encoding mitochondrial
protein, mRNA.
CYBB 0.11 0.00317 0.0113 X Homo sapiens cytochrome b-245, beta polypeptide (chronic granuloma-
tous disease) (CYBB), mRNA.
PRKRIR 0.13 0.00322 0.0113 11 Homo sapiens protein-kinase, interferon-inducible double stranded
RNA dependent inhibitor, repressor of (P58 repressor) (PRKRIR),
mRNA.
HEBP2 0.12 0.00326 0.0115 6 Homo sapiens heme binding protein 2 (HEBP2), mRNA.
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PTGER2 0.11 0.0033 0.0115 14 Homo sapiens prostaglandin E receptor 2 (subtype EP2), 53kDa (PT-
GER2), mRNA.
CD3D 0.13 0.00333 0.0116 11 Homo sapiens CD3d molecule, delta (CD3-TCR complex) (CD3D),
transcript variant 2, mRNA.
TOMM6 0.1 0.00335 0.0117 6 Homo sapiens translocase of outer mitochondrial membrane 6 ho-
molog (yeast) (TOMM6), nuclear gene encoding mitochondrial protein,
mRNA.
SSB 0.1 0.00352 0.0121 2 Homo sapiens Sjogren syndrome antigen B (autoantigen La) (SSB),
mRNA.
CNIH 0.12 0.00365 0.0125 14 Homo sapiens cornichon homolog (Drosophila) (CNIH), transcript vari-
ant 2, mRNA.
TMEM14C 0.14 0.00366 0.0125 6 Homo sapiens transmembrane protein 14C (TMEM14C), mRNA.
FYTTD1 0.1 0.00388 0.0131 3 Homo sapiens forty-two-three domain containing 1 (FYTTD1), tran-
script variant 2, mRNA.
SELK 0.12 0.00394 0.0132 3 Homo sapiens selenoprotein K (SELK), mRNA.
TMEM181 0.1 0.00411 0.0136 6 Homo sapiens transmembrane protein 181 (TMEM181), mRNA.
STAMBPL1 0.1 0.00416 0.0137 10 Homo sapiens STAM binding protein-like 1 (STAMBPL1), mRNA.
ZBTB33 0.11 0.00416 0.0137 X Homo sapiens zinc finger and BTB domain containing 33 (ZBTB33),
mRNA.
PFDN5 0.18 0.00465 0.015 12 Homo sapiens prefoldin subunit 5 (PFDN5), transcript variant 3,
mRNA.
MGC87895 0.11 0.00474 0.0151 PREDICTED: Homo sapiens similar to ribosomal protein S14
(MGC87895), mRNA.
C20ORF199 0.13 0.00496 0.0156 20 Homo sapiens chromosome 20 open reading frame 199 (C20orf199),
transcript variant 3, non-coding RNA.
RPL4 0.1 0.00505 0.0158 15 Homo sapiens ribosomal protein L4 (RPL4), mRNA.
DNAJB14 0.12 0.00522 0.0162 4 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 14
(DNAJB14), transcript variant 2, mRNA.
PTPN12 0.1 0.00598 0.018 7 Homo sapiens protein tyrosine phosphatase, non-receptor type 12
(PTPN12), mRNA.
SACM1L 0.11 0.00621 0.0185 3 Homo sapiens SAC1 suppressor of actin mutations 1-like (yeast)
(SACM1L), mRNA.
PGLYRP1 0.2 0.00627 0.0186 19 Homo sapiens peptidoglycan recognition protein 1 (PGLYRP1),
mRNA.
CPD 0.1 0.00688 0.0199 17 Homo sapiens carboxypeptidase D (CPD), mRNA.
HIST1H4C 0.14 0.00699 0.0201 6 Homo sapiens histone cluster 1, H4c (HIST1H4C), mRNA.
C6ORF160 0.15 0.00772 0.0218 PREDICTED: Homo sapiens chromosome 6 open reading frame 160,
transcript variant 4 (C6orf160), mRNA.
MRPS18C 0.12 0.00819 0.0228 4 Homo sapiens mitochondrial ribosomal protein S18C (MRPS18C), nu-
clear gene encoding mitochondrial protein, mRNA.
RAP1BL 0.11 0.00921 0.025 Homo sapiens hCG1757335 (RAP1BL), mRNA.
C17ORF45 0.13 0.00929 0.0252 17 Homo sapiens chromosome 17 open reading frame 45 (C17orf45),
mRNA.
RPL21 0.15 0.00985 0.0265 13 Homo sapiens ribosomal protein L21 (RPL21), mRNA.
GIMAP2 0.19 0.01 0.0268 7 Homo sapiens GTPase, IMAP family member 2 (GIMAP2), mRNA.
KCNJ2 0.11 0.0101 0.027 17 Homo sapiens potassium inwardly-rectifying channel, subfamily J,
member 2 (KCNJ2), mRNA.
SH2D1A 0.11 0.0104 0.0275 X Homo sapiens SH2 domain protein 1A, Duncan’s disease (lymphopro-
liferative syndrome) (SH2D1A), mRNA.
TNFAIP6 0.17 0.0117 0.0302 2 Homo sapiens tumor necrosis factor, alpha-induced protein 6 (TN-
FAIP6), mRNA.
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C12ORF57 0.11 0.012 0.0309 12 Homo sapiens chromosome 12 open reading frame 57 (C12orf57),
mRNA.
CD93 0.1 0.0124 0.0315 20 Homo sapiens CD93 molecule (CD93), mRNA.
CREB5 0.12 0.0132 0.033 7 Homo sapiens cAMP responsive element binding protein 5 (CREB5),
transcript variant 1, mRNA.
PTGS2 0.16 0.014 0.0345 1 Homo sapiens prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase) (PTGS2), mRNA.
ANXA1 0.11 0.0145 0.0353 9 Homo sapiens annexin A1 (ANXA1), mRNA.
PLEKHA1 0.1 0.0156 0.0375 10 Homo sapiens pleckstrin homology domain containing, family A (phos-
phoinositide binding specific) member 1 (PLEKHA1), transcript variant
2, mRNA.
C5ORF32 0.1 0.0166 0.0393 5 Homo sapiens chromosome 5 open reading frame 32 (C5orf32),
mRNA.
IL1B 0.1 0.0192 0.0441 2 Homo sapiens interleukin 1, beta (IL1B), mRNA.
Continued on next page
151
Table A.1 – continued from previous page
Gene logFC p-value q-value CHR Definition
Down-regulated
HNRNPUL2 -0.18 0.000000226 0.000206 11 Homo sapiens heterogeneous nuclear ribonucleoprotein U-like 2 (HN-
RNPUL2), mRNA.
RBM14 -0.12 0.000000251 0.000206 11 Homo sapiens RNA binding motif protein 14 (RBM14), mRNA.
TMEM69 -0.11 0.00000086 0.000276 1 Homo sapiens transmembrane protein 69 (TMEM69), mRNA.
SCAP -0.13 0.00000249 0.000367 3 Homo sapiens SREBF chaperone (SCAP), mRNA.
FAM110A -0.15 0.0000025 0.000367 20 Homo sapiens family with sequence similarity 110, member A
(FAM110A), transcript variant 3, mRNA.
RBM10 -0.11 0.00000263 0.000367 X Homo sapiens RNA binding motif protein 10 (RBM10), transcript vari-
ant 2, mRNA.
ZNF296 -0.15 0.00000363 0.000399 19 Homo sapiens zinc finger protein 296 (ZNF296), mRNA.
PNPT1 -0.11 0.00000424 0.000433 2 Homo sapiens polyribonucleotide nucleotidyltransferase 1 (PNPT1),
mRNA.
RASGRP2 -0.11 0.00000439 0.000433 11 Homo sapiens RAS guanyl releasing protein 2 (calcium and DAG-
regulated) (RASGRP2), transcript variant 1, mRNA.
DENND4B -0.11 0.00000505 0.000436 1 Homo sapiens DENN/MADD domain containing 4B (DENND4B),
mRNA.
ZC3H5 -0.1 0.00000614 0.000466 PREDICTED: Homo sapiens zinc finger CCCH-type containing 5
(ZC3H5), mRNA.
CXXC1 -0.11 0.00000662 0.000466 18 Homo sapiens CXXC finger 1 (PHD domain) (CXXC1), mRNA.
SUPT5H -0.13 0.00000717 0.000485 19 Homo sapiens suppressor of Ty 5 homolog (S. cerevisiae) (SUPT5H),
mRNA.
GANAB -0.11 0.00000814 0.00052 11 Homo sapiens glucosidase, alpha; neutral AB (GANAB), transcript vari-
ant 2, mRNA.
PHF15 -0.13 0.00000866 0.000529 5 Homo sapiens PHD finger protein 15 (PHF15), mRNA.
KIAA1267 -0.1 0.00000931 0.000533 17 Homo sapiens KIAA1267 (KIAA1267), mRNA.
CLSTN1 -0.15 0.00000958 0.000533 1 Homo sapiens calsyntenin 1 (CLSTN1), transcript variant 1, mRNA.
POM121C -0.12 0.00001 0.000533 7 Homo sapiens POM121 membrane glycoprotein C (POM121C),
mRNA.
TSSC4 -0.1 0.00001 0.000533 11 Homo sapiens tumor suppressing subtransferable candidate 4 (TSSC4),
mRNA.
UBQLN4 -0.11 0.0000104 0.000533 1 Homo sapiens ubiquilin 4 (UBQLN4), mRNA.
RANGAP1 -0.12 0.0000105 0.000533 22 Homo sapiens Ran GTPase activating protein 1 (RANGAP1), mRNA.
OSBPL7 -0.13 0.0000106 0.000533 17 Homo sapiens oxysterol binding protein-like 7 (OSBPL7), transcript
variant 1, mRNA.
WDR23 -0.11 0.0000118 0.000558 14 Homo sapiens WD repeat domain 23 (WDR23), transcript variant 1,
mRNA.
FBXO46 -0.16 0.0000122 0.000563 19 PREDICTED: Homo sapiens F-box protein 46, transcript variant 5
(FBXO46), mRNA.
PRKD2 -0.14 0.0000123 0.000563 19 Homo sapiens protein kinase D2 (PRKD2), mRNA.
VAMP2 -0.11 0.0000128 0.000575 17 Homo sapiens vesicle-associated membrane protein 2 (synaptobrevin 2)
(VAMP2), mRNA.
NUMA1 -0.12 0.0000132 0.000579 11 Homo sapiens nuclear mitotic apparatus protein 1 (NUMA1), mRNA.
ST3GAL1 -0.13 0.0000136 0.000587 8 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 1
(ST3GAL1), transcript variant 1, mRNA.
EDC4 -0.1 0.0000138 0.000587 16 Homo sapiens enhancer of mRNA decapping 4 (EDC4), mRNA.
SIK3 -0.11 0.000016 0.000653 11 Homo sapiens SIK family kinase 3 (SIK3), mRNA.
CD97 -0.16 0.0000166 0.000658 19 Homo sapiens CD97 molecule (CD97), transcript variant 1, mRNA.
TLN1 -0.2 0.0000174 0.000676 9 Homo sapiens talin 1 (TLN1), mRNA.
STIP1 -0.13 0.0000177 0.000682 11 Homo sapiens stress-induced-phosphoprotein 1 (Hsp70/Hsp90-
organizing protein) (STIP1), mRNA.
ITPKB -0.12 0.0000182 0.000693 1 Homo sapiens inositol 1,4,5-trisphosphate 3-kinase B (ITPKB), mRNA.
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RAB35 -0.1 0.0000189 0.000696 12 Homo sapiens RAB35, member RAS oncogene family (RAB35),
mRNA.
RAB11FIP1 -0.13 0.0000198 0.000696 8 Homo sapiens RAB11 family interacting protein 1 (class I)
(RAB11FIP1), transcript variant 3, mRNA.
RASAL3 -0.11 0.00002 0.000696 19 Homo sapiens RAS protein activator like 3 (RASAL3), mRNA.
WASF2 -0.17 0.0000206 0.000703 1 Homo sapiens WAS protein family, member 2 (WASF2), mRNA.
PHRF1 -0.11 0.0000207 0.000703 11 Homo sapiens PHD and ring finger domains 1 (PHRF1), mRNA.
ICAM2 -0.1 0.0000229 0.000726 17 Homo sapiens intercellular adhesion molecule 2 (ICAM2), transcript
variant 1, mRNA.
HGS -0.1 0.0000233 0.000726 17 Homo sapiens hepatocyte growth factor-regulated tyrosine kinase sub-
strate (HGS), mRNA.
MEF2D -0.11 0.000024 0.000726 1 Homo sapiens myocyte enhancer factor 2D (MEF2D), mRNA.
SPG7 -0.1 0.0000277 0.000759 16 Homo sapiens spastic paraplegia 7 (pure and complicated autosomal
recessive) (SPG7), nuclear gene encoding mitochondrial protein, tran-
script variant 1, mRNA.
XRCC6 -0.12 0.000029 0.000771 22 Homo sapiens X-ray repair complementing defective repair in Chinese
hamster cells 6 (XRCC6), mRNA.
FYN -0.1 0.0000297 0.000777 6 Homo sapiens FYN oncogene related to SRC, FGR, YES (FYN), tran-
script variant 2, mRNA.
PDPR -0.2 0.0000303 0.000784 PREDICTED: Homo sapiens pyruvate dehydrogenase phosphatase reg-
ulatory subunit (PDPR), mRNA.
TRIM28 -0.13 0.0000319 0.000807 19 Homo sapiens tripartite motif-containing 28 (TRIM28), mRNA.
AKAP13 -0.11 0.0000345 0.00084 15 Homo sapiens A kinase (PRKA) anchor protein 13 (AKAP13), tran-
script variant 2, mRNA.
AP1G2 -0.1 0.0000348 0.000844 14 Homo sapiens adaptor-related protein complex 1, gamma 2 subunit
(AP1G2), mRNA.
MED25 -0.2 0.000035 0.000845 19 Homo sapiens mediator complex subunit 25 (MED25), mRNA.
GP9 -0.31 0.0000369 0.000846 3 Homo sapiens glycoprotein IX (platelet) (GP9), mRNA.
PRF1 -0.25 0.0000375 0.000846 10 Homo sapiens perforin 1 (pore forming protein) (PRF1), transcript vari-
ant 1, mRNA.
LBA1 -0.17 0.0000375 0.000846 3 Homo sapiens lupus brain antigen 1 (LBA1), mRNA.
PBX2 -0.12 0.0000378 0.000846 6 Homo sapiens pre-B-cell leukemia homeobox 2 (PBX2), mRNA.
YY1AP1 -0.14 0.0000383 0.000846 1 Homo sapiens YY1 associated protein 1 (YY1AP1), transcript variant
2, mRNA.
CLCN7 -0.12 0.0000386 0.000846 16 Homo sapiens chloride channel 7 (CLCN7), mRNA.
UBA52 -0.1 0.0000409 0.000868 19 Homo sapiens ubiquitin A-52 residue ribosomal protein fusion product
1 (UBA52), transcript variant 1, mRNA.
CDK5RAP3 -0.1 0.000042 0.000868 17 Homo sapiens CDK5 regulatory subunit associated protein 3
(CDK5RAP3), mRNA.
PACS1 -0.16 0.0000431 0.000882 11 Homo sapiens phosphofurin acidic cluster sorting protein 1 (PACS1),
mRNA.
C20ORF55 -0.15 0.0000433 0.000882 20 Homo sapiens chromosome 20 open reading frame 55 (C20orf55), tran-
script variant 1, mRNA.
USP7 -0.16 0.0000451 0.000904 16 Homo sapiens ubiquitin specific peptidase 7 (herpes virus-associated)
(USP7), mRNA.
GCN1L1 -0.11 0.0000482 0.00094 12 Homo sapiens GCN1 general control of amino-acid synthesis 1-like 1
(yeast) (GCN1L1), mRNA.
SRRM2 -0.11 0.0000487 0.000941 16 Homo sapiens serine/arginine repetitive matrix 2 (SRRM2), mRNA.
DIAPH1 -0.15 0.0000488 0.000941 5 Homo sapiens diaphanous homolog 1 (Drosophila) (DIAPH1), tran-
script variant 1, mRNA.
DNAJB6 -0.11 0.0000495 0.000943 7 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 6
(DNAJB6), transcript variant 1, mRNA.
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CORO7 -0.11 0.0000508 0.000946 16 Homo sapiens coronin 7 (CORO7), mRNA.
CD7 -0.14 0.0000508 0.000946 17 Homo sapiens CD7 molecule (CD7), mRNA.
ABCF1 -0.11 0.000051 0.000946 6 Homo sapiens ATP-binding cassette, sub-family F (GCN20), member 1
(ABCF1), transcript variant 1, mRNA.
POLDIP3 -0.13 0.0000516 0.000953 22 Homo sapiens polymerase (DNA-directed), delta interacting protein 3
(POLDIP3), transcript variant 2, mRNA.
SMARCA4 -0.12 0.0000526 0.000964 19 Homo sapiens SWI/SNF related, matrix associated, actin dependent reg-
ulator of chromatin, subfamily a, member 4 (SMARCA4), mRNA.
SEPT5 -0.28 0.0000535 0.000977 22 Homo sapiens septin 5 (SEPT5), mRNA.
UBA1 -0.16 0.0000554 0.00101 X Homo sapiens ubiquitin-like modifier activating enzyme 1 (UBA1),
transcript variant 1, mRNA.
DDX24 -0.12 0.000056 0.00101 14 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 24
(DDX24), mRNA.
RALY -0.1 0.0000566 0.00101 20 Homo sapiens RNA binding protein, autoantigenic (hnRNP-associated
with lethal yellow homolog (mouse)) (RALY), transcript variant 2,
mRNA.
RNF31 -0.12 0.0000597 0.00104 14 Homo sapiens ring finger protein 31 (RNF31), mRNA.
NRGN -0.28 0.0000622 0.00106 11 Homo sapiens neurogranin (protein kinase C substrate, RC3) (NRGN),
mRNA.
NCOR2 -0.13 0.0000623 0.00106 12 Homo sapiens nuclear receptor co-repressor 2 (NCOR2), transcript vari-
ant 1, mRNA.
PIK3CD -0.13 0.0000625 0.00106 1 Homo sapiens phosphoinositide-3-kinase, catalytic, delta polypeptide
(PIK3CD), mRNA.
HEXDC -0.11 0.0000628 0.00106 17 Homo sapiens hexosaminidase (glycosyl hydrolase family 20, catalytic
domain) containing (HEXDC), mRNA.
UBE1 -0.15 0.0000646 0.00108 X Homo sapiens ubiquitin-activating enzyme E1 (UBE1), transcript vari-
ant 1, mRNA.
DYNC1H1 -0.12 0.0000716 0.00114 14 Homo sapiens dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1),
mRNA.
STAG3L2 -0.13 0.0000722 0.00114 7 Homo sapiens stromal antigen 3-like 2 (STAG3L2), mRNA.
DCTN1 -0.13 0.0000725 0.00114 2 Homo sapiens dynactin 1 (p150, glued homolog, Drosophila) (DCTN1),
transcript variant 2, mRNA.
HSPB1 -0.15 0.0000731 0.00114 7 Homo sapiens heat shock 27kDa protein 1 (HSPB1), mRNA.
CLPTM1 -0.11 0.0000734 0.00114 19 Homo sapiens cleft lip and palate associated transmembrane protein 1
(CLPTM1), mRNA.
MOBKL2A -0.16 0.0000734 0.00114 19 Homo sapiens MOB1, Mps One Binder kinase activator-like 2A (yeast)
(MOBKL2A), mRNA.
C21ORF58 -0.11 0.0000789 0.0012 21 Homo sapiens chromosome 21 open reading frame 58 (C21orf58),
mRNA.
WDR13 -0.1 0.0000809 0.00121 X Homo sapiens WD repeat domain 13 (WDR13), mRNA.
STAG3L3 -0.13 0.0000846 0.00125 7 Homo sapiens stromal antigen 3-like 3 (STAG3L3), mRNA.
TRIM41 -0.12 0.0000912 0.0013 5 Homo sapiens tripartite motif-containing 41 (TRIM41), transcript vari-
ant 2, mRNA.
TAGLN2 -0.15 0.0000914 0.0013 1 Homo sapiens transgelin 2 (TAGLN2), mRNA.
ESYT1 -0.11 0.0000916 0.0013 12 Homo sapiens extended synaptotagmin-like protein 1 (ESYT1), mRNA.
INTS3 -0.12 0.0000928 0.0013 1 Homo sapiens integrator complex subunit 3 (INTS3), mRNA.
PHKA2 -0.1 0.0000963 0.00133 X Homo sapiens phosphorylase kinase, alpha 2 (liver) (PHKA2), mRNA.
CARD11 -0.11 0.0000984 0.00135 7 Homo sapiens caspase recruitment domain family, member 11
(CARD11), mRNA.
CTNS -0.1 0.0000993 0.00135 17 Homo sapiens cystinosis, nephropathic (CTNS), transcript variant 2,
mRNA.
GPR137 -0.1 0.000102 0.00138 11 Homo sapiens G protein-coupled receptor 137 (GPR137), mRNA.
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KPNA6 -0.12 0.000103 0.00138 1 Homo sapiens karyopherin alpha 6 (importin alpha 7) (KPNA6),
mRNA.
SLC35A4 -0.11 0.000107 0.00141 5 Homo sapiens solute carrier family 35, member A4 (SLC35A4),
mRNA.
TNRC6B -0.1 0.000108 0.00142 22 Homo sapiens trinucleotide repeat containing 6B (TNRC6B), transcript
variant 2, mRNA.
DPF2 -0.11 0.000108 0.00142 11 Homo sapiens D4, zinc and double PHD fingers family 2 (DPF2),
mRNA.
TCTA -0.16 0.000113 0.00145 3 Homo sapiens T-cell leukemia translocation altered gene (TCTA),
mRNA.
CLDN14 -0.11 0.000115 0.00147 21 Homo sapiens claudin 14 (CLDN14), transcript variant 2, mRNA.
SEC31A -0.1 0.000119 0.0015 4 Homo sapiens SEC31 homolog A (S. cerevisiae) (SEC31A), transcript
variant 1, mRNA.
FLJ12078 -0.12 0.00012 0.0015 PREDICTED: Homo sapiens hypothetical protein FLJ12078
(FLJ12078), misc RNA.
TSPAN33 -0.19 0.000121 0.00151 7 Homo sapiens tetraspanin 33 (TSPAN33), mRNA.
DNM2 -0.11 0.000122 0.00152 19 Homo sapiens dynamin 2 (DNM2), transcript variant 2, mRNA.
AATF -0.1 0.000132 0.0016 17 Homo sapiens apoptosis antagonizing transcription factor (AATF),
mRNA.
SIPA1 -0.1 0.000134 0.00161 11 Homo sapiens signal-induced proliferation-associated gene 1 (SIPA1),
transcript variant 2, mRNA.
EIF4G1 -0.1 0.000139 0.00164 3 Homo sapiens eukaryotic translation initiation factor 4 gamma, 1
(EIF4G1), transcript variant 1, mRNA.
SEC16A -0.11 0.00014 0.00164 9 Homo sapiens SEC16 homolog A (S. cerevisiae) (SEC16A), mRNA.
RHOC -0.14 0.000142 0.00165 1 Homo sapiens ras homolog gene family, member C (RHOC), transcript
variant 1, mRNA.
LAT -0.11 0.000146 0.00167 16 Homo sapiens linker for activation of T cells (LAT), transcript variant
2, mRNA.
PLOD3 -0.1 0.000149 0.00169 7 Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
(PLOD3), mRNA.
SP2 -0.15 0.00016 0.00175 17 Homo sapiens Sp2 transcription factor (SP2), mRNA.
CCDC92 -0.1 0.000175 0.00186 12 Homo sapiens coiled-coil domain containing 92 (CCDC92), mRNA.
ILF3 -0.1 0.000177 0.00187 19 Homo sapiens interleukin enhancer binding factor 3, 90kDa (ILF3),
transcript variant 1, mRNA.
SERTAD1 -0.13 0.000182 0.00188 19 Homo sapiens SERTA domain containing 1 (SERTAD1), mRNA.
PIAS4 -0.11 0.000185 0.0019 19 Homo sapiens protein inhibitor of activated STAT, 4 (PIAS4), mRNA.
SLC44A2 -0.1 0.000188 0.00193 19 Homo sapiens solute carrier family 44, member 2 (SLC44A2), mRNA.
SEMA4D -0.1 0.000191 0.00195 9 Homo sapiens sema domain, immunoglobulin domain (Ig), transmem-
brane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
(SEMA4D), mRNA.
RNF40 -0.16 0.000194 0.00196 16 Homo sapiens ring finger protein 40 (RNF40), mRNA.
FOXJ2 -0.11 0.000198 0.00199 12 Homo sapiens forkhead box J2 (FOXJ2), mRNA.
GATAD2A -0.1 0.000202 0.002 19 Homo sapiens GATA zinc finger domain containing 2A (GATAD2A),
mRNA.
PNPLA6 -0.1 0.000205 0.00202 19 Homo sapiens patatin-like phospholipase domain containing 6 (PN-
PLA6), mRNA.
FAM53B -0.11 0.000206 0.00202 10 Homo sapiens family with sequence similarity 53, member B
(FAM53B), mRNA.
POLR2A -0.14 0.000229 0.00214 17 Homo sapiens polymerase (RNA) II (DNA directed) polypeptide A,
220kDa (POLR2A), mRNA.
RBM6 -0.1 0.000232 0.00216 3 Homo sapiens RNA binding motif protein 6 (RBM6), mRNA.
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PAF1 -0.11 0.000237 0.00218 19 Homo sapiens Paf1, RNA polymerase II associated factor, homolog (S.
cerevisiae) (PAF1), mRNA.
SBK1 -0.12 0.000253 0.00229 16 Homo sapiens SH3-binding domain kinase 1 (SBK1), mRNA.
PSD4 -0.12 0.00027 0.00237 2 Homo sapiens pleckstrin and Sec7 domain containing 4 (PSD4),
mRNA.
IRF3 -0.23 0.000284 0.00245 19 Homo sapiens interferon regulatory factor 3 (IRF3), mRNA.
TBCD -0.13 0.000292 0.00249 17 Homo sapiens tubulin folding cofactor D (TBCD), mRNA.
MLL4 -0.11 0.000294 0.0025 19 Homo sapiens myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4),
mRNA.
IRX1 -0.28 0.000296 0.00251 5 Homo sapiens iroquois homeobox 1 (IRX1), mRNA.
SH2D3C -0.12 0.000307 0.00258 9 Homo sapiens SH2 domain containing 3C (SH2D3C), transcript variant
2, mRNA.
INPPL1 -0.12 0.000311 0.00261 11 Homo sapiens inositol polyphosphate phosphatase-like 1 (INPPL1),
mRNA.
UBE2L3 -0.12 0.000328 0.00272 22 Homo sapiens ubiquitin-conjugating enzyme E2L 3 (UBE2L3), tran-
script variant 2, mRNA.
CSNK2A1 -0.23 0.000343 0.0028 20 Homo sapiens casein kinase 2, alpha 1 polypeptide (CSNK2A1), tran-
script variant 2, mRNA.
STK10 -0.11 0.000344 0.0028 5 Homo sapiens serine/threonine kinase 10 (STK10), mRNA.
SMARCC2 -0.13 0.000346 0.0028 12 Homo sapiens SWI/SNF related, matrix associated, actin dependent reg-
ulator of chromatin, subfamily c, member 2 (SMARCC2), transcript
variant 2, mRNA.
SIDT2 -0.15 0.000348 0.00281 11 Homo sapiens SID1 transmembrane family, member 2 (SIDT2),
mRNA.
ZNF493 -0.11 0.000349 0.00281 19 Homo sapiens zinc finger protein 493 (ZNF493), transcript variant 3,
mRNA.
FAM38A -0.11 0.00036 0.00286 16 Homo sapiens family with sequence similarity 38, member A
(FAM38A), mRNA.
ITGAL -0.1 0.000364 0.00288 16 Homo sapiens integrin, alpha L (antigen CD11A (p180), lymphocyte
function-associated antigen 1; alpha polypeptide) (ITGAL), mRNA.
BAT3 -0.16 0.000367 0.0029 6 Homo sapiens HLA-B associated transcript 3 (BAT3), transcript variant
3, mRNA.
CASC3 -0.12 0.000373 0.00292 17 Homo sapiens cancer susceptibility candidate 3 (CASC3), mRNA.
CDKN1A -0.18 0.000374 0.00293 6 Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1)
(CDKN1A), transcript variant 1, mRNA.
LPAR5 -0.11 0.000384 0.00299 12 Homo sapiens lysophosphatidic acid receptor 5 (LPAR5), mRNA.
FKBP8 -0.26 0.000415 0.00312 19 Homo sapiens FK506 binding protein 8, 38kDa (FKBP8), mRNA.
MCM5 -0.1 0.000421 0.00312 22 Homo sapiens minichromosome maintenance complex component 5
(MCM5), mRNA.
FBXO18 -0.1 0.000437 0.00317 10 Homo sapiens F-box protein, helicase, 18 (FBXO18), transcript variant
2, mRNA.
ITPK1 -0.14 0.000437 0.00317 14 Homo sapiens inositol 1,3,4-triphosphate 5/6 kinase (ITPK1), mRNA.
UBN1 -0.14 0.000454 0.00326 16 Homo sapiens ubinuclein 1 (UBN1), transcript variant 2, mRNA.
PTPN7 -0.13 0.000458 0.00326 1 Homo sapiens protein tyrosine phosphatase, non-receptor type 7
(PTPN7), transcript variant 2, mRNA.
VPS37B -0.1 0.000476 0.00337 12 Homo sapiens vacuolar protein sorting 37 homolog B (S. cerevisiae)
(VPS37B), mRNA.
AKNA -0.1 0.000481 0.00339 Homo sapiens AT-hook transcription factor (AKNA), mRNA.
TAF15 -0.13 0.00049 0.00342 17 Homo sapiens TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 68kDa (TAF15), transcript variant 1, mRNA.
SMG7 -0.1 0.000502 0.00345 1 Homo sapiens Smg-7 homolog, nonsense mediated mRNA decay factor
(C. elegans) (SMG7), transcript variant 1, mRNA.
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VAV1 -0.11 0.000504 0.00346 19 Homo sapiens vav 1 guanine nucleotide exchange factor (VAV1),
mRNA.
MYO9B -0.1 0.00051 0.00348 19 Homo sapiens myosin IXB (MYO9B), mRNA.
MLLT6 -0.1 0.000522 0.00352 17 Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 6 (MLLT6), mRNA.
CLIC3 -0.23 0.000525 0.00353 9 Homo sapiens chloride intracellular channel 3 (CLIC3), mRNA.
ARHGAP1 -0.1 0.000525 0.00353 11 Homo sapiens Rho GTPase activating protein 1 (ARHGAP1), mRNA.
CMIP -0.12 0.000532 0.00357 16 Homo sapiens c-Maf-inducing protein (CMIP), transcript variant Tc-
mip, mRNA.
SEMA4B -0.11 0.000546 0.00362 15 Homo sapiens sema domain, immunoglobulin domain (Ig), transmem-
brane domain (TM) and short cytoplasmic domain, (semaphorin) 4B
(SEMA4B), transcript variant 2, mRNA.
VCL -0.13 0.000552 0.00363 10 Homo sapiens vinculin (VCL), transcript variant 1, mRNA.
MARCKSL1 -0.1 0.000588 0.00377 1 Homo sapiens MARCKS-like 1 (MARCKSL1), mRNA.
MYADM -0.15 0.000596 0.00379 19 Homo sapiens myeloid-associated differentiation marker (MYADM),
transcript variant 4, mRNA.
ACTRT1 -0.29 0.000598 0.0038 X Homo sapiens actin-related protein T1 (ACTRT1), mRNA.
CABIN1 -0.11 0.000602 0.00382 22 Homo sapiens calcineurin binding protein 1 (CABIN1), mRNA.
MBD6 -0.12 0.000606 0.00382 12 Homo sapiens methyl-CpG binding domain protein 6 (MBD6), mRNA.
ARF3 -0.12 0.000608 0.00382 12 Homo sapiens ADP-ribosylation factor 3 (ARF3), mRNA.
FAM153B -0.18 0.00062 0.00387 5 Homo sapiens family with sequence similarity 153, member B
(FAM153B), mRNA.
VWCE -0.37 0.000639 0.00394 11 Homo sapiens von Willebrand factor C and EGF domains (VWCE),
mRNA.
HCFC1 -0.12 0.00071 0.00424 X Homo sapiens host cell factor C1 (VP16-accessory protein) (HCFC1),
mRNA.
FBRS -0.11 0.000712 0.00425 16 Homo sapiens fibrosin (FBRS), mRNA.
DHX34 -0.13 0.00073 0.00433 19 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 34 (DHX34),
mRNA.
ITGA5 -0.11 0.000748 0.00438 12 Homo sapiens integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
(ITGA5), mRNA.
ZYG11B -0.11 0.000783 0.00451 1 Homo sapiens zyg-11 homolog B (C. elegans) (ZYG11B), mRNA.
TPP1 -0.13 0.000785 0.00451 11 Homo sapiens tripeptidyl peptidase I (TPP1), mRNA.
UBXN6 -0.22 0.000785 0.00451 19 Homo sapiens UBX domain protein 6 (UBXN6), mRNA.
TRIM38 -0.11 0.000794 0.00455 6 Homo sapiens tripartite motif-containing 38 (TRIM38), mRNA.
CYBASC3 -0.1 0.000797 0.00456 11 Homo sapiens cytochrome b, ascorbate dependent 3 (CYBASC3),
mRNA.
TRIM26 -0.1 0.00081 0.0046 6 Homo sapiens tripartite motif-containing 26 (TRIM26), mRNA.
ARAF -0.14 0.000816 0.00461 X Homo sapiens v-raf murine sarcoma 3611 viral oncogene homolog
(ARAF), mRNA.
MBNL3 -0.26 0.000834 0.00467 X Homo sapiens muscleblind-like 3 (Drosophila) (MBNL3), transcript
variant R, mRNA.
CARM1 -0.19 0.000846 0.00471 19 Homo sapiens coactivator-associated arginine methyltransferase 1
(CARM1), mRNA.
PPP2R2B -0.1 0.000857 0.00475 5 Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit
B, beta isoform (PPP2R2B), transcript variant 5, mRNA.
DTX2 -0.1 0.000877 0.00481 7 Homo sapiens deltex homolog 2 (Drosophila) (DTX2), mRNA.
TSC22D1 -0.16 0.000885 0.00483 13 Homo sapiens TSC22 domain family, member 1 (TSC22D1), transcript
variant 2, mRNA.
PILRB -0.11 0.000885 0.00483 7 Homo sapiens paired immunoglobin-like type 2 receptor beta (PILRB),
transcript variant 1, mRNA.
ANKRD30B -0.1 0.000897 0.00484 18 Homo sapiens ankyrin repeat domain 30B (ANKRD30B), mRNA.
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LRRC33 -0.1 0.00092 0.00489 3 Homo sapiens leucine rich repeat containing 33 (LRRC33), mRNA.
RRBP1 -0.11 0.000921 0.00489 20 Homo sapiens ribosome binding protein 1 homolog 180kDa (dog)
(RRBP1), transcript variant 1, mRNA.
CD37 -0.1 0.000926 0.0049 19 Homo sapiens CD37 antigen (CD37), mRNA.
NUAK2 -0.13 0.000927 0.0049 1 Homo sapiens NUAK family, SNF1-like kinase, 2 (NUAK2), mRNA.
TARDBP -0.16 0.000947 0.00494 1 Homo sapiens TAR DNA binding protein (TARDBP), mRNA.
MSN -0.13 0.00095 0.00495 X Homo sapiens moesin (MSN), mRNA.
LYL1 -0.17 0.000957 0.00498 19 Homo sapiens lymphoblastic leukemia derived sequence 1 (LYL1),
mRNA.
CLK2 -0.25 0.000961 0.00499 PREDICTED: Homo sapiens CDC-like kinase 2, transcript variant 4
(CLK2), mRNA.
TUBB1 -0.2 0.000971 0.00501 20 Homo sapiens tubulin, beta 1 (TUBB1), mRNA.
CKAP5 -0.1 0.000984 0.00506 11 Homo sapiens cytoskeleton associated protein 5 (CKAP5), transcript
variant 1, mRNA.
NOMO2 -0.1 0.001 0.00514 16 Homo sapiens NODAL modulator 2 (NOMO2), transcript variant 2,
mRNA.
PNPLA7 -0.15 0.00102 0.00517 9 Homo sapiens patatin-like phospholipase domain containing 7 (PN-
PLA7), mRNA.
MYH9 -0.14 0.00102 0.00519 22 Homo sapiens myosin, heavy chain 9, non-muscle (MYH9), mRNA.
PXN -0.11 0.00105 0.00527 12 Homo sapiens paxillin (PXN), mRNA.
TMEM140 -0.15 0.00105 0.00529 7 Homo sapiens transmembrane protein 140 (TMEM140), mRNA.
C9ORF164 -0.12 0.00106 0.00532 9 Homo sapiens chromosome 9 open reading frame 164 (C9orf164),
mRNA.
ADRA2C -0.29 0.00107 0.00533 PREDICTED: Homo sapiens adrenergic, alpha-2C-, receptor
(ADRA2C), mRNA.
CXXC5 -0.12 0.00107 0.00536 5 Homo sapiens CXXC finger 5 (CXXC5), mRNA.
CTSB -0.13 0.00108 0.00537 8 Homo sapiens cathepsin B (CTSB), transcript variant 1, mRNA.
CSF1R -0.13 0.00108 0.00538 5 Homo sapiens colony stimulating factor 1 receptor, formerly Mc-
Donough feline sarcoma viral (v-fms) oncogene homolog (CSF1R),
mRNA.
SLC6A10P -0.31 0.00109 0.00542 16 Homo sapiens solute carrier family 6 (neurotransmitter transporter, cre-
atine), member 10 (pseudogene) (SLC6A10P) on chromosome 16.
DDR1 -0.26 0.0011 0.00542 6 Homo sapiens discoidin domain receptor tyrosine kinase 1 (DDR1),
transcript variant 1, mRNA.
WBP1 -0.11 0.00113 0.00549 2 Homo sapiens WW domain binding protein 1 (WBP1), mRNA.
GMIP -0.11 0.00114 0.00551 19 Homo sapiens GEM interacting protein (GMIP), mRNA.
MEGF10 -0.35 0.00114 0.00552 5 Homo sapiens multiple EGF-like-domains 10 (MEGF10), mRNA.
HLA-DRB6 -0.1 0.00118 0.00564 6 Homo sapiens major histocompatibility complex, class II, DR beta 6
(pseudogene) (HLA-DRB6), non-coding RNA.
PVRIG -0.11 0.00118 0.00564 7 Homo sapiens poliovirus receptor related immunoglobulin domain con-
taining (PVRIG), mRNA.
PRPF8 -0.13 0.00121 0.00575 17 Homo sapiens PRP8 pre-mRNA processing factor 8 homolog (S. cere-
visiae) (PRPF8), mRNA.
SNAPC2 -0.15 0.00124 0.00584 19 Homo sapiens small nuclear RNA activating complex, polypeptide 2,
45kDa (SNAPC2), mRNA.
COQ6 -0.16 0.00124 0.00585 14 Homo sapiens coenzyme Q6 homolog, monooxygenase (S. cerevisiae)
(COQ6), transcript variant 1, mRNA.
TOP3A -0.12 0.00125 0.00586 17 Homo sapiens topoisomerase (DNA) III alpha (TOP3A), mRNA.
ERGIC1 -0.12 0.00126 0.00591 5 Homo sapiens endoplasmic reticulum-golgi intermediate compartment
(ERGIC) 1 (ERGIC1), transcript variant 1, mRNA.
MARCH2 -0.17 0.00127 0.00593 19 Homo sapiens membrane-associated ring finger (C3HC4) 2
(MARCH2), transcript variant 3, mRNA.
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STK40 -0.1 0.00127 0.00593 1 Homo sapiens serine/threonine kinase 40 (STK40), mRNA.
MKNK2 -0.1 0.00127 0.00594 19 Homo sapiens MAP kinase interacting serine/threonine kinase 2
(MKNK2), transcript variant 1, mRNA.
FAM65A -0.1 0.00129 0.00599 16 Homo sapiens family with sequence similarity 65, member A
(FAM65A), mRNA.
FCGR3A -0.35 0.0013 0.006 1 Homo sapiens Fc fragment of IgG, low affinity IIIa, receptor (CD16a)
(FCGR3A), transcript variant 1, mRNA.
SEC14L1 -0.15 0.0013 0.006 17 Homo sapiens SEC14-like 1 (S. cerevisiae) (SEC14L1), transcript vari-
ant 1, mRNA.
CENTD2 -0.11 0.00133 0.00612 11 Homo sapiens centaurin, delta 2 (CENTD2), transcript variant 3,
mRNA.
CTSA -0.13 0.00133 0.00615 20 Homo sapiens cathepsin A (CTSA), transcript variant 1, mRNA.
EIF2C2 -0.14 0.00137 0.00629 8 Homo sapiens eukaryotic translation initiation factor 2C, 2 (EIF2C2),
mRNA.
FZD7 -0.23 0.00137 0.00629 2 Homo sapiens frizzled homolog 7 (Drosophila) (FZD7), mRNA.
RUNX3 -0.1 0.00138 0.00631 1 Homo sapiens runt-related transcription factor 3 (RUNX3), transcript
variant 2, mRNA.
PTGS1 -0.19 0.00142 0.00643 9 Homo sapiens prostaglandin-endoperoxide synthase 1 (prostaglandin
G/H synthase and cyclooxygenase) (PTGS1), transcript variant 2,
mRNA.
USP4 -0.1 0.00143 0.00646 3 Homo sapiens ubiquitin specific peptidase 4 (proto-oncogene) (USP4),
transcript variant 1, mRNA.
CPSF1 -0.11 0.00144 0.00647 8 Homo sapiens cleavage and polyadenylation specific factor 1, 160kDa
(CPSF1), mRNA.
LRCH4 -0.1 0.00145 0.00651 7 Homo sapiens leucine-rich repeats and calponin homology (CH) do-
main containing 4 (LRCH4), mRNA.
CHD4 -0.19 0.0015 0.00668 12 Homo sapiens chromodomain helicase DNA binding protein 4 (CHD4),
mRNA.
SF3A2 -0.1 0.00151 0.0067 19 Homo sapiens splicing factor 3a, subunit 2, 66kDa (SF3A2), mRNA.
ZAP70 -0.1 0.00153 0.00677 2 Homo sapiens zeta-chain (TCR) associated protein kinase 70kDa
(ZAP70), transcript variant 1, mRNA.
ALDOC -0.11 0.00157 0.00689 17 Homo sapiens aldolase C, fructose-bisphosphate (ALDOC), mRNA.
C2ORF24 -0.16 0.00159 0.00695 2 Homo sapiens chromosome 2 open reading frame 24 (C2orf24),
mRNA.
HDAC6 -0.22 0.00162 0.00701 X Homo sapiens histone deacetylase 6 (HDAC6), mRNA.
C7ORF41 -0.13 0.00167 0.00718 7 Homo sapiens chromosome 7 open reading frame 41 (C7orf41),
mRNA.
TGFBR3 -0.16 0.00167 0.00718 1 Homo sapiens transforming growth factor, beta receptor III (TGFBR3),
mRNA.
CREBBP -0.11 0.00168 0.00721 16 Homo sapiens CREB binding protein (CREBBP), transcript variant 2,
mRNA.
ATP6V0C -0.14 0.00171 0.00729 PREDICTED: Homo sapiens ATPase, H+ transporting, lysosomal
16kDa, V0 subunit c (ATP6V0C), mRNA.
FLJ20699 -0.16 0.00184 0.00769 22 Homo sapiens hypothetical protein FLJ20699 (FLJ20699), mRNA.
CHD8 -0.1 0.00187 0.00777 14 Homo sapiens chromodomain helicase DNA binding protein 8 (CHD8),
mRNA.
DNA2 -0.28 0.00187 0.00777 10 Homo sapiens DNA replication helicase 2 homolog (yeast) (DNA2),
mRNA.
LRP10 -0.1 0.00194 0.00795 14 Homo sapiens low density lipoprotein receptor-related protein 10
(LRP10), mRNA.
DENR -0.12 0.00197 0.00802 12 Homo sapiens density-regulated protein (DENR), mRNA.
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CD79A -0.15 0.00199 0.00805 19 Homo sapiens CD79a molecule, immunoglobulin-associated alpha
(CD79A), transcript variant 2, mRNA.
FOXO4 -0.15 0.002 0.0081 X Homo sapiens forkhead box O4 (FOXO4), mRNA.
IGF2R -0.13 0.00205 0.00826 6 Homo sapiens insulin-like growth factor 2 receptor (IGF2R), mRNA.
PRR5 -0.13 0.00209 0.00838 22 Homo sapiens proline rich 5 (renal) (PRR5), transcript variant 5,
mRNA.
CAPN1 -0.1 0.0021 0.0084 11 Homo sapiens calpain 1, (mu/I) large subunit (CAPN1), mRNA.
TIMP1 -0.11 0.00211 0.00843 X Homo sapiens TIMP metallopeptidase inhibitor 1 (TIMP1), mRNA.
PI4KAP2 -0.1 0.00212 0.00844 Homo sapiens phosphatidylinositol 4-kinase, catalytic, alpha polypep-
tide pseudogene 2 (PI4KAP2), mRNA.
FCRL2 -0.25 0.00214 0.00851 1 Homo sapiens Fc receptor-like 2 (FCRL2), transcript variant 2, mRNA.
PPP1R15A -0.1 0.0022 0.00867 19 Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 15A
(PPP1R15A), mRNA.
SORL1 -0.13 0.00224 0.00878 11 Homo sapiens sortilin-related receptor, L(DLR class) A repeats-
containing (SORL1), mRNA.
GPR175 -0.22 0.00226 0.0088 3 Homo sapiens G protein-coupled receptor 175 (GPR175), mRNA.
SPOCK2 -0.1 0.00227 0.00882 10 Homo sapiens sparc/osteonectin, cwcv and kazal-like domains proteo-
glycan (testican) 2 (SPOCK2), mRNA.
CD3E -0.11 0.0023 0.00891 11 Homo sapiens CD3e molecule, epsilon (CD3-TCR complex) (CD3E),
mRNA.
ZNFX1 -0.11 0.0023 0.00891 20 Homo sapiens zinc finger, NFX1-type containing 1 (ZNFX1), mRNA.
ATG2A -0.12 0.0023 0.00891 11 Homo sapiens ATG2 autophagy related 2 homolog A (S. cerevisiae)
(ATG2A), mRNA.
MAP1S -0.16 0.00232 0.00898 19 Homo sapiens microtubule-associated protein 1S (MAP1S), mRNA.
BRD3 -0.12 0.00239 0.00917 9 Homo sapiens bromodomain containing 3 (BRD3), mRNA.
ATXN10 -0.26 0.00239 0.00917 22 Homo sapiens ataxin 10 (ATXN10), mRNA.
PDCD4 -0.11 0.00242 0.00926 10 Homo sapiens programmed cell death 4 (neoplastic transformation in-
hibitor) (PDCD4), transcript variant 2, mRNA.
MAST3 -0.11 0.00255 0.00956 19 Homo sapiens microtubule associated serine/threonine kinase 3
(MAST3), mRNA.
ACTN4 -0.13 0.00257 0.00964 19 Homo sapiens actinin, alpha 4 (ACTN4), mRNA.
RNF10 -0.23 0.00258 0.00965 12 Homo sapiens ring finger protein 10 (RNF10), mRNA.
FXR2 -0.17 0.00258 0.00966 17 Homo sapiens fragile X mental retardation, autosomal homolog 2
(FXR2), mRNA.
EIF2AK4 -0.12 0.00265 0.00982 15 Homo sapiens eukaryotic translation initiation factor 2 alpha kinase 4
(EIF2AK4), mRNA.
TAPBP -0.1 0.00268 0.00989 6 Homo sapiens TAP binding protein (tapasin) (TAPBP), transcript vari-
ant 1, mRNA.
MIDN -0.11 0.00271 0.00994 19 Homo sapiens midnolin (MIDN), mRNA.
SNTB2 -0.1 0.00275 0.0101 16 Homo sapiens syntrophin, beta 2 (dystrophin-associated protein A1,
59kDa, basic component 2) (SNTB2), transcript variant 1, mRNA.
ELMO1 -0.1 0.00289 0.0105 7 Homo sapiens engulfment and cell motility 1 (ELMO1), transcript vari-
ant 1, mRNA.
MAP7D1 -0.12 0.0029 0.0105 1 Homo sapiens MAP7 domain containing 1 (MAP7D1), mRNA.
STXBP2 -0.11 0.00299 0.0108 19 Homo sapiens syntaxin binding protein 2 (STXBP2), mRNA.
PNPLA2 -0.14 0.00313 0.0111 11 Homo sapiens patatin-like phospholipase domain containing 2 (PN-
PLA2), mRNA.
FLJ35390 -0.12 0.00318 0.0113 7 Homo sapiens hypothetical LOC255031 (FLJ35390), transcript variant
1, non-coding RNA.
IL8RB -0.14 0.00321 0.0113 2 Homo sapiens interleukin 8 receptor, beta (IL8RB), mRNA.
C22ORF25 -0.13 0.00321 0.0113 22 Homo sapiens chromosome 22 open reading frame 25 (C22orf25),
mRNA.
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S1PR5 -0.18 0.00325 0.0115 19 Homo sapiens sphingosine-1-phosphate receptor 5 (S1PR5), mRNA.
SPTAN1 -0.11 0.00335 0.0117 9 Homo sapiens spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) (SP-
TAN1), mRNA.
N4BP2 -0.11 0.00343 0.0119 4 Homo sapiens Nedd4 binding protein 2 (N4BP2), mRNA.
MOSPD3 -0.22 0.00343 0.0119 7 Homo sapiens motile sperm domain containing 3 (MOSPD3), transcript
variant 2, mRNA.
PYGB -0.1 0.0035 0.0121 20 Homo sapiens phosphorylase, glycogen; brain (PYGB), mRNA.
FLJ38717 -0.1 0.00359 0.0123 6 Homo sapiens FLJ38717 protein (FLJ38717), mRNA.
TNFSF14 -0.11 0.0036 0.0123 19 Homo sapiens tumor necrosis factor (ligand) superfamily, member 14
(TNFSF14), transcript variant 2, mRNA.
MAP4K4 -0.2 0.00361 0.0124 2 Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4
(MAP4K4), transcript variant 3, mRNA.
DOPEY2 -0.12 0.00364 0.0124 21 Homo sapiens dopey family member 2 (DOPEY2), mRNA.
DPYSL5 -0.27 0.00366 0.0125 2 Homo sapiens dihydropyrimidinase-like 5 (DPYSL5), mRNA.
SIPA1L3 -0.23 0.00384 0.013 19 Homo sapiens signal-induced proliferation-associated 1 like 3
(SIPA1L3), mRNA.
SLC9A1 -0.1 0.00389 0.0131 1 Homo sapiens solute carrier family 9 (sodium/hydrogen exchanger),
member 1 (SLC9A1), mRNA.
LYPD3 -0.25 0.00395 0.0133 19 Homo sapiens LY6/PLAUR domain containing 3 (LYPD3), mRNA.
SYTL3 -0.1 0.00402 0.0134 6 Homo sapiens synaptotagmin-like 3 (SYTL3), mRNA.
ST6GALNAC4 -0.2 0.00407 0.0136 9 Homo sapiens ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1, 3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4
(ST6GALNAC4), transcript variant 1, mRNA.
FASN -0.12 0.00408 0.0136 17 Homo sapiens fatty acid synthase (FASN), mRNA.
UBE2W -0.22 0.00409 0.0136 8 Homo sapiens ubiquitin-conjugating enzyme E2W (putative)
(UBE2W), transcript variant 2, mRNA.
ZNF669 -0.1 0.00414 0.0137 1 Homo sapiens zinc finger protein 669 (ZNF669), mRNA.
HDAC7A -0.24 0.00417 0.0137 12 Homo sapiens histone deacetylase 7A (HDAC7A), transcript variant 2,
mRNA.
SMU1 -0.19 0.00426 0.014 9 Homo sapiens smu-1 suppressor of mec-8 and unc-52 homolog (C. ele-
gans) (SMU1), mRNA.
ZNF786 -0.1 0.00438 0.0143 7 Homo sapiens zinc finger protein 786 (ZNF786), mRNA.
MT2A -0.17 0.00443 0.0144 16 Homo sapiens metallothionein 2A (MT2A), mRNA.
TTC38 -0.15 0.00448 0.0146 22 Homo sapiens tetratricopeptide repeat domain 38 (TTC38), mRNA.
LSP1 -0.12 0.0045 0.0146 11 Homo sapiens lymphocyte-specific protein 1 (LSP1), transcript variant
2, mRNA.
RARA -0.1 0.00454 0.0147 17 Homo sapiens retinoic acid receptor, alpha (RARA), transcript variant
1, mRNA.
ANKRD13D -0.13 0.00456 0.0148 PREDICTED: Homo sapiens ankyrin repeat domain 13 family, member
D, transcript variant 7 (ANKRD13D), mRNA.
SLC25A39 -0.15 0.00465 0.015 17 Homo sapiens solute carrier family 25, member 39 (SLC25A39),
mRNA.
NOC4L -0.22 0.0047 0.0151 PREDICTED: Homo sapiens nucleolar complex associated 4 homolog
(S. cerevisiae) (NOC4L), mRNA.
RNF24 -0.12 0.0047 0.0151 20 Homo sapiens ring finger protein 24 (RNF24), mRNA.
AHR -0.1 0.0047 0.0151 7 Homo sapiens aryl hydrocarbon receptor (AHR), mRNA.
HIST2H2BE -0.13 0.00473 0.0151 1 Homo sapiens histone cluster 2, H2be (HIST2H2BE), mRNA.
SPRYD3 -0.24 0.00477 0.0152 12 Homo sapiens SPRY domain containing 3 (SPRYD3), mRNA.
COL8A2 -0.22 0.00483 0.0153 1 Homo sapiens collagen, type VIII, alpha 2 (COL8A2), mRNA.
CTSD -0.13 0.00498 0.0157 11 Homo sapiens cathepsin D (CTSD), mRNA.
YPEL3 -0.11 0.00508 0.0159 16 Homo sapiens yippee-like 3 (Drosophila) (YPEL3), transcript variant 1,
mRNA.
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FAM40B -0.14 0.0051 0.0159 7 Homo sapiens family with sequence similarity 40, member B
(FAM40B), mRNA.
C22ORF13 -0.13 0.0051 0.0159 22 Homo sapiens chromosome 22 open reading frame 13 (C22orf13),
mRNA.
RERE -0.1 0.00513 0.016 1 Homo sapiens arginine-glutamic acid dipeptide (RE) repeats (RERE),
transcript variant 3, mRNA.
MED1 -0.23 0.00514 0.016 17 Homo sapiens mediator complex subunit 1 (MED1), mRNA.
CEP27 -0.13 0.00518 0.0161 15 Homo sapiens centrosomal protein 27kDa (CEP27), mRNA.
ROPN1B -0.23 0.00518 0.0161 3 Homo sapiens ropporin, rhophilin associated protein 1B (ROPN1B),
mRNA.
DCLRE1C -0.11 0.00529 0.0164 10 Homo sapiens DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae)
(DCLRE1C), transcript variant b, mRNA.
SLC25A45 -0.21 0.00537 0.0166 11 Homo sapiens solute carrier family 25, member 45 (SLC25A45), tran-
script variant 2, mRNA.
GNL3L -0.13 0.00542 0.0167 X Homo sapiens guanine nucleotide binding protein-like 3 (nucleolar)-
like (GNL3L), mRNA.
C14ORF173 -0.13 0.0055 0.0169 14 Homo sapiens chromosome 14 open reading frame 173 (C14orf173),
transcript variant 2, mRNA.
CTSZ -0.11 0.00558 0.0171 20 Homo sapiens cathepsin Z (CTSZ), mRNA.
C16ORF35 -0.18 0.00562 0.0172 16 Homo sapiens chromosome 16 open reading frame 35 (C16orf35), tran-
script variant 2, mRNA.
RUNDC2C -0.12 0.00575 0.0175 16 Homo sapiens RUN domain containing 2C (RUNDC2C), non-coding
RNA.
CD79B -0.13 0.00575 0.0175 17 Homo sapiens CD79b molecule, immunoglobulin-associated beta
(CD79B), transcript variant 3, mRNA.
EOMES -0.13 0.00575 0.0175 3 Homo sapiens eomesodermin homolog (Xenopus laevis) (EOMES),
mRNA.
KIAA0513 -0.1 0.0058 0.0176 16 Homo sapiens KIAA0513 (KIAA0513), mRNA.
TMEM86B -0.16 0.00588 0.0178 19 Homo sapiens transmembrane protein 86B (TMEM86B), mRNA.
NOL10 -0.21 0.00596 0.018 2 Homo sapiens nucleolar protein 10 (NOL10), mRNA.
RAXL1 -0.11 0.00597 0.018 19 Homo sapiens retina and anterior neural fold homeobox like 1
(RAXL1), mRNA.
NADK -0.1 0.00601 0.0181 1 Homo sapiens NAD kinase (NADK), mRNA.
FAM134A -0.1 0.00603 0.0181 2 Homo sapiens family with sequence similarity 134, member A
(FAM134A), mRNA.
UBL7 -0.1 0.00607 0.0182 15 Homo sapiens ubiquitin-like 7 (bone marrow stromal cell-derived)
(UBL7), transcript variant 2, mRNA.
PKNOX1 -0.15 0.0061 0.0182 21 Homo sapiens PBX/knotted 1 homeobox 1 (PKNOX1), mRNA.
C19ORF22 -0.14 0.00622 0.0185 19 Homo sapiens chromosome 19 open reading frame 22 (C19orf22),
mRNA.
LMNA -0.25 0.00628 0.0186 1 Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA.
PSENEN -0.22 0.00639 0.0188 19 Homo sapiens presenilin enhancer 2 homolog (C. elegans) (PSENEN),
mRNA.
GYPC -0.14 0.00643 0.0189 2 Homo sapiens glycophorin C (Gerbich blood group) (GYPC), transcript
variant 2, mRNA.
XKR8 -0.1 0.00646 0.019 1 Homo sapiens XK, Kell blood group complex subunit-related family,
member 8 (XKR8), mRNA.
ATHL1 -0.14 0.00664 0.0194 11 Homo sapiens ATH1, acid trehalase-like 1 (yeast) (ATHL1), mRNA.
CSDA -0.16 0.00665 0.0194 12 Homo sapiens cold shock domain protein A (CSDA), mRNA.
VRK3 -0.1 0.00667 0.0194 19 Homo sapiens vaccinia related kinase 3 (VRK3), transcript variant 2,
mRNA.
VASP -0.12 0.00677 0.0197 19 Homo sapiens vasodilator-stimulated phosphoprotein (VASP), mRNA.
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STX10 -0.12 0.00693 0.02 19 Homo sapiens syntaxin 10 (STX10), mRNA.
TBC1D10B -0.19 0.00704 0.0202 16 Homo sapiens TBC1 domain family, member 10B (TBC1D10B),
mRNA.
CCL5 -0.12 0.00718 0.0205 17 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5), mRNA.
SH3BP1 -0.1 0.00725 0.0207 22 Homo sapiens SH3-domain binding protein 1 (SH3BP1), mRNA.
SLC4A5 -0.13 0.00746 0.0212 2 Homo sapiens solute carrier family 4, sodium bicarbonate cotransporter,
member 5 (SLC4A5), transcript variant c, mRNA.
C4ORF34 -0.12 0.00755 0.0214 4 Homo sapiens chromosome 4 open reading frame 34 (C4orf34),
mRNA.
IP6K1 -0.1 0.00762 0.0216 3 Homo sapiens inositol hexakisphosphate kinase 1 (IP6K1), transcript
variant 2, mRNA.
RNF213 -0.24 0.00764 0.0216 17 Homo sapiens ring finger protein 213 (RNF213), mRNA.
NDE1 -0.1 0.00769 0.0217 16 Homo sapiens nudE nuclear distribution gene E homolog 1 (A. nidu-
lans) (NDE1), mRNA.
ACTN1 -0.11 0.00776 0.0218 14 Homo sapiens actinin, alpha 1 (ACTN1), mRNA.
MAP2K3 -0.15 0.00791 0.0222 17 Homo sapiens mitogen-activated protein kinase kinase 3 (MAP2K3),
transcript variant A, mRNA.
APBB1IP -0.1 0.00802 0.0224 10 Homo sapiens amyloid beta (A4) precursor protein-binding, family B,
member 1 interacting protein (APBB1IP), mRNA.
PIP5K2B -0.1 0.00827 0.023 17 Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type II, beta
(PIP5K2B), transcript variant 2, mRNA.
IGF2BP2 -0.2 0.0085 0.0235 3 Homo sapiens insulin-like growth factor 2 mRNA binding protein 2
(IGF2BP2), transcript variant 1, mRNA.
LLPH -0.1 0.00877 0.0241 12 Homo sapiens LLP homolog, long-term synaptic facilitation (Aplysia)
(LLPH), mRNA.
RTF1 -0.18 0.00895 0.0244 15 Homo sapiens Rtf1, Paf1/RNA polymerase II complex component, ho-
molog (S. cerevisiae) (RTF1), mRNA.
IL2RB -0.12 0.00897 0.0245 22 Homo sapiens interleukin 2 receptor, beta (IL2RB), mRNA.
PATE2 -0.11 0.00919 0.025 11 Homo sapiens prostate and testis expressed 2 (PATE2), mRNA.
STAT3 -0.1 0.00931 0.0252 17 Homo sapiens signal transducer and activator of transcription 3 (acute-
phase response factor) (STAT3), transcript variant 3, mRNA.
EPB49 -0.21 0.00935 0.0253 8 Homo sapiens erythrocyte membrane protein band 4.9 (dematin)
(EPB49), mRNA.
G6PD -0.1 0.00968 0.0261 X Homo sapiens glucose-6-phosphate dehydrogenase (G6PD), transcript
variant 1, mRNA.
ARID3A -0.1 0.00969 0.0261 19 Homo sapiens AT rich interactive domain 3A (BRIGHT-like)
(ARID3A), mRNA.
FAM83F -0.21 0.00995 0.0267 22 Homo sapiens family with sequence similarity 83, member F
(FAM83F), mRNA.
LPAR2 -0.1 0.01 0.0268 19 Homo sapiens lysophosphatidic acid receptor 2 (LPAR2), mRNA.
ABHD5 -0.1 0.0102 0.0271 3 Homo sapiens abhydrolase domain containing 5 (ABHD5), mRNA.
C5ORF28 -0.1 0.0105 0.0279 5 Homo sapiens chromosome 5 open reading frame 28 (C5orf28),
mRNA.
PTPLAD2 -0.12 0.0106 0.0281 9 Homo sapiens protein tyrosine phosphatase-like A domain containing 2
(PTPLAD2), mRNA.
MYO1F -0.1 0.0108 0.0284 19 Homo sapiens myosin IF (MYO1F), mRNA.
SEMA6B -0.19 0.0109 0.0286 19 Homo sapiens sema domain, transmembrane domain (TM), and cyto-
plasmic domain, (semaphorin) 6B (SEMA6B), mRNA.
MUC6 -0.25 0.0111 0.029 11 Homo sapiens mucin 6, oligomeric mucus/gel-forming (MUC6),
mRNA.
CD19 -0.16 0.012 0.0308 16 Homo sapiens CD19 molecule (CD19), mRNA.
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WARS -0.12 0.012 0.0308 14 Homo sapiens tryptophanyl-tRNA synthetase (WARS), transcript vari-
ant 1, mRNA.
SDHALP1 -0.1 0.012 0.0308 Homo sapiens succinate dehydrogenase complex, subunit A, flavopro-
tein pseudogene 1 (SDHALP1) on chromosome 3.
SLC25A23 -0.1 0.0121 0.0309 19 Homo sapiens solute carrier family 25 (mitochondrial carrier; phos-
phate carrier), member 23 (SLC25A23), nuclear gene encoding mito-
chondrial protein, mRNA.
CXCR1 -0.12 0.0126 0.0318 2 Homo sapiens chemokine (C-X-C motif) receptor 1 (CXCR1), mRNA.
PLA2G2D -0.11 0.0127 0.0321 1 Homo sapiens phospholipase A2, group IID (PLA2G2D), mRNA.
VPS41 -0.11 0.0129 0.0325 7 Homo sapiens vacuolar protein sorting 41 homolog (S. cerevisiae)
(VPS41), transcript variant 1, mRNA.
NUBPL -0.1 0.0131 0.0328 14 Homo sapiens nucleotide binding protein-like (NUBPL), mRNA.
ANKRD9 -0.17 0.0135 0.0334 14 Homo sapiens ankyrin repeat domain 9 (ANKRD9), mRNA.
ABCA7 -0.12 0.0137 0.0338 19 Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 7
(ABCA7), mRNA.
ZNF223 -0.13 0.0139 0.0342 Homo sapiens zinc finger protein 223 (ZNF223), mRNA.
HBQ1 -0.16 0.0142 0.0348 16 Homo sapiens hemoglobin, theta 1 (HBQ1), mRNA.
SERPINA13 -0.33 0.0145 0.0353 14 Homo sapiens serpin peptidase inhibitor, clade A (alpha-1 antipro-
teinase, antitrypsin), member 13 (pseudogene) (SERPINA13), mRNA.
C9ORF130 -0.14 0.0145 0.0353 PREDICTED: Homo sapiens chromosome 9 open reading frame 130
(C9orf130), mRNA.
MATK -0.11 0.0146 0.0353 19 Homo sapiens megakaryocyte-associated tyrosine kinase (MATK), tran-
script variant 3, mRNA.
MCOLN1 -0.15 0.0151 0.0365 19 Homo sapiens mucolipin 1 (MCOLN1), mRNA.
BCR -0.23 0.0152 0.0366 22 Homo sapiens breakpoint cluster region (BCR), transcript variant 2,
mRNA.
FAM116B -0.15 0.0168 0.0396 Homo sapiens family with sequence similarity 116, member B
(FAM116B), mRNA.
FOXO3 -0.11 0.0169 0.0399 6 Homo sapiens forkhead box O3 (FOXO3), transcript variant 2, mRNA.
GUK1 -0.12 0.0175 0.0409 1 Homo sapiens guanylate kinase 1 (GUK1), mRNA.
UCP2 -0.12 0.0177 0.0414 11 Homo sapiens uncoupling protein 2 (mitochondrial, proton carrier)
(UCP2), nuclear gene encoding mitochondrial protein, mRNA.
EVI5 -0.11 0.0185 0.0426 1 Homo sapiens ecotropic viral integration site 5 (EVI5), mRNA.
REPS2 -0.12 0.0188 0.0432 X Homo sapiens RALBP1 associated Eps domain containing 2 (REPS2),
transcript variant 1, mRNA.
C15ORF39 -0.1 0.0198 0.0451 15 Homo sapiens chromosome 15 open reading frame 39 (C15orf39),
mRNA.
ASCC2 -0.13 0.0203 0.046 22 Homo sapiens activating signal cointegrator 1 complex subunit 2
(ASCC2), mRNA.
CXCR5 -0.13 0.0203 0.046 11 Homo sapiens chemokine (C-X-C motif) receptor 5 (CXCR5), tran-
script variant 2, mRNA.
SLC25A37 -0.12 0.0204 0.0462 8 Homo sapiens solute carrier family 25, member 37 (SLC25A37), nu-
clear gene encoding mitochondrial protein, mRNA.
GFOD1 -0.1 0.0204 0.0462 6 Homo sapiens glucose-fructose oxidoreductase domain containing 1
(GFOD1), mRNA.
ICA1 -0.1 0.0219 0.0487 7 Homo sapiens islet cell autoantigen 1, 69kDa (ICA1), transcript variant
3, mRNA.
DNAJB2 -0.11 0.0219 0.0488 2 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 2
(DNAJB2), transcript variant 2, mRNA.
TYW1 -0.12 0.0225 0.0499 7 Homo sapiens tRNA-yW synthesizing protein 1 homolog (S. cerevisiae)
(TYW1), mRNA.
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Full List of Enrichment Results for differential expression
Table A.2 Enriched Pathways for Differentially Expressed Probes (Complete)
Enriched Category Library Overlap p-value q-value
Up-regulated
SRP-dependent cotranslational protein targeting to membrane (GO:0006614) GO BP 43 0.0001 0.0001
viral transcription (GO:0019083) GO BP 36 0.0001 0.0001
cotranslational protein targeting to membrane (GO:0006613) GO BP 43 0.0001 0.0001
protein targeting to membrane (GO:0006612) GO BP 48 0.0001 0.0001
establishment of protein localization to endoplasmic reticulum (GO:0072599) GO BP 44 0.0001 0.0001
protein targeting to ER (GO:0045047) GO BP 43 0.0001 0.0001
translational termination (GO:0006415) GO BP 36 0.0001 0.0003
protein localization to endoplasmic reticulum (GO:0070972) GO BP 43 0.0001 0.0004
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
(GO:0000184)
GO BP 41 0.0001 0.0006
translational elongation (GO:0006414) GO BP 37 0.0001 0.0016
macromolecular complex disassembly (GO:0032984) GO BP 41 0.0001 0.0026
cellular protein complex disassembly (GO:0043624) GO BP 36 0.0001 0.0035
protein complex disassembly (GO:0043241) GO BP 39 0.0001 0.0081
mRNA catabolic process (GO:0006402) GO BP 48 0.0001 0.0084
protein localization to membrane (GO:0072657) GO BP 54 0.0001 0.0093
establishment of protein localization to membrane (GO:0090150) GO BP 53 0.0001 0.0105
viral life cycle (GO:0019058) GO BP 38 0.0001 0.0121
nuclear-transcribed mRNA catabolic process (GO:0000956) GO BP 47 0.0001 0.0123
translational initiation (GO:0006413) GO BP 41 0.0001 0.0301
RNA catabolic process (GO:0006401) GO BP 50 0.0001 0.0308
protein targeting (GO:0006605) GO BP 53 0.0001 0.0426
translation (GO:0006412) GO BP 56 0.0001 0.0559
protein localization to organelle (GO:0033365) GO BP 62 0.0001 0.1022
cellular component disassembly (GO:0022411) GO BP 50 0.0001 0.1185
establishment of protein localization to organelle (GO:0072594) GO BP 56 0.0001 0.1252
single-organism cellular localization (GO:1902580) GO BP 70 0.0002 0.3246
ribonucleoprotein complex biogenesis (GO:0022613) GO BP 15 0.0005 0.9245
defense response to Gram-positive bacterium (GO:0050830) GO BP 11 0.0011 1
cellular component biogenesis (GO:0044085) GO BP 17 0.0011 1
hydrogen transport (GO:0006818) GO BP 20 0.004 1
ribosomal subunit (GO:0044391) GO CC 42 0.0001 0.0001
cytosolic large ribosomal subunit (GO:0022625) GO CC 23 0.0001 0.0042
large ribosomal subunit (GO:0015934) GO CC 25 0.0001 0.0052
ribosome (GO:0005840) GO CC 40 0.0001 0.0139
cytosolic part (GO:0044445) GO CC 43 0.0001 0.143
cytosolic small ribosomal subunit (GO:0022627) GO CC 14 0.004 1
small ribosomal subunit (GO:0015935) GO CC 17 0.0056 1
side of membrane (GO:0098552) GO CC 24 0.0135 1
cell-cell junction (GO:0005911) GO CC 23 0.0303 1
methyltransferase complex (GO:0034708) GO CC 11 0.033 1
receptor complex (GO:0043235) GO CC 18 0.0361 1
external side of plasma membrane (GO:0009897) GO CC 17 0.0414 1
mitochondrial membrane part (GO:0044455) GO CC 23 0.0471 1
histone deacetylase complex (GO:0000118) GO CC 8 0.0482 1
structural constituent of ribosome (GO:0003735) GO MF 42 0.0001 0.0013
calmodulin binding (GO:0005516) GO MF 13 0.0042 1
Continued on next page
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Table A.2 – continued from previous page
Enriched Category Library Overlap p-value q-value
small conjugating protein binding (GO:0032182) GO MF 12 0.0065 1
monovalent inorganic cation transmembrane transporter activity (GO:0015077) GO MF 20 0.0066 1
ubiquitin binding (GO:0043130) GO MF 11 0.0139 1
hydrogen ion transmembrane transporter activity (GO:0015078) GO MF 16 0.0174 1
inorganic cation transmembrane transporter activity (GO:0022890) GO MF 23 0.0258 1
cysteine-type peptidase activity (GO:0008234) GO MF 12 0.0463 1
cysteine-type endopeptidase activity (GO:0004197) GO MF 8 0.0482 1
Ribosome Homo sapiens hsa03010 KEGG 2016 43 0.0001 0.0001
Parkinson’s disease Homo sapiens hsa05012 KEGG 2016 24 0.0265 1
Oxidative phosphorylation Homo sapiens hsa00190 KEGG 2016 24 0.0359 1
Hematopoietic cell lineage Homo sapiens hsa04640 KEGG 2016 12 0.037 1
PGC SCZ Pirooznia 24 0.0226 1
miR-137 Pirooznia 26 0.0277 1
BloodPlatelets customArray Gnatenko2 Blood 36 0.0231 1
turquoise M14 Nucleus HumanMeta Brain 83 0.0001 0.0001
salmon M12 Ribosome HumanMeta Brain 32 0.0001 0.0499
yellow M18 CTX Brain 79 0.0001 0.1612
salmon M12 Ribosome MouseMeta Brain 23 0.0046 1
green M10 GlutamatergicSynapticFunction CTX Brain 44 0.0099 1
greenyellow M6 GlutatmatergicSynapse MouseMeta Brain 25 0.0233 1
red M11 Neuron HumanMeta Brain 34 0.0374 1
brown pyramidalNeurons Layer5/basolateralAmygdala Sugino/Winden Brain 31 0.0476 1
Substantia Innominata localMarker(top200) IN Basal Forebrain HBA 10 0.0484 1
Differential Expression of Medication Subgroups
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Figure A.1 Visualizations of Differential Expression (Medicated group)
Shows a volcanoplot of limma differential expression results between medicated FEP and healthy
controls (HC) samples. Blue probes are up regulated in FEP and green probes are down-regulated.
Red probes are considered unchanged either due to low q-value, or low differential expression.
167
Figure A.2 Visualizations of Differential Expression (Olanzapine)
Shows a volcanoplot of limma differential expression results between Olanzapine medicated FEP and
HC samples. Blue probes are up regulated in FEP and green probes are down-regulated. Red probes
are considered unchanged either due to low q-value, or low differential expression.
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Figure A.3 Visualizations of Differential Expression (Risperidone)
Shows a volcanoplot of limma differential expression results between Risperidone medicated FEP
and HC samples. Blue probes are up regulated in FEP and green probes are down-regulated. Red
probes are considered unchanged either due to low q-value, or low differential expression.
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Figure A.4 Visualizations of Differential Expression (Anti-psychotic Free)
Shows a volcanoplot of limma differential expression results between medication free FEP and HC
samples. Blue probes are up regulated in FEP and green probes are down-regulated. Red probes are
considered unchanged either due to low q-value, or low differential expression.
Appendix B
Supplementary Material: Chapter 5































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tables of results including GAP model predictions in Dejong
data
Table B.1 AUC for split 1 of GAP and Dejong Models tested on both datasets
Built on Tested on
Machine Learning Model
svmLinear svmPoly glmnet nb pcaNNet rf ensemble
GAP GAP 0.62 0.65 0.61 0.62 0.61 0.64 0.63
Dejong 0.68 0.7 0.74 0.71 0.71 0.73 0.72
Dejong Dejong 0.82 0.87 0.87 0.86 0.84 0.84 0.84
GAP 0.67 0.69 0.69 0.66 0.68 0.66 0.68
Table of AUC for all 7 machine learning models in the first split of both Dejong and GAP Models.
The first column shows the data set used to build models, the second column shows the dataset used
for testing. Models built on GAP were created using the same methods as described for the Dejong
models. Data for models built on Dejong is identical to what is shown in Chapter 5. Results show that
models built on GAP, in all cases, are more accurate at predicting the external Dejong data, than the
internal GAP validation data. In addition GAP data is predicted more accuratly by models trained on
Dejong Data, than by models trained on GAP.
Table B.2 Analysis of Classification predictions in Dejong data from GAP models
GAP_Data Method Accuracy Balanced.Accuracy Sensitivity Specificity
Split_1 svmLinear2 0.614 0.622 0.453 0.792
svmPoly 0.658 0.66 0.623 0.698
glmnet 0.649 0.649 0.632 0.667
nb 0.639 0.638 0.642 0.635
pcaNNet 0.624 0.625 0.594 0.656
rf 0.649 0.648 0.66 0.635
ensemble 0.644 0.651 0.509 0.792
Table showing performance of models trained on GAP data, in the Dejong dataset. These results
mirror Table 5.5, where data is presented on performance of Dejong models in GAP data.
